Company Stories P

Stories that earlier appeared in Nelson's News Note 1: Carl Nelson Consulting, Inc is not an investment adviser and may hold a financial interest or client relationship in companies discussed.
(Note 2: Carl Nelson Consulting does not endorse these companies or organizations or their activities.) Looking for other older stories? Visit the archives

helping small high-tech companies get from idea to market

....

P3I (Hopkinton, MA)

A massive U.S. Air Force contract has been awarded to a group of five small businesses that will share in the $851 million worth of work, according to Washington Technology ... sharing the contract: Abacus Technology (Chevy Chase, MD); EIS (Vienna, VA); Odyssey Systems Consulting Group(Wakefield, MA); P3I (Hopkinton, MA); and SpectrumS4 (Burlington, MA). [Dayton Business Journal, Nov 1, 12] No SBIR to any.

Pace Packaging (Fairfield, NJ)

Fast-growing packaging manufacturer Pro Mach (Cincinnati, OH; no SBIR) is continuing its acquisition streak, purchasing two companies ... Benchmark Automation (Athens, GA; no SBIR, 30 employees) and Pace Packaging (Fairfield, NJ; no SBIR, 52 employees) mark Pro Mach’s 12th and 13th acquisitions, respectively, in the last three years. [Andy Brownfield, Cincinnati Business Courier, Sep 12, 14] Pro Mach [in turn] announced that affiliates of AEA Investors LP are acquiring the packaging machinery leader from The Jordan Company. [company press release, Sep 16, 14]

Pacific Biosciences of California (Menlo Park, CA)

Pacific Biosciences, (Menlo Park, CA; no SBIR) developing disruptive technology to detect biological events at single molecule resolution, said it received grants totaling more than $1.9 million from the National Institutes of Health. [Silicon Valley/San Jose Business Journal, Oct 8, 09]

Pacific Biosciences(Menlo Park, CA; no SBIR) makes novel use of fluorescent labels that allows it to read long stretches of DNA fragments, base by base, quickly and efficiently. Stephen Turner, the firm’s founder and chief technology officer, is confident that his firm will soon be able to sequence a complete human genome in under 15 minutes. He expects its first commercial product within two years. [The Economist, Apr 18, 09]

Pacific Biosciences (Menlo Park, CA; no SBIR) is a company that startup people are willing to leave hefty jobs for because it sits on so much potential. ... building a next generation gene-sequencing machine. The goal of the three-and-a-half-year-old company is to bring gene sequencing to the masses ... Over the summer, PacBio raised $100 million in funding in its fifth round of financing. [Michael Copeland, Fortune, Sep 29, 08]

[The Who's Who of ]Investors are pumping $100 million into a start-up developing technology to propel DNA sequencing into mainstream medicine. The infusion is expected to enable Pacific Biosciences of California (no SBIR) to introduce in 2010 its high-speed system for reading the chemical "letters" of DNA. The technology is designed to expand the use of sequencing to develop treatments tailored to patients' genetic makeup. [Wall Street Journal, Jul 14]

Padlock Therapeutics (Cambridge, MA)

Bristol Myers Squibb has agreed to acquire Padlock Therapeutics (Cambridge, MA; no SBIR, founded 2014) in a deal that could be worth up to $600 million if everything breaks right. Specifically, Bristol will pay up to $225 million in “upfront and near term” milestone payments ... raised just about $18 million since its inception .... zeroed in on what are known as protein-arginine deiminases, or PAD enzymes, and targeted them to make new drugs for autoimmune diseases. PAD enzymes can transform normal proteins into slightly modified forms attract the immune system’s attention, spurring it to attack otherwise healthy tissue. [Ben Fidler, xconomy.com, Mar 22, 16]

Johnson & Johnson Innovation said it has formed alliances with six Massachusetts-based life science and research companies to further innovation in pharmaceuticals, medical devices and diagnostic and consumer healthcare. .... • Minerva Neurosciences (Cambridge, MA; no SBIR)– Partnering with Janssen Pharmaceutica N.V., Johnson & Johnson Innovation and the Janssen neuroscience therapeutic area, Minerva has begun a program that will focus on the treatment of patients with primary and secondary insomnia and potentially treating other related neuropsychiatric disorders. • Rodin Therapeutics (Cambridge, MA; no SBIR)- With initial investment from Johnson & Johnson Development Corporation, Rodin’s will work in collaboration with Johnson & Johnson Innovation in studying the inheritable changes in gene activity for the treatment of cognitive disorders, including Alzheimer’s disease. • Energesis Pharmaceuticals (Cambridge, MA; no SBIR) - Janssen Pharmaceuticals Inc. and Johnson & Johnson Innovation have established a collaboration with biotechnology company Energesis to identify biological compounds that stimulate the formation of brown fat for use in treating metabolic diseases. The company’s approach is a novel strategy, leveraging recent scientific insights in BAT biology to increase the body’s ability to burn stored fat and lower insulin resistance. • Navitor Pharmaceuticals (Cambridge, MA; no SBIR) - Johnson & Johnson Development Corporation has made an equity investment in Navitor, which will work in collaboration with Johnson & Johnson Innovation to develop highly-specific modulators to regulate a cell’s response to nutrient availability, including cell growth and function. • Ascelegen Therapeutics (Cambridge, MA; no SBIR)– With an equity investment from Johnson & Johnson Development Corporation, and in collaboration with Johnson & Johnson Innovation, Ascelegen is working on developing novel therapies for cardiovascular diseases, including heart failure. Ascelegen’s work builds on research conducted at the Harvard Stem Cell Institute and Brigham and Women's Hospital. • Padlock Therapeutics (Cambridge, MA; no SBIR) – With an investment from Johnson & Johnson Development Corporation, and in collaboration with Johnson & Johnson Innovation, Padlock is developing new therapies targeting a protein that mediates how protein conversions lead to rheumatoid arthritis and how it drives inflammation and immune complex formation in active autoimmune disease. [Boston Business Journal, Jun 19, 14]

Pain Therapeutics (Austin, TX)

FDA rejects Pain Therapeutics' lead drug, Company makes major pivot away from painkillers to Alzheimer's [Austin Business Journal, Aug 8, 18]

Pain Thera down 71% [Jun 27, 18] announced that [FDA commitees) voted against the approval of REMOXY ER (oxycodone extended-release capsules) for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. [company press release, Jun 26, 18]

Pain Thera down 11% [Jun 22, 18]

Pain Thera down 13% [Jun 21, 18]

Pain Thera up 16% [May 16, 18]

Pain Thera up 10% [May 10, 18]

Pain Thera up 10% [Mar 2, 18]

Pain Thera up 13% [Jan 17, 18]

Pain Thera down 10% [Jan 16, 18]

Pain Thera up 103% [Jan 9, 18] announced positive results from a human abuse potential study of its late-stage drug candidate, REMOXY. Study results indicate that in non-dependent, recreational opioid users, nasal administration of REMOXY resulted in significantly lower abuse potential compared to immediate-release (IR) oxycodone. [company press release, Jan 9, 18]

Pain Thera down 10% [Oct 30, 17]

Pain Thera up 27% [Oct 24, 17] announced the completion of a Phase I clinical study for PTI-125, a new experimental drug therapy to treat Alzheimer's Disease. .... Key Findings: PTI-125 was safe and well-tolerated at all doses studied ; PTI-125 demonstrated favorable pharmacokinetics for further drug development. [company press release, Oct 24, 17]

Pain Therapeutics (Austin, TX; $200K SBIR, founded 1998) announced today it has been awarded an approximately $1.8 million [NIH] research grant. This grant will support innovative technology developed by the Company to diagnose Alzheimer's disease with a simple blood test. [company press release, Sep 18, 17] also announced that it has been awarded a research and development grant from the National Institute on Drug Abuse (NIDA). The grant of approximately $2.2 million provides Pain Therapeutics with a path forward to develop FENROCK™, a drug candidate for severe pain. FENROCK is a transdermal patch that contains the prescription drug fentanyl to manage pain and incorporates novel abuse-deterrent technology. [company press release, Sep 18, 17]

Pain Thera up 11% [Sep 14,17]

Pain Thera down 53% [Oct 27, 14] believes it will regain full development and commercial rights to REMOXY from Pfizer, ...Pfizer intention to terminate development of REMOXY. Actual termination will become effective six months from today, [company press release, Oct 24, 14]

Pain Therapeutics has stepped up its research on Fenrock, a new early-stage drug candidate that will administer the pain reliever fentanyl using a transdermal patch. The expected market for fentanyl patches in the U.S. is estimated to be as much as $900 million because the use of a patch prevents users from abusing the drug, which can have intense euphoric effects. .... not yet been submitted to [FDA] ... The company’s main drug, Remoxy, is going through a prolonged journey to the market in its partnership with Pfizer Inc. and the development of additional drugs is part of its strategy to widen its drug pipeline and become less dependent on the success of that one drug. [Chad Swiatecki, Austin Business Journal, Sep 26, 14]

Pain Thera down 10% [Jun 27, 14]

Pain Thera up 21% [Feb 5, 14]

Pain Thera down 14% [Jan 15, 14]

Pain Thera up 11% [Nov 25, 13]

Pain Thera up 10% [Nov 8, 13]

Pain Thera up 16% [Oct 22, 13]

Pain Thera up 36% [Aug 16, 13]

Pain Thera down 50% [May 10, 13] Pfizer said it could not decide whether to pursue regulatory approval for Pain Therapeutics painkiller Remoxy, for which the [FDA] sought additional studies [Reuters, May 10, 13]

Pain Thera up 15% [May 7, 13]

Pain Therapeutics (2 SBIRs) up 26% [Apr 30, 13] following Pfizer's conference call and what Gabelli's Kevin Kedra told Dow Jones are "positive" comments about Remoxy, a long-acting oxycodone capsule the pair have been developing. [Wall Street Journal, Apr 30]

Pain Therapeutics (two SBIRs) declared a special dividend.

[Nov 2012]

Pain Therapeutics down 37% [Oct 31, 12] Pfizer Says to make "go or no go" decision by March 2013 on whether to renew marketing application for Remoxy pain medicine * Says its decision on drug, partnered with Pain Therapeutics , will hinge on new trial results [Reuters, Nov 1, 12]

Pain Theraup 10% [Aug 6, 12]

Pain Therapeutics up 11% [Oct 10, 11]

Pain Thera up 15% [Aug 9, 11]

Pain Thera down 26% [Jun 27, 11]

Pain Thera down 43% [Jun 24, 11] delayed in gaining U.S. approval for a second time of a new type of painkiller designed to curb drug abuse [Bloomberg, Jun 24, 11]

Pain Therapeutics up 13% [Mar 30, 11]

Pain Therapeutics up 10% [Feb 11, 11]

Pain Therapeutics down 17% [Jul 7, 09] after its partner for painkiller Remoxy -- King Pharmaceuticals -- said it plans to resubmit a new drug application later than investors had expected. [Wall Street Journal, Jul 8]

Pain Thera down 10% [Mar 5, 09]

Pain Thera up 20% [Mar 3, 09]

Pain Thera down 26% [Mar 2, 09]

Pain Therapeutics down 21% [Dec 11, 08]

An FDA panel on Thursday gave Pain Therapeutics’s tamper-free pain pill mixed reviews. At least 10 members of the Food and Drug Administration panel said Remoxy, the drug developed by Pain Therapeutics and licensed by King Therapeutics Inc., was less likely to be abused than painkillers currently on the market, according to the news agency Reuters. But eight members said Pain Therapeutics didn’t show that the long-acting, tamper-proof version of the $2 billion painkiller oxycodone would prevent abuse. [San Francisco Business Times, Nov 13, 08]

Pain Thera up 11% [Oct 16, 08]

Pain Therapeutics up 12% [Sep 18, 08]

PaizaBio (Albuquerque, NM)

PaizaBio (Albuquerque, NM; no SBIR) announced an agreement with Taiwan-based JHL Biotech to provide fill-finish services for multiple projects, specifically, turning compounds into injectables for clinical trials in both oncology and immunology therapy. ... because the China Food and Drug Administration, the country’s counterpart to the United States Food and Drug Administration, is finally moving to implement reform in manufacturing standards. “There are over 5,000 pharmaceutical manufacturing companies in China, and 3,000 of them aren’t going to meet quality standards,” said [founder and CEO Stuart] Rose. [Joe Cardillo, Albuquerque Business First, May 18, 16]

Palantir Technologies (Palo Alto, CA)

Palantir Technologies (Palo Alto, CA; spooks don't do SBIR) disclosed that it has raised $50 million more in a funding round that now totals about $444 million. .... backers include the CIA's In-Q-Tel venture fund and Thiel's Founders Fund. Its customers include government intelligence agencies such as the National Security Agency. [Cromwell Schubarth, Valley Business Journal, Sep 15, 14]

Palatin Technologies (Cranbury, NJ)

Palatin Technologies (Cranbury, NJ; $1.8M SBIR) up 26% [Sep 8, 22] announced the initiation of a Phase 2 clinical study of PL8177, a potent melanocortin-1 receptor agonist, in ulcerative colitis (UC). [company press release, Sep 8, 22]

Palleon Pharmaceuticals (Waltham, MA)

Palleon Pharmaceuticals (Waltham, MA; no SBIR) cancer drug startup has scored $47.6 million [Series A round] in financing from Big Pharma investors as it pursues a unique method of exposing tumors to immune system attacks. ... developing treatments that target sugar molecules found on the surface of cancer cells. When receptors on immune cells bind to such molecules, the resulting interaction can hit the brakes on the immune system, preventing the body from detecting and destroying tumors. [Max Stendahl, Boston Business Journal, Oct 4, 17]

Palmer Labs (Durham, NC)

A giant nonprofit and a technology startup in the Triangle each snagged a slice of a $78 million federal stimulus grant to promote biofuels research. Both grant recipients are hiring engineers, project managers and other scientists for the research efforts. ... Palmer Labs (Durham, NC; no SBIR), 18-month-old, nearly $1.5million .. RTI International $750,000 to study new ways of cooking wood waste [John Murawski, Raleigh News & Observer, Jan 15, 10] Love stimulus? Remember that somebody has to pay for it, and the government has no money of its own.

Paloma Pharmaceuticals (Jamaica Plain, MA)

Paloma Pharmaceuticals (Jamaica Plain, MA; no SBIR) has pulled in $500,000 in a first tranche of a planned $2 million securities offering, according to a regulatory filing. [Mass High Tech, Sep 4, 09]

Palmaz Scientific (San Antonio, TX)

Palmaz Scientific (San Antonio, TX; no SBIR). is selling $32.2 million in a private-placement [Series C financing] offering from shareholders as a way to keep the company afloat, the San Antonio Express News reported [Nov 19]. The company, headed by heart stent developer Dr. Julio Palmaz, is a research and development company that is working to commercialize a pipeline of metallurgical and nanotechnology processes that can aid in cardiovascular procedures. However, ever since its founding in 2008, Palmaz Scientific has not been able to launch any of its technology to market, according to the newspaper. [James Aldridge, San Antonio Business Journal, Nov 19, 15]

Palvella Therapeutics (Wayne, PA)

Palvella Therapeutics (Wayne, PA; no BIR) developing treatments for rare disease, raised $3.4 million in equity financing. ... about four months after Palvella entered into a $10 million development funding and royalties agreement with Ligand Pharmaceuticals. [John George, Philadelphia Business Journal, Apr 15, 19]

Panacea Solutions (Research Triangle Park, NC)

NC IDEA has awarded more than $200,000 in grants to five North Carolina startups. Three of them are: FokusLabs (Wake Forest, NC; no SBIR) has developed an intervention tool designed to remind individuals with autism and ADHD to get back on task when their attention wanders. NIRvana Sciences (Durham, NC; no SBIR) is focused on novel fluorescent dyes developed at N.C. State University for use with medical diagnostic and imaging tests. Panacea Solutions (Research Triangle Park, NC; no SBIR) is using robotic technology to create low-cost, 30-day supply nutritional packets that are personalized for an individual’s needs. [David Ranii, Raleigh News & Observer, Dec 10, 13]

Panacos Pharmaceuticals

Panacos Pharmaceuticals (Gaithersburg, MA; $3M SBIR) has announced a number of restructuring efforts, including layoffs of seven employees, the closing of the company’s Gaithersburg, Md., facility and the retainment of a financial advisor for the purpose of exploring a possible sale of the company or of its HIV development efforts. [Mass High Tech, Feb 24, 09]

Panacos Pharmaceuticals said it has sold the rights and assets of bevirimat, a potential HIV drug, for $7 million. The buyer is another biotech firm, Myriad Pharmaceuticals of Salt Lake City, Panacos said. [Boston Globe, Jan 21, 09]

Panacos Pharmaceuticals (Watertown, MA; $4.5M SBIR) has laid off 18 employees, about 55 percent of its staff, and has announced that the company’s strategic considerations include financing, partnering or selling the company or its assets, Panacos officials said. In September, Panacos reported a quarterly loss of $8.2 million on total quarterly revenue of $20,000[Mass High Tech, Dec 12, 08]

Panacos Pharmaceuticals (Gaithersburg, MD; $4M SBIR) reports it has completed negotiations to sever ties with its former partner Hercules Technology Growth Capital Inc. VC firm Hercules had on Nov. 19 accused Panacos of defaulting on a loan agreement signed in June 2007. [Mass High Tech, Nov 24, 08]

Panacos Pharmaceuticals (Watertown, MA; $5+M SBIR) has been warned by NASDAQ for being below the buck. [Mass High Tech, Feb 1, 08]

Pandion (Cambridge, MA)

Pandion Therapeutics (Watertown, MA; no SBIR) biotech developing engineered T cells for autoimmune diseases, filed to raise $75M in an IPO. [Rowan Walrath, BostInno, Jun 29. 20] totall funding $135M [crunchbase.com]

Pandion Therapeutics (Cambridge, MA: no SBIR), a clinical-stage biotechnology company developing modular protein therapeutics for autoimmune disease, announced that it has closed an $80 million Series B financing [to] support the continued development of multiple product candidates in Pandion’s pipeline, including lead clinical-stage program, PT101, a novel interleukin 2 (IL-2) mutein Fc fusion protein, which is currently in Phase 1 clinical development. [company press release, Apr 1, 20] total prior fundng $58M [crunchbase.com]

Pandion Therapeutics (Cambridge, MA; no SBIR) and Astellas Pharma (Japan) announced a License and Collaboration Agreement directed toward the research, development, and commercialization of locally acting immunomodulators for autoimmune diseases of the pancreas. Pandion could receive up to $45 million as upfront and payments related to research and preclinical activities. Additionally, if Astellas develops and commercializes multiple candidates for multiple pancreatic autoimmune diseases, Pandion is potentially eligible to receive more than $750 million in future development and commercial milestone payments from Astellas. Pandion may also receive royalties on worldwide net sales of any commercial products developed through the collaboration. [joint companies press release, Oct 31, 9]

Pandion (Cambridge, MA; no SBIR, founded 2017) raised $58 million in series A funding to make bispecific antibodies that dial a dysregulated immune system back toward homeostasis. [Ryan Cross, Chemical and Enginering News, Jan 18, 18]

Pandromics (San Jose, CA)

startup Pandromics (San Jose, CA; n SBIR) won an $18 million contract [from DARPA’s $65 million brain-machine interface program], vaulting it into the top ranks of Silicon Valley companies surging into the field of brain-machine interfaces. ... It wants to squeeze a device the size of a mobile phone into a chip small enough to insert into a human brain, where it would “read” nerve signals and replace senses and abilities lost due to injury or diseases. [CEO Matt] Angle said a model of his device for animal research should be available next year, but it might be a decade before it’s ready to be sold to people. [Charles Piller, statnews.com, Aug 17, 17]

Pan Genome Systems (Madison, WI)

Seven [Wisconsin] companies each will receive a $75,000 grant under a new program aimed at helping them commercialize their products. The first-ever grants are being distributed by a program called SBIR Advance. ... with $1 million from the Wisconsin Economic Development Corp. and administered by the UW-Extension Center for Technology Commercialization. All of the companies have already received [SBIR or STTR]. But they aren't able to use those funds for activities like patent work and customer development and validation. receiving the grants are: C-Motive Technologies (Madison, WI; one SBIR) Isthmus Biosciences (Madison, WI; one SBIR); Nutrient Recovery and Upcycling LLC (Madison, WI; one SBIR); Pan Genome Systems (Madison, WI; one SBIR); V-Glass LLC (Milwaukee, WI; one SBIR); Fiberstar Bio-Ingredient Technologies (Eau Claire,WI; one SBIR); Medical Cyberworlds (Verona, WI; $600K SBIR). [Kathleen Gallagher, Milwaukee Journal Sentinel. Sep 25, 14]

Panomics (Fremont, CA)

Affymetrix agreed to buy Panomics (Fremont, CA; $2.3M SBIR) for $73 million in cash. -... Panomics makes products for genetic, protein and cellular analysis. [San Francisco Business Times, Nov 11, 08]

PanTheryx ((Boulder,CO)

PanTheryx (Boulder, CO; no SBIR, founded 2007) CEO Mark Braman says the [first mother's milk] fluid’s components can also help resolve gastrointestinal disorders rooted in the gut microbiome. Now, the company has $50 million in new capital to ramp up its research. [Frank Vinluan, xconomy.com, Jun 26, 19] prior funding $88M [crunchbase.com]

Aiming to maximize the potential of bovine colostrum to benefit global health, PanTheryx (Boulder, CO; no SBIR, founded 2007) is announcing two major acquisitions that make it the world’s premiere manufacturer of nutrient rich colostrum. In separate purchases, PanTheryx has acquired the two leading producers of colostrum and related nutritional products, APS BioGroup (Phoenix,AZ; no SBIR) and La Belle Associates (Bellingham, WA; no SBIR). In March of 2016, PanTheryx announced that it entered into a $53 million financing with Pegasus Capital Advisors. ... The terms of the acquisitions were not released. [company press release, Feb 14, 17]

Paper Battery (Troy, NY)

Paper Battery (Troy, NY; no SBIR), developer of an innovative supercapacitorbased energy storage and battery enhancement technology, announced the completion of UL certification for its PowerResponder® product line. PowerResponder is a line of new hybrid supercapacitors with technology enhancements that aim to replace traditional lithium ion batteries in select applications. PowerResponder has also been certified as RoHS compliant, giving it added environmental and safety benefits. The product line will be available in a range of sizes from 90F to 9000F with initial products available to OEM customers by the end of the year. [company press release, Dec 14, 15]

[CEO] says Paper Battery (Troy, NY; no SBIR) remains on track to generate revenue in 2015. ... says the battery technology startup continues to test its ultrathin supercapacitor products in up to four verticals. [Megan Rogers, Albany Business Review, Mar 23, 15]

Two Albany area startups in the battery and energy storage industry have been awarded $250,000 in New York state funding for product development. Eonix (Colonie, NY; no SBIR) [startup developing technology to expand the capacity of ultracapacitors] and Combined Energies (Latham, NY; SBIR) [developing distributed generation systems to extend the life of electrochemical batteries] were among the nine companies that received funding from the New York State Energy Research and Development Authority. ... also gave $250,000 to Hollingsworth & Vose (East Walpole, MA; no SBIR) an advanced materials manufacturing company with filtration, battery separator and industrial applications. [Megan Rogers, Albany Business Review, Oct 27, 14] Since 2012, the state agency has funded Paper Battery Co., BESS Technologies, Rensselaer Polytechnic Institute, and many other state entities.

A new $3 million investment will help take Paper Battery (Troy, NY; no SBIR, founded 2009) from the lab to the market. "It will go towards developing the rest of the pilot line and scaling it up," said Shreefal Mehta, president and CEO of Paper Battery. ... has developed an ultrathin ultracapacitor technology that seeks to re-define the way cell phones, bluetooth headsets and wireless speakers operate and perform. The paper-thin device helps lithium batteries last longer and charge quicker. The now five-year-old company has partnered with TWS Industrial, a major battery supplier in China. [Keshia Clukey, Albany Business Review, Jun 12, 14]

Paper Battery (Troy, NY; no SBIR) startup developing a paper-thin energy technology, has been named to a Silicon Valley list for the 50 hottest early-stage tech companies. .... expects to generate its first revenue from products this year as the company makes the transition from development to commercialization. [The Business Review (Albany), May 23, 13]

Paper Battery (Troy, NY; no SBIR) , a nanotechnology/energy startup, developing a battery as thin as a piece of paper received a $1 million grant to take the next step in the production process. ... trying to break into the $500 million ultra capacitor market [Michael DeMasi, Business Review (Albany), Sep 26, 11]

PapGene (Baltimore, MD)

PapGene (Baltimore, MD; no prior SBIR) announced that it was recently awarded a highly competitive Fast-Track NIH SBIR [Phase I plus contingent Phase II] to commercialize a test to detect ovarian and endometrial cancers. ... The PapGene test couples massively parallel sequencing (MPS) with a proprietary error-reducing technology developed in the Ludwig Center at the Johns Hopkins Kimmel Cancer Center. [company press release, Feb 4, 16]

Parabricks (Ann Arbor, MI)

Parabricks (Ann Arbor, MI; one prior SBIR, founded 2016) has been awarded a NSF SBIR) Phase II $748,104 to commercialize innovative technology to greatly accelerate secondary genomics processing and analysis using graphics processing units (GPUs). The Michigan Emerging Technologies Fund matched the grant with $125,000 to support commercialization efforts. [company press release, Oct 11, 18]

Paradigm Diagnostics (Phoenix, AZ)

Paradigm Diagnostics (Phoenix, AZ; no SBIR) announced the near completion of their $7M Series B financing, adding an additional $3M ... towards further accelerating commercial adoption of the flagship Paradigm Cancer Diagnostic Test, PCDx, a comprehensive genomic profiling test and expanding the Paradigm cancer registry. .... PCDx is a comprehensive clinical-grade NGS-based test that is designed to provide physicians and patients with a more targeted, personalized approach to cancer treatment by identifying the underlying genomic and proteomic alterations of a tumors DNA, RNA & protein. [company press release, Feb 16, 17]

Paradigm Sensors (Milwaukee,WI

Paradigm Sensors (Milwaukee, WI; no SBIR) will begin production of biodiesel testing devices this year from a new home inside a business incubator ... start-up firm hopes to hire more than 25 people in the coming year as it starts manufacturing handheld devices that analyze biodiesel to ensure product quality ... will soon close its first round of venture-capital funding after a $200,000 investment announced Tuesday by the Wisconsin Housing and Economic Development Authority. [Thomas Content, Milwaukee Journal-Sentinel, Apr 3, 08]

Paradromics (San Jose, CA)

Paradromics (Austin, TX; $800K SBIR), a company Bloomberg identified as a competitor to Elon Musk's Neuralink, announced it had raised $20 million in seed funding. The company makes high data rate brain-computer interfaces. [AustinInno, Jul 22, 21]

More fruits of miniaturization. DARPA selected [Matt] Angle’s small company, Paradromics (San Jose, CA; no SBIR), to lead one of six consortia it is backing with $65 million to develop technologies able to record from one million individual neurons inside a human brain simultaneously. Matt Angle for years insisted that the key to solving one of neuroscience’s most intractable challenges lay in a 1960s-era technology invented in the tiny nation of Moldova. [Adam Piore, Technology Review, July 10, 17] recently been awarded an $18.3M [DARPA] contract to build a high bandwidth cortical implant. The Neural Input–Output Bus, or NIOB, will be capable of reading and stimulating brain activity from 1 million neurons with an effective data rate of > 1 Gbps. [company press release, Jul 10, 17] DARPA has awarded contracts to five research organizations and one company that will support the Neural Engineering System Design (NESD) program: Brown University; Columbia University; Fondation Voir et Entendre (The Seeing and Hearing Foundation); John B. Pierce Laboratory; Paradromics(San Jose, CA; no SBIR), Inc.; and the University of California, Berkeley. [DARPA press release, Jul 10, 17]

ParaGen Technologies (Columbus, OH)

Paragen Technologies (Columbus, OH; no SBIR) raised $3M to redefine tissue engineering by addressing the problems associated with synthetic and biologic implants; while incorporating their advantages. [crunchbase.com, Nov 29, 18]

A tissue engineering company developing materials to heal wounds and grow new blood vessels has raised $4.1 million in a round led by a "startup nursery." ParaGen Technologies LLC (Columbus, OH; no SBIR) is a parent company for medical device subsidiaries that use its core microfilament technology for specific applications. The first four are for healing skin, treating sports injuries, growing blood vessels and repairing hernias. company is a joint venture of Nanofiber Solutions LLC ($150K SBIR), which invented the technology, and Ikove Capital Partners. [Carrie Ghose, Columbus Business Journal, Dec 15, 17] three subsidiary companies are RenovoDerm, Atreon Orthopedics, and Vascular Genesis. [ParaGen website]

ParaGen Technologies (Columbus, OH; no SBIR) secured $4.1 million in seed financing and expects to close a $5 million Series A round early next year. ..... aims to redefine tissue engineering by addressing the problems associated with synthetic and biologic implants; while incorporating their advantages. The company is utilizing synthetic nanofiber scaffolds that promote healing by mimicking the physical structures found naturally in the body. ParaGen Technologies is launching medical device companies that tailor this technology to meet the needs of specific clinical verticals. [comapny press release, Dec 12, 17]

Paragon Bioservices (Baltimore, MD)

Paragon Bioservices (Baltimore, MD; no SBIR) has raised $5M in a funding round disclosed last week in SEC filings. The company, which develops and manufactures biopharmaceuticals, previously had hauled in $15M in a Series A round [DCInno, Aug 13, 18]

Paragon Dynamics (Aurora,CO)

Mercury Computer Systems (Chelmsford, MA; no SBIR, market cap $400M) will pay $70 million to acquire a pair of companies that make electronic warfare and intelligence-gathering systems. Mercury is buying KOR Electronics (Cypress, CA; $6.8M SBIR mostly USAF) which makes digital radio and radar test gear, as well as Paragon Dynamics (Aurora, CO; no SBIR), which provides intelligence analysis and exploitation services. [Hiawatha Bray, Boston Globe, Dec 23, 11]

Paragonix Technologies (Cambridge, MA)

Paragonix Tech (Cambridge, MA; $150K SBIR) working on organ transport tech, announced a $24M Series B round
[Hannah Green, BostInno, March 7, 2023]

Paragonix Technologies (Braintree, MA; no SBIR) cleared another major hurdle [FDA premarket clearance] toward commercializing the company's Sherpa Pak Transport Systems products, which are based on organ transplant transportation technology developed by researchers in San Antonio. [James Aldridge, San Antonio Business Journal, Dec 2, 14]

Some Bay State largesse. The Massachusetts Life Sciences Center, a quasi-public agency tasked with implementing the state’s ten-year, $1 billion Life Sciences Initiative, today announced the awarding of $2.2 million in loans [$750K each] to three early-stage life sciences companies. Intelligent Bio-Systems, (Waltham, MA; $6.3m SBIR) DNA sequencing company with a patented, higher performance, lower cost, DNA sequencing instrument and consumable system; Allurion Technologies,(Wellesley, MA; no SBIR) company that is developing a novel medical device designed to induce significant weight loss by displacing volume in the stomach. The device can be delivered without surgery and it can be eliminated via an orally available, non-toxic dissolution agent; and Paragonix Technologies,(Cambridge, MA; no SBIR) company that is commercializing first-in-class, single-use and highly portable organ preservation and transport devices called ‘Sherpas.’ Paragonix has begun with a Sherpa for kidney transport, but is planning to expand their ‘Sherpa’ product line for other organs. [DC Dennison, Boston Globe, Dec 28, 11]

Paragon Space Development (Tucson, AZ)

Paragon Space Development (Tucson, AZ; $15M SBIR) wins $5M in government contracts Company currently is working on 23 contracts [ Hayley Ringle, Phoenix Businesss Journal, Aug 6, 19] to develop COSMIC is a full flow phase separation device that separates liquid condensate from air with low power draw and low pressure drop in the flow path while supplying the separated condensate at pressure to the Water Processing Assembly (WPA) onboard the International Space Station (ISS). [company press release, Jul 10, 19]

Parasol Therapeutics (Cambridge,MA)

Paratek Pharma up 13% [Oct 4, 18]

biotech startup Visterra, formerly known as Parasol Therapeutics, (Cambridge, MA; no SBIR) has landed $6 million in its first round of funding ... develops technology to “interrogate how pathogens interact with human cells,” which is used to develop diagnostics, vaccines and therapeutics [Mass High Tech, Jul 12, 10]

Paratek Pharmaceuticals (Boston, MA)

Paratek Pharma up 20% [Feb 26, 20]

Paratek Pharma up 25% [Nov 5, 19]

Paratek Pharma down 11% [Oct 5, 18]

Paratek Pharmaceuticals announced that the [FDA] approved NUZYRA™ (omadacycline) for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute skin and skin structure infections (ABSSSI). NUZYRA, a modernized tetracycline, is a once-daily IV and oral antibiotic that exhibits activity across a spectrum of bacteria, including Gram-positive, Gram-negative, atypicals, and drug resistant strains. [company press release, Oct 2, 18]

Paratek Pharma up 12% [Aug 6, 18]

With little surprise, Pain Therapeutics has been hit with a complete response letter from the FDA for Remoxy ER, its extended-release, capsule gel form of the opioid oxycodone. .... According to FDA: “The data submitted in [the] NDA do not support the conclusion that the benefits of [REMOXY] Extended-Release Capsules outweigh the risks,” the company said in a brief update. [Ben Adams, Fierce Biotech, Aug 6, 18]

Paratek Pharma down 15% [Apr 19, 18]

Paratek Pharma up 27% [Aug 23, 17] announced that [FDA] informed the Company that the FDA (i) has completed its review of the Company's responses to requests from the FDA for additional information relating to certain findings observed in nonclinical toxicology studies of lumateperone in an animal species and (ii) agrees that the Company has presented adequate data to support its position that the metabolic pathway in the animal species is distinctive from humans, which indicates that the toxicity observed in the animal species is not relevant to humans. [company press release, Aug 23, 17] Bloomberg said the company, gearing up to file a new antibiotic, is considering a sale. [Phil Taylor, Fierce Biotech, Aug 23, 17]

Paratek Pharma down 11% [Aug 9, 17]

Paratek Pharma (Boston, MA; $3.8M SBIR) up 11% [Aug 7, 17]

Paratek Pharma (Boston, MA; $3.8M SBIR) up 15% [May 4, 17] Reported positive top-line efficacy and safety data in the OPTIC study, a Phase 3 registration study of omadacycline in CABP [company press release, May 3, 17]

Paratek Pharmaceuticals (Boston, MA; $3.8M SBIR) up 23% [Apr 4, 17] reports that its antibiotic, omadacycline, has hit all its main and secondary goals in a study of 774 patients with hospital-acquired pneumonia. It is the second of two trials; last year, Paratek’s antibiotic succeeded in a study of 645 patients with certain types of bacterial skin infections. Omadacycline is being developed both as an IV treatment and once-a-day pill, which would allow patients to continue taking the drug once discharged from the hospital. [Ben Fidler, xconomy.com, Apr 4, 17]

Paratek Pharma down 20% [Jun 21, 16]

Paratek Pharmaceuticals (Boston, MA; $3.8M SBIR) surged more than 20 percent after its antibiotic, omadacycline, succeeded in the first of two Phase 3 trials. [Alex Lash, xconomy,com, Jun 17, 16]

Paratek Pharma (Boston, MA; $3.8M SBIR) down 18% [Nov 12, 15] after reporting quarterly results

Paratek Pharma down 10% [Jan 2, 15]

Paratek Pharma up 17% [Dec 17, 14]

Paratek Pharma up 20% [Dec 10, 14]

Paratek Pharma up 13% [Dec 9, 14]

Paratek Pharma ($3.8M SBIR) up 14% [Dec 8, 14]

Paratek Pharma up 10% [Nov 3, 14]

Paratek Pharmaceuticals (Boston, MA; $3.7M SBIR in two Phase 2s) said that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission relating to a proposed initial public offering of shares of its common stock. According to its website, engaged in the discovery and commercialization of new therapeutics that treat life threatening infectious and other serious diseases. [Boston Globe, Sep 28, 12]

Paratek Pharmaceuticals (Boston, MA; $3.8M SBIR) signed a worldwide license and commercialization agreement with Novartis, in which Paratek stands to receive up to $485 million in milestone and upfront payments. The agreement centers around Paratek’s antibiotic PTK 0796, currently in Phase 3 clinical trials. [Mass High Tech, Oct 8, 09]

Paratek Pharmaceuticals (Boston, MA; $3.8M SBIR) closed the $22M first tranche of a $40M private financing to be used to push development of its broad-spectrum antibiotics. [Mass High Tech, Oct 25]

Parexel International

Parexel International, a clinical research organization that helps biotechs to bring their drugs to market, said it has unveiled a new brand promise: “Your Journey. Our Mission.” That promise is part of an effort to convince biotechnology firms that Waltham-based Parexel is the ideal partner for simplifying and accelerating all aspects of drug product development, the company said in a Wednesday press release. [Boston Globe, Feb 13]

Parhelion (Apex,NC)

Parhelion (Apex, NC; no SBIR) behind a laser light known as the “Firefly,” filed for bankruptcy April 30 [Lauren Ohnesorge, Triangle Business Journal, May 1, 19]

Parion Sciences (Durham, NC)

Shire plc (Lexington, MA) and Parion Sciences (Durham, NC; $2.4M SBIR, emerged from [UNC] in 1999) announced they have entered into an agreement granting Shire exclusive worldwide rights to develop and commercialize P-321. Shire will lead development of P-321, an investigational epithelial sodium channel (ENaC) inhibitor for the potential treatment of dry eye disease in adults, with the opportunity for Parion to co-fund. [joint companies press release, May 1, 17]

Parion Sciences (Durham, NC; $2.6M SBIR, 14 employees) start-up with no products on the market, has signed the biggest deal in its 16-year history: a licensing agreement worth up to $1.17 billion with Vertex Pharmaceuticals. ... will collaborate to develop an inhaler that stimulates hydration and clears out the sticky mucus clogging the lungs of cystic fibrosis patients. Under the deal, privately-owned Parion will receive an up-front payment of $80 million and nearly $1.1 billion in milestone payments for development of the drug for cystic fibrosis and other pulmonary conditions. [John Murawski, Raleigh News & Observer, Jun 5, 15]

drug developer Parion Sciences (Durham, NC; $2.8M SBIR) received $3 million from Cystic Fibrosis Foundation Therapeutics (CFFT) to continue work on its investigational treatment for cystic fibrosis (CF). ... will speed up the timeline for a Phase 2 trial in which Parion will test its experimental drug, called P-1037, in patents with CF. [Jason deBruyn, Triangle Business Journal, Sep 16, 14]

Parion Sciences (Durham, NC; $1.8M SBIR), working on treatments for pulmonary diseases, received a biodefense grant from the National Institutes of Health worth about $850,000. ... to continue testing of its most advanced experimental medicine to prevent radiation-induced lung injuries after a nuclear incident. .... founded in 2001 and employs about 10. Its research into diseases that result from a failure of the body's mucosal defenses is based on technology developed at UNC-Chapel Hill. [Sabine Vollmer, Raleigh News & Observer, Dec 17, 08]

Parion Sciences (Durham, NC; $1.8M SBIR) has signed a $25 million deal with a Korean company to test an experimental medicine. [Raleigh News & Observer, Oct 29, 08]

ParkerVision (Jacksonville, FL)

The U.S. Supreme Court declined to hear ParkerVision (Jacksonville, FL; no SBIR)’s patent infringement lawsuit against Qualcomm, putting an end to an intellectual property dispute dating back to 2011. ... the federal judge overseeing the [2013] case voided the jury verdict in 2014, saying the technical evidence didn’t support the jury’s findings. .... ParkerVision launched a 10-to-1 reverse split [Mike Freeman, San Diego Union Tribune, Mar 29, 31]

A U.S. appeals court upheld a lower court's decision to clear Qualcomm in a patent lawsuit by ParkerVision (no SBIR), allowing it to escape a $173 million verdict for infringement. [Reuters, Jul 31, 15] ParkerVision has accused Qualcomm of being the chief impediment to the adoption of its wireless designs by the telecommunications industry. [Susan Decker, Bloomberg News]

The Florida jury ordered Qualcomm to pay $173 million in damages to Jacksonville-based ParkerVision for infringing on patents related to semiconductors used in smartphones. [Mike Freeman, utsandiego.com, Oct 24, 13]

A Florida jury found that Qualcomm infringed on four patents from ParkerVision (Jacksonville, FL; no SBIR) for semiconductor chips used in smartphones. [Mke Freeman, utsandiego.com, Oct 18, 13]

Partner Therapeutics (Boston, MA )

Partner Therapeutics (Boston, MA; no SBIR) startup formed by former Merrimack Pharmaceuticals CEO Robert Mulroy and ex-Seragon Pharmaceuticals chief medical officer Debasish Roychowdhury, raised $60 million and bought an immune system boosting drug from Sanofi. [Frank Vinluan, xconomy.com, Feb 1, 18] Partner bought Sanofi’s sargramostim (Leukine), a drug used to help acute myeloid leukemia patients fight infections after undergoing bone marrow transplants. Partner aims to test the drug in different diseases, like melanoma and radiation poisoning. [Ben Fidler, xconomy.com, Feb 1, 18]

Partpic (Atlanta, GA)

Partpic (Atlanta, GA; no SBIR) which has developed visual recognition software technology, has raised $1.5 million from angel investors. ... The startup sells to manufacturers, distributors and retailers who use the technology to identify product parts, co-founder Jason Crain said. [Urvaksh Karkaria, Atlanta Business Chronicle, Jun 16, 15]

Passage Bio (Philadelphia, PA)

Passage Bio (Philadelphia, PA; no SBIR) a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders with limited or no approved treatment options, today announced the pricing of its [IPO to raise] $216.0 million. [company press release, Feb 27, 20]

Passage Bio (Philadelphia,PA; no SBIR) which launched last year, filed regulatory papers laying out its plans to raise $125 million [IPO] to advance its gene therapies, which were discovered at the University of Pennsylvania. [Sarah de Crescenzo, xconomy.com, Feb 3, 20]

Passage Bio (Philadelphia, PA; no SBIR) debuted with a $115.5 million Series A financing ... to develop a portfolio of five therapeutic candidates to treat rare monogenic CNS diseases. These programs are being developed under a research, collaboration and license agreement with the University of Pennsylvania (Penn) and its Gene Therapy Program (GTP) together with the Penn Orphan Disease Center (ODC), with the support of co-founder James M. Wilson, M.D., Ph.D. [company press release, Feb 14, 19]

Passport Systems (N Billerica, MA)

In its first federal filing in five years, cargo container scanning company Passport Systems (N Billerica, MA; $1.4M SBIR) reports that it’s secured $3.8 million in debt financing out of a $4.5 million offering. .... founded in 2002 to fill the post-Sept. 11, 2001 demand for better ability to tell what’s inside shipping containers in a fraction of the time required by other systems. The company’s website says it has completed preliminary designs for a full-scale NRF scanner with more than $35 million in government and private funding. In 2009, the company won an $8.6 million contract with its partner American Science and Engineering for development of a system for X-ray analysis of cargo, and later that year, reported that it won a $9.8 million contract for a nuclear detection system with the U.S. Navy. [Don Seiffert, Mass High Tech, Jun 12, 12]

Pasteuria Bioscience (Alachua; FL)

Pasteuria Bioscience, (Alachua; FL; one SBIR) a venture-backed biopesticide company focusing on the development and commercialization of a platform of natural products for the control of nematodes in agriculture, received the Ag Innovation Showcase “2010 High Yield Business Award.” [LARTA Vox, Jul 13, 10]

Pathfinder (Cambridge, MA)

Pathfinder (Cambridge, MA; no SBIR) cell-based therapeutics firm, and New Jersey biomaterials firm SyntheMed (no SBIR) have merged, the two companies announced [Mass High Tech, Dec 23, 10]

PathoGenetix (Woburn, MA)

PathoGenetix (Woburn, MA; no SBIR), which raised $4 million in August, has added $7.5 million to round out its Series B financing, the company announced. ... first knwon as U.S. Genomics said it plans to apply the $11.5 million total investment toward development and commercialization of its Genome Sequence Scanning (GSS) technology, aimed at identifying thousands of bacteria strains in one test in three hours. [Michelle Lang, Mass High Tech, Nov 1, 11]

PathoVax (Baltimore, MD)

PathoVax (Baltimore, MD; at least $2.6M SBIR, founded 2014) raised $2.75M ... PathoVax has been working to create and commercialize a vaccine called RGVax, which aims to prevent cancers associated with human papillomavirus virus (HPV). [Baltimore BusinessJournal, Oct 16, 18] total private funding $3M [crunchbase.com]

PathoVax (Baltimore, MD; at least one prior STTR, founded 2014), a biotech startup founded out of Johns Hopkins, has been awarded two federal grants worth $2.3 million. They will be used to push the company's first product toward clinical trials. [Baltimore Business Journal, Jan 2, 18] created to develop the nascent Human Papillomavirus (HPV) prophylactic vaccine technology RGVax [company website]

startup PathoVax (Baltimore, MD; no SBIR, founded 2014) won $500,000 as a finalist company at the 43North [of Start-Up New York] pitch [Morgan Eichensehr, Baltimore Business Journal,Oct 31, 16] committed to addressing the devastating economic burden, social stigma, and poor compliance rates resulting from the incomplete protection of current HPV vaccines. [company website]

Pathway Genomics (San Diego, CA)

FDA has a clear message for Pathway Genomics (San Diego CA; no SBIR), the company that just unveiled a blood test that it claims can detect various cancer types: “[Y]ou are offering a high risk test that has not received adequate clinical validation and may harm the public health,” the agency wrote in a letter to Pathway’s founder and CEO Jim Plante. The FDA has given Plante two weeks to respond and set up a time to meet with the agency. ... And this isn’t the first warning that Plante has fielded from the FDA. In 2010, the agency sent him a similar warning letter regarding Pathway’s Genetic Health Report, a home-use saliva test that reportedly screened individuals’ genomes for a slew of disease risks. [Bob Grant, the-scientist.com, September 25, 2015]

Pathway Genomics (San Diego, CA; no SBIR, founded 2008), known for pushing the boundaries of direct-to-consumer genetic testing, will launch a cancer screening test designed to detect bits of cancer DNA in the blood of otherwise healthy people. ... a first in the rapidly developing field of "liquid biopsies," which use gene sequencing technology to screen blood samples for trace amounts of DNA associated with different cancers. ... The cost to consumers begins at $299 to periodically check for DNA in their blood ... Guardant Health and Personal Genome Diagnostics Inc already offer blood tests for cancer patients. Roche-backed Foundation Medicine Inc, Genomic Health Inc, Illumina Inc and Sequenom Inc say they have similar tests in the works. [Julie Steenhuysen, Reuters, Sep 9, 15]

PatientStream

Univ of Washington will announce that seventeen startups were started last fiscal year to exploit technology developed at the school. Among the ventures it called out is GraphLab, Professor Carlos Guestrin’s analytics venture, which draws on his research into machine learning. Also noted was PatientStream, an electronic information system developed at Harborview Medical Center that replaces traditional whiteboards in hospitals. [Brier Dudley, Seattle Times, Jul 17, 13] The UW Center for Commercialization& says UW students, faculty or technology are behind more than 250 companies.

PatientWise (Middleton, WI)

Six young Wisconsin bioscience companies have been chosen by the state's biotech trade organization as emerging companies with good growth potential. The companies have all transitioned successfully out of research and development and are developing commercial products, said Bryan Renk, executive director of BioForward .... : Fused Innocation (Neenah; WI) VibeTech (Sheboygan, WI); Somna Therapeutics (Germantown, WI); PatientWise (Middleton, WI); NanoOncology, a subsidiary of Peptimed (Madison, WI); PharmaSeek Financial Services (Middleton, WI). [Kathleen Gallagher, Milwaukee Journal Sentinel, Aug 30, 12] None had SBIR.

Patton Medical Devices (Austin TX)

Patton Medical Devices (Austin TX; no SBIR) raised $15M to step up the national launch of its first product, a "port" through which diabetics inject insulin. ... the company's first [money] from institutional investors ... has raised about $12M from other investors since its founding in 2004 [Austin American-Statesman, Oct 18]

Patton Surgical (Austin TX)

Patton Surgical (Austin, TX; no SBIR) has received $3 million from the Texas Emerging Technology Fund to commercialize its devices, which are used in minimally invasive surgery. Founded in 2002, Patton has developed several devices, including a trocar with a shielded cutting tip. The trocar is used to insert medical instruments into a patient's abdominal cavity during what's known as laparoscopic surgery. [Austin American-Statesman, Oct 23, 09]

Pavilion Technologies (Austin TX)

Pavilion Technologies (Austin TX; $1.5M SBIR), independent software development, has agreed to be acquired by Rockwell Automation [Austin American-Statesman, Oct 31] SBIR advocates often plead that SBIR should help companies remain independent. Nonsense, that is just using taxpayer funds to support companies in the life-style to which they would like to be accustomed.

Pax Streamline (San Rafael, CA)

ARPA-E winners in San Francisco Bay area: Envia Systems (Hayward); NanOasis Technologies (Richmond); Pax Streamline, (San Rafael); and Stanford University. None had SBIR. official list of winners

PaxVax (San Diego, CA)

Emergent BioSolutions announced it has entered into an agreement to acquire PaxVax (Redwood City, CA; $7M SBIR, founded 2009), focused on specialty vaccines that protect against existing and emerging infectious diseases, for a $270 million [cash]. [Emergent press release, Aug 13, 18] total fundung $200+M [crunchbase.com]

The FDA approved a cholera vaccine, Vaxchora, giving PaxVax (Redwood City, CA; $300K SBIR) its second commercial product. [Alex Lash, xconomy,com, Jun 17, 16]

Biotech company PaxVax (Redwood City, CA; 4300K SBIR, founded 2007) raised $105 million in funding to develop vaccines for diseases such as typhoid and cholera. Cerberus Capital Management led the funding and has acquired a majority economic interest in the company. ... manufactures and markets Vivotif, a typhoid vaccine which is currently licensed in 27 countries [Gina Hall, San Francisco Business Times, Dec 8, 15]

Vaccine maker PaxVax (Redwood City, CA; $300K SBIR), said it raised up to $50 million in debt financing and sold $12 million of its Series B stock. ... At the same time the firm said it acquired from Crucell an oral typhoid vaccine called Vivotif, which has been on the market for more than 20 years, as well as infrastructure and Crucell employees involved in the Vivotif business. PaxVax has a cholera vaccine in Phase 3 trials and aims to grow in the market aimed at travelers. [Alex Lash, xconomy.com, Jul 31, 14]

A single-dose experimental cholera vaccine from PaxVax (Redwood City, CA; $300K SBIR) passed a key test toward becoming the only vaccine for U.S. residents traveling abroad. .... was effective 10 days and 90 days after vaccination when compared against patients given a placebo in a late-stage trial. ... in December lined up $22 million in Series B financing and converted $35 million in debt to move forward with its clinical trials. [Ron Leuty, San Francisco Business Times, Jul 3, 14]

PaxVax, (San Diego, CA; no SBIR) startup backed by Seattle’s Ignition Capital, has raised $2 million of a planned $6 million investment round, according to a document filed with the [SEC]. ... founded in early 2007 to develop new oral vaccine technology based on a common cold virus called the adenovirus. [signonSanDiego, Nov 9, 09]

PDF Solutions (Pittsburgh, PA)

PDF Solutions (Pittsburgh, PA; $1.3M SBIR) up 26% [Nov 10, 21] reported third quarter financials engages in the provision of an end-to-end analytics platform that empowers engineers and data scientists across the semiconductor ecosystem [company website]

PDI Therapeutics (San Diego, CA)

Avalon Ventures and UK-based drug giant GSK said they have formed another San Diego biotech startup. ... PDI Therapeutics (named for the enzyme protein disulfide isomerase, La Jolla, CA) , will develop immunotherapies for cancer. Like all other companies formed under the three-year-old partnership, PDI will be housed at Avalon's COI Pharmaceuticals, an incubator that provides shared facilities and management. Meanwhile, Avalon said the first two companies created under the collaboration, Sitari Pharmaceuticals and Silarus Therapetics, have identified a clear path to potential drugs, thus meeting their first milestones, said Jay Lichter, an Avalon managing director and also COI's president and CEO. Sitari and Silarus are respectively developing drugs for celiac disease and iron overload disorders. ... GSK and Avalon established their partnership in April 2013, with up to $465 million from GSK and up to $30 million from Avalon to form up to 10 companies in San Diego. Up to $10 million in Series A funding is to be invested in each company to get it off the ground. ... The five other companies founded by the Avalon/GSK collaboration are Thyritope Biosciences, Adrenergics, CadheRx Therapeutics, Calporta Therapeutics, and Iron Horse Therapeutics. [Bradley Fikes, San Diego Union Tribune, May 20, 16]

PDL BioPharma PDLI

PDL Biopharma down 15% [Nov 23, 16]

PDL Biopharma down 18% [Nov 16, 16]

PDL BioPharma down 12% [Sep 17, 14]

PDL BioPharma (no SBIR) fell 32% [Mar 5, 08]. The biotechnology company abandoned plans to sell itself and said it will cut an additional 250 jobs in an effort to reduce costs. [Wall Street Journal, Mar 6]

PDS Biotechnology (North Brunswick, NJ)

PDS Biotechnology (Princeton, NJ; $1.8M SBIR) down 31% [Jun 5, 2023

PDS Biotechnology (Princeton, NJ; $1.8M SBIR) up 27% [May 26, 2023] announced promising interim data from the VERSATILE-002 (NCT04260126) Phase 2 clinical trial investigating PDS0101 in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with unresectable, recurrent or metastatic human papillomavirus (HPV)16-positive head and neck cancer. [company press release, May 25, 2023]

PDS Biotechnology (North Brunswick, NJ; $1.8M SBIR) down 20% [Jan 3, 2023] announced an exclusive global license agreement with Merck KGaA, Darmstadt, Germany for the tumor-targeting IL-12 fusion protein M9241 (formerly known as NHS-IL12), which will join the pipeline as PDS0301. M9241 appears to enhance the proliferation, potency and longevity of T cells in the tumor. The combination of Versamune® and IL-12 is patented by PDS Biotech and is designed to overcome tumor immune suppression utilizing a different mechanism from checkpoint inhibitors. ... Merck will receive an upfront cash payment of $5 million and will be entitled to up to $11 million in development and regulatory milestone payments including first commercial sales for the first 2 indications, and up to $105 million in commercial milestones, and a 10% royalty on future sales of M9241 with standard step-down provisions. Merck KGaA will receive 378,787 shares of PDS Biotech’s common stock having a value of $5 million [company press release, Jan 3, 2023]

PDS Biotechnology (North Brunswick, NJ; $1.8M SBIR) up 24% [Dec 28, 2022] announced expanded interim data in a Phase 2 clinical trial investigating the PDS0101-based triple combination therapy in advanced human papillomavirus (HPV)-positive cancers. The triple combination of PDS0101 with the tumor-targeting IL-12 fusion protein M9241 (formerly known as NHS-IL12), and bintrafusp alfa, a bifunctional fusion protein targeting two independent immunosuppressive pathways (PD-L1 and TGF-β), is being studied in CPI-naïve and CPI-refractory patients with advanced HPV-positive anal, cervical, head and neck, vaginal, and vulvar cancers. [company press release, Dec 28, 2022]

PDS Biotechnology (Princeton NJ; $1.8M SBIR) up 23% [Nov 15, 22]

PDS Biotechnology (Princeton NJ; $1.8M SBIR) up 26% [Nov 14, 22] reported 100% (9/9) showed clinical response (>60% tumor shrinkage at mid-point evaluation) [company press release, Nov 14, 2022]

PDS Biotechnology (Princeton, NJ; $1.7M SBIR) down 27% [May 31. 22] announced the acceptance of its Clinical Trial Application (CTA) from the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom (UK) to allow expansion of its VERSATILE-002 study of PDS0101 in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) to the UK. [company press relesase, May 31, 2022]

PDS Biotechnology (New Brunswick, NJ; $1.8M SBIR) up 53% [Feb 9, 21]

PDS Biotechnology down 28% [Jun 15, 21] announced that it has commenced an underwritten public offering of shares of its common stock. [company press release, Jun 14, 21]

PDS Biotechnology (New Brunswick, NJ; $1.8M SBIR) up 53% [Feb 9, 21]

Heat Biologics (Durham, NC; $300K SBIR) up 50% [Feb 9, 21] reported positive interim data of the Company's fully-enrolled Phase 2 trial of HS-110, in combination with Bristol-Myers Squibb's (BMS) OPDIVO(R) (nivolumab) in advanced non-small cell lung cancer (NSCLC). HS-110 is an "off-the-shelf" allogeneic cell-based therapy designed to activate patients' immune system against multiple cancer testis antigens to elicit a diverse and robust immune response against tumor cells. [company press release, Feb 9, 21]

PDS Biotech up 31% [Oct 3, 19] announced a modification of the clinical trial collaboration agreement with a subsidiary of Merck (known as MSD outside the United States and Canada) to evaluate the combination of PDS's lead Versamune(R) -based immunotherapy, PDS0101, with Merck's anti-PD-1 therapy, KEYTRUDA(R) (pembrolizumab), in a Phase II clinical trial. [company press release, Oct 3, 19]

PDS Biotechnology (Berkeley Heights, NJ; no SBIR) up 41% [May 15, 19] clinical-stage immuno-oncology company pioneering the development of multifunctional immunotherapeutic products, today announced a peer-reviewed publication supporting the novel mechanisms of action of its proprietary Versamune(R) platform in cancer immunotherapy. [company press release, May 15, 19]

An experimental head injury drug took Edge Therapeutics (Berkeley Heights, NJ; no SBIR) all the way to [2015 IPO]. But one failed clinical trial later and the company announced plans to merge with PDS Biotechnology (North Brunswick, NJ; $1.9M SBIR in various places), that is developing a group of cancer immunotherapies. [Ben Fidler, xconomy.com, Nov 26, 18]

Pearl Therapeutics (Redwood City, CA)

Clarus Ventures, which has backed some big Bay Area biotech M&A winners over the past year, is raising $375 million for a third fund, part of a $2 billion or more surge in life sciences VC funds over the past year. .... It invested in the East Bay's FerroKin BioSciences ($100K SBIR) which Shire bought in 2012 for up to $325 million, Redwood City respiratory disease drug developer Pearl Therapeutics (Redwood City, no SBIR), which AstraZeneca bought in June for $1 billion, and eye drug maker SARcode Bioscience (no SBIR) purchased a year ago by Shire for at least $160 million. It also has put money into up-and-comers like cancer drug developer Cleave Biosciences (Burlingame, no SBIR). [Ron Leuty, San Francisco Business Times, Feb 7, 14]

Respiratory disease business Pearl Therapeutics (Redwood City, CA; no SBIR) raised $15 million in loans that will be converted to equity in its next round of venture funding. [SEF Brown, San Francisco Business Times, Feb 2, 10]

[VC] firm Clarus Venures has invested in $18 M dollar financing of Pearl Therapeutics (no SBIR), a California-based biopharmaceutical company developing products for major respiratory diseases. ..... Pearl, founded in 2006, has raised $36 M of VC and other funding to date. Nektar Therapeutics (no SBIR) has licensed advanced particle technology to Pearl, and the company it is using to develop technology that will give patients and their health care providers a choice of formulations and dosage strengths of respiratory treatments. [Mass High Tech, Jul 7, 08]

Pear Therapeutics (Boston, MA)

Pear Therapeutics (Boston, MA; $1.6M SBIR) prescription digital therapeutics company, raised an additional $20M in equity, per an SEC filing [BostInno, Mar 3, 21]

“Digital therapeutics” startup Pear Therapeutics raised $64 million, a Series C financing that comes less than a month after the FDA cleared the company’s mobile app as a treatment for opioid abuse disorder. [Frank Vinluan, xconomy.com, Jan 4, 19]

Pear Therapeutics (Boston, MA; no SBIR) with offices in San Francisco, has received $20 million in series A funding ... for an an app could make subsrnce abuse therapy more effective. [Jessica Bartlett, Boston Business Journal, Feb 4, 16]

PECA Labs (Pittsburgh, PA)

The latest round of investments from the Open Field Entrepreneurs Fund is headed to six startup companies, all with Carnegie Mellon University ties. Includes PECA Labs (Pittsburgh, PA; no SBIR) developing a heart specifically designed for pediatric patients. Called the Masa Valve and going through FDA approval process. [Malia Spencer, Pittsburgh Business Times, Jan 7, 13]

Pediatric Bioscience (San Diego, CA)

Pediatric Bioscience (San Diego, CA; no SBIR, founded 2006) In a potentially major advance in diagnosing autism spectrum disorder, San Diego's Pediatric Bioscience is preparing to sell a blood test later this year that would detect risk of one of its most common forms. The company's test detects antibodies in a woman’s blood that can cause what it calls “maternal autoantibody-related” autism, which the company says, based on clinical studies, represents 23 percent of all autism cases. [Bradley Fikes, utsandiego.com, Jan 15, 15] is a specialty clinical diagnostic company that was formed by a group of researchers and experienced business leaders to identify and develop promising new discoveries in the field of autism [company website]

Peerless Technologies (Fairborn, OH)

Future Army contracts. The Army revealed a new roster of industry partners under a potential $37.4B contract that covers knowledge-based professional engineering support services to command, control, communications, computers, intelligence, surveillance and reconnaissance programs. SBIR companies: Artel (now big, $300K); Dynetics (now big, 31 awards); Macaulay-Brown (now big, 23 awards); NetCentric (now big, $900K); Scientific Research (Now big, $16M); Array Information Technology (one SBIR); Bennett Aerospace (21 SBIR awards); Envistacom (one SBIR); Fibertek (127 SBIRs); Future Technologies ($1M); Fulcrum ($1.2M); LinQuest ($1M); Manufacturing Techniques (One SBIR); Navmar Applied Sciences (68 awards); Peerless Technologies ($2.6M); Research Innovations (one SBIR); Sonalysts (128 awards); SURVICE Engineering (50 awards); Truestone (one SBIR).[GovConWire, Oct 19, 18]

Peerless Technologies (Beavercreek, OH; $2.6M SBIR) One of the fastest growing companies in the Dayton region was awarded a five-year [$24M] contract with the U.S. Air Force. [John Bush, Dayton Business Journal, Aug 21, 18]

Peerless Technologies [Fairborn, OH; $3M SBIR) will get as much as $53.7 million during the next four years to support Air Force Research Laboratory. [Joe Cogliano, Dayton Business Journal, Dec 25, 15] Is that a win for SBIR? The SBIR advocates will certainly claim so, but a real economist would look askance at such claims and ask how much political pressure was involved for a favored class. If they won the deal in open competition with no consideration of their sheltered class, OK. But it's not a new market and no new jobs, only shifting the supplier of what the government would buy anyway.

Peerless Technologies (Fairborn, OH; $2.5M SBIR) will get as much as $68 million during the next five years to support the F-22 program office at Wright-Patterson. ... will provide management and professional support services; engineering and technical services; and studies, analyses and evaluations to help the F-22 division to sustain and modernize the Air Force fleet. [Joe Cogliano, Dayton Business Journal, Jan 16, 15] Presumed innovation SBIRs lead to government support contracts, no new markets, nor new jobs, nor economic growth, just substutting for another company to perform the service. Not a market-failure.

Peerless Technologies (Fairborn, OH; $2.6M SBIR) has been selected for a $110 million deal with NASA, marking the biggest single contract the company's 14-year history. .... for the PACE IV, a five-year effort for professional, administrative, computational and engineering support, according to a statement on the General Service Administration's contractor Web site at FBO.gov. [Joe Cogliano, Dayton Business Journal, Feb 11, 14]

Pegasus Sustainability Solutions (Fitchburg, WI)

[Wisconsin]EDC certified four other companies to receive the tax credits They were: MPSP LLC, Milwaukee; HuTerra LLC, De Pere; and HealthMyne, Madison. Pegasus Sustainability Solutions, Fitchburg, was approved to receive the certification and a $125,000 loan. WEDC also said Tuesday that it has approved low-interest loans for two other emerging companies. Xolve , Middleton, will receive a $330,000 loan; and Shamrock Energy, Neenah, will get a $150,000 loan.[Kathleen Gallagher, Milwaukee Journal Sentinel, Jul 2, 13] None had SBIR.

Pelican Products (Torrance, CA)

Minnesota Thermal Science (Plymouth, MN; no SBIR; founded 2004), which once won the U.S. Army's Greatest Inventions Award for its gear that keeps blood fresh and usable, has been bought by storage-products company Pelican Products (Torrance, CA; no SBIR) .... Datamonitor Financial Deals Tracker valued the deal at $26 million. [Mark Reilly, Minneapolis / St Paul Business Journal, Jan 9, 13]

Pelican Therapeutics (San Antonio,TX)

Pelican Therapeutics, a biotech startup recently re-acquired by the company that founded it, is moving [from Austin] to San Antonio and receiving about $200,000 from the city’s government to do so. The San Antonio City Council approved a plan last week to give the grant to Pelican’s parent company, Heat Biologics (Durham, NC; $300K SBIR) as long as Pelican creates at least 22 new jobs in the next five years. [David Holley, xconomy,com, Sep 25, 17]

Pelican Therapeutics (Austin, TX; no SBIR, two employees) announced that it won a $15M from the Cancer Prevention and Research Institute of Texas (CPRIT). ... to develop agonists directed at TNFRSF25, a recently discovered T cell costimulator for immuno-oncology indications. TNFRSF25 antibodies have a distinct mechanism for preferential activation of the tumor cell-killing (CD8+) arm of the immune system, making TNFRSF25 a potential best-in-class target among peer programs targeting OX40, 4-1BB, GITR, CD40 & ICOS. [company press release, May 19, 16]

PellePharm (San Francisco, CA)

Danish dermatology specialists LEO Pharma and rare disease pioneers PellePharma (San Francisco, CA; no SBIR, founded 2012) announced a strategic development and commercialization collaboration to address unmet medical needs across various skin diseases with no approved treatments, advancing innovation and access to potential therapies for patients with life-altering conditions, such as Gorlin Syndrome and High Frequency Basal Cell Carcinoma (BCC), two distinct and rare forms of skin cancer. PellePharm and stockholders eligible to receive up to an aggregate of US$760 million including equity investment; development and commercialization support; merger consideration; and development, regulatory and commercial milestone payments [joint companies press release, Nov 20, 18] Pelle total prior funding $109M [crunchbase.com]

Pellion Tech (Cambridge, MA)

using the computational tools developed by his materials genome project,Pellion, a startup (Cambridge, MA; no SBIR), that he cofounded in 2009, has identified new cathodes for a magnesium-based battery. If it works, Ceder says, the batteries could have double or triple the energy density of today's lithium-ion batteries. [David Rotman, Technology Review, J/F12]

ARPA-E Awards. The administration announced $106M in ARPA-E stimulus awards. Small biz winners: Ginkgo BioWorks (Boston, MA; one SBIR) $6M primary; OPX Biotech (no SBIR) $6M primary; Logos Tech (Arlington, VA; $2M SBIR) secondary; Sion Power (Tucson, AZ; $250K SBIR) $5M primary; ReVolt Tech (no SBIR) $5M primary; PolyPlus Battery (Berkeley, CA; one SBIR) $5M; Pellion Tech (no SBIR) $3.2M primary; A123 Systems secondary, twice; Planar Energy Devices (no SBIR) $4M;Maxpower (Harleysville, PA; $9M SBIR) secondary; NanoLab (Newton, MA; $5M SBIR) secondary; Codexis (no SBIR) $4.6M; Nexant (no SBIR) secondary.

Peloton Therapeutics (Dallas, TX)

Peloton Therapeutics (Dallas and San Francisco; no SBIR) is targeting $115 million in its IPO, which will fund late-stage studies testing kidney cancer drug PT2977. [Alex Lash, xconomy.com, May 3, 19]

Peloton Therapeutics (Dallas TX; no SBIR), a drug discovery and development company focused on advancing first-in-class, small molecule cancer therapies, announced the completion of a $52.4 million Series D financing round ... “The company’s lead program targeting hypoxia-inducible factor-2α (HIF-2α) has generated exciting responses in patients with renal cell carcinoma, with potential applications in von Hippel-Lindau disease, glioblastoma multiforme and other diseases with high unmet medical need.” [company press release, Sep 15, 16]

Peninsula Pharmaceuticals

Adynxx (San Francisco, CA; no SBIR) has kept a low profile since its founding five years ago, but is discussing its work publicly today, announcing it has completed enrollment in its initial clinical trial of 30 healthy volunteers. ... supported by a Series A venture financing of $18 million from Domain Associates from 2010, is composed of people who worked together on a series of Domain-backed companies that were acquired, including Peninsula Pharmaceuticals (no SBIR), Cerexa (no SBIR), and Calixa Therapeutics (no SBIR). [Luke Timmerman, xconomy,com, Aug 7, 12]

PennAlt Organics (Pittsburgh, PA)

A newly formed life sciences company PennAlt Organics (Pittsburgh, PA; no SBIR) raised $6 million Series A financing round [Patty Tascarella, Pittsburgh Business Times, Oct 14] focuses on neurological disorders

Penumbra (Alameda, CA)

Penumbra (Alameda, CA; SBIR, founded 2004 ) up 38% [Sep 18, 15] past its [$120 million] IPO marks, with its stock jumping by nearly 38 percent on first day trading. [Cromwell Schubarth, Silicon Valley Business Journal, Sep 18, 15] designs and develops medical technology aimed at helping people who have suffered strokes and other neurovascular conditions. Among the company's products is the Penumbra System, which acts like a minimally invasive 'vacuum' inside the artery to quickly remove a blood clot from the brain. [San Jose Mercury News, Sep 18, 15]

Penumbra (Alameda, CA; no SBIR) medical device company has disclosed its IPO pricing to raise up to $122.4 million .... markets surgical access devices for neuro and peripheral vascular conditions and diseases. [Riley McDermid, Silicon Valley Business Journal, Sep 8, 15]

Penumbra (Alameda, CA; no SBIR, founded 2004) medical device developer wants to use a $115 million initial public offering to boost its product offerings, research and sales force.... its steady stream of revenue from catheters and coils that treat strokes, aneurysms and other vascular conditions make it a rarity. Most drug developers have longer timelines for bringing drugs to market, but medical device development can move much more quickly. [Ron Leuty, San Francisco Business Times, Aug 20, 15]

PepGen (Alameda, CA)

PepGen(Alameda, CA; $2.3M SBIR) down 17% [Jun 20, 2023]

PepGen (Alameda, CA; $2.3M SBIR) down 25% [Jun 9, 2023]

PepGen (Alameda, CA; $2.3M SBIR) up 20% [Mar 17, 2023]

PepGen down 24% [Sep 29, 2022]

PepGen (Alameda, CA; $2.7M SBIR) up 110% [Sep 28, 2022] announced results from its completed Phase 1 healthy normal volunteer (HNV) trial of PGN-EDO51, the company’s lead product candidate for the treatment of DMD patients whose mutations are amenable to an exon 51 skipping approach. ... announce that we have observed very high levels of oligonucleotide delivery and exon skipping in muscle in our Phase 1 HNV trial. [company press release, Sep 28, 2022]

Great Duchenne muscular dystrophy (DMD) therapies are just not getting enough medicine into the cells, and PepGen (Alameda, CA; $2.3M SBIR) hopes to change that thanks to a $112.5 million raise that will advance a new candidate into the clinic early next year. [Nick Paul Taylor, Fierce Biotech, Aug 5, 2021]

PeproMene Bio (Irvine, CA)

PeproMene Bio (Irvine, CA; no SBIR, founded 2016) with a blood cancer immunotherapy licensed from City of Hope, has received $40.2 million in investor funding. ... developing an investigational CAR-T therapy for the treatment of non-Hodgkin lymphoma [Dana Bartholomew. LA Business Journal, Jun 14, 18]

Peptilogics (Pittsburgh, PA)

Peptilogics (Pittsburgh, PA; no SBIR), a pre-clinical stage company utilizing an innovative peptide platform to treat multidrug-resistant bacterial infections, announced that it closed a $5.5 million Series A financing with participation from Peter Thiel, Stefan Roever, BlueTree Ventures and others. Peptilogics’ eCAP (engineered cationic antibiotic peptide) platform offers the prospect of a completely new class of antibiotics and has shown potent activity against a broad spectrum of resistant bacteria in multiple non-clinical models. [company press release, Sep 29, 17]

Peptilogics (Pittsburgh, PA; no SBIR, founded 2013), plans clinical trials in two years for a new class of antibiotics that attack bacteria in a different way when compared to conventional drugs, with the promise of fewer side effects and a longer-lasting solution. ... to commercialize novel ways of killing bacteria, especially kinds already resistant to antibiotics... University of Pittsburgh spinout ... Pharmaceutical industry veteran Rick Oleson is Peptilogics’ chief development officer. Oleson worked for 18 years at Cubist Pharmaceuticals Inc. where he was vice president of nonclinical development. Merck acquired Cubist in 2014 for $8.4 billion. [Matt Lepri, ideafoundry.org, Sep 28, 15]

Peptimed (Madison, WI)

PeptiMed (Jefferson, WI; no SBIR) raised $200,000 in equity funding from a single investor, according to [SEC] document. [Jeff Buchanan, xconomy.com, Jun 27, 16] ... one of the drugs it’s invented is aimed at treating various cancers—breast, prostate, lung, colon, ovarian, and skin—using ribonucleic acid interference (RNAi). [company website ]

Six young Wisconsin bioscience companies have been chosen by the state's biotech trade organization as emerging companies with good growth potential. The companies have all transitioned successfully out of research and development and are developing commercial products, said Bryan Renk, executive director of Fused Innocation (Neenah; WI) VibeTech (Sheboygan, WI); Somna Therapeutics (Germantown, WI); PatientWise (Middleton, WI); NanoOncology, a subsidiary of Peptimed (Madison, WI); PharmaSeek Financial Services (Middleton, WI). [Kathleen Gallagher, Milwaukee Journal Sentinel, Aug 30, 12] None had SBIR.

Peptimmune (Cambridge, MA)

Peptimmune (Cambridge, MA; one SBIR) announced today that it has granted drug maker Novartis an exclusive option to obtain exclusive worldwide rights to develop and commercialize Peptimmune's multiple sclerosis drug candidate. [Chris Reidy, Boston Globe, Jan 15] ... could net Peptimmune a half billion dollars and more. [MHT, Jan 16, 09]

Biotechnology companies in the United States are raising less cash than they have in a decade, in part because of the global economic crisis. The reductions have led to bankruptcies and threaten development of drugs based on biomedical breakthroughs. ... Twenty-five percent of the 370 public U.S. biotechnology companies have less than six months of cash, according to data compiled by the Biotechnology Industry Organization, a trade group in Washington. .... Among others,Peptimmune (Cambridge, MA; one SBIR), a 6-year-old firm, said it is struggling to pay for clinical trials of its multiple sclerosis drug. ... cut its staff more than half, to 22 people; moved to smaller offices to conserve the $6.5 million it has on hand; and is delaying research on drugs for Alzheimer's disease and Parkinson's disease, chief executive Thomas Mathers said. .... On Nov. 10, MicroIslet (San Diego, CA; $1.8M SBIR) developer of diabetes treatments, and Accentia BioPharmaceuticals (Tampa, FL; no SBIR) sought bankruptcy protection to reorganize, each citing an inability to raise money. [David Olmos and Rob Waters, Bloomberg News, Dec 1, 08]

Peptimmune (Cambridge, MA; one SBIR) reports it has landed $8.9 million in a second close of a Series D preferred stock offering. [Mass High Tech, Jul 17, 08]

Peptimmune (Cambridge, MA; one SBIR a decade ago) closed on an $8.2 M first tranche of a Series D funding ... to advance clinical development of Peptimmune's multiple sclerosis treatment, PI-2301 [Mass High Tech, Jan 17]

Perceptive Navigation (Baltimore, MD)

Perceptive Navigation (Baltimore, MD; no SBIR, founded 2012) looking to raise $4M [Baltimore Business Journal, Mar 6, 18] ... total funding to date $1M core technology provides for an image-guided interventional device [crunchbase.com]

medical device startup Perceptive Navigation (Baltimore, MD; no SBIR) raised $500,000 toward securing federal regulatory approval for its ultrasound device. ... developing an invasive ultrasound device with imaging technology on its tip. [Sarah Gantz, Baltimore Business Journal, Aug 26, 15]

Perceptive Sciences (Austin, TX)

They're trained to know when you're fooling yourself, and by identifying that in their subjects they can help clients get better feedback to develop better products..... Perceptive Sciences (Austin, TX; one SBIR) with an academic approach to product testing, market research and user experience. ... About a third of Perceptive's work focuses on Web sites, a third on software and a third on gadgets. [Dan Zehr, Austin American Statesman, Mar 3]

Perceptron (Plymouth, MI)

Perceptron down 27% [Jul 15, 20]

Perceptron (Plymouth, MI; one SBIR in 1987) up 112% [Jul 14, 20] a leading global provider of 3D automated in-line measurement solutions and coordinate measuring machines, announced that a global, Tier-1 automotive supplier has selected Perceptron's in-line measurement technology to measure the battery frame, compartment, and lid for an upcoming new electric vehicle launch. [company press release, Jul 13, 20]

Perceptron (Plymouth, MI; one SBIR) up 11% [Feb 10, 14]

Perceptron down 10% [Jan 24, 14]

Perceptron up 23% [Jan 10, 14] announced that, starting in March 2014, it expects to begin shipping 45 inline gauging systems to a premium German automotive manufacturer. [Market Wired, Jan 9]

Perceptron (Plymouth, MI; one SBIR, 229 employees) down 10% [Feb 13, 13]

Perceptron (Plymouth, MI; one SBIR) up 10% [Jan 9, 13]

PercipEnz Technologies (Madison WI)

Three [Wisconsin] angel investment groups have banded together to put more than $1 M into a Madison software company [PercipEnz Technologies; $1.6M SBIR] aiming to dramatically expand its clinical data management business. This is the first time several of the groups involved did their due diligence and negotiated terms together, "and that bodes well for bigger deals in Wisconsin," said Charles Goff, general partner of Appleton-based NEW Capital Fund. [Kathleen Gallagher, Milwaukee Journal-Sentinel, Aug 22]

Peregrine Semiconductor (San Diego, CA)

Perigrine Semiconductor (San Diego, CA; $3.7M SBIR) down 16% [Feb 4, 14]

Peregrine Semiconductor (San Diego, CA; $3.7M SBIR) down 11% [Sep 20, 13]

PeriphaGen (Pittsburgh, PA)

PeriphaGen (Pittsburgh, PA; no SBIR) a life sciences company has closed on $6.5 million [capital raise] ... for product development and hiring ... originally Nurel, a University of Pittsburgh spinout that was acquired by a Stockholm-based medical company, Diamyd Medical AB, in 2006. In October 2012, a management group bought the business from Diamyd. [Patty Tascarella, Pittsburgh Business Times, Apr 1, 14]

Permeon Biologics (Cambridge, MA)

Biotech startup Permeon Biologics (Cambridge, MA; no SBIR) has taken in $2.5 million in an equity and debt financing round .... looking to develop therapies based on the discovery of a class of proteins that will allow protein-based therapies otherwise too complex to finally get inside a cell wall. The company was founded by Harvard University professor and Howard Hughes Medical Institute investigator David R. Liu, also the founder of Ensemble Therapeutics (no SBIR). [Rodney Brown, Mass High Tech, Dec 30, 11]

Perosphere (Danbury, CT)

Perosphere Pharmaceuticals (Danbury, CT; no SBIR) and its lead compound ciraparantag, a drug developed to reverse the effects of blood thinners, depending on the progress of the Phase 2 drug, shareholders could earn up to $140 million more in milestones. [Frank Vinluan,xconomy.com, Dec 14, 18]

Perosphere (Danbury, CT; no SBIR), a small pharmaceutical company, borrowed $1.5 million from Connecticut Innovations [from CI's Bio-Facilities Fund, established in 1998. [which] has spent more than $40 million] .... looking to improve the drug delivery methods for drugs already on the market, but also is working on new indications for already approved drugs, such as seeing if an anticonvulsant can be administered in such a way that it could reduce brain cell damage after a heart attack, stroke, or traumatic brain injury . It also is working on developing fast-acting rescue drugs. The company's lead drug candidate, a reversal agent for anticoagulants, is in Phase II clinical trials. [Mara Lee, Hartford Courant, Jul 7, 14]

Perscitus Biosciences (Madison WI)

The Wisconsin Department of Commerce has qualified two biotech companies to receive investor tax credits, the agency said Thursday. Perscitus Biosciences LLC, Madison, is developing a molecule that has shown an ability to protect healthy human cells against the harmful effects of chemotherapy and radiation. HTSS LLC, Milwaukee, is developing a technology that analyzes muscle activity to help reduce injuries during exercise regimens. Certain investors in both companies are now eligible to claim tax credits under legislation known as Act 255. [Milwaukee Journal-Sentinel, Jun 27] No SBIR.

Perseon (Salt Lake City, UT)

Galil Medical (St Paul, MN; no SBIR, founded in Israel, under 100 employees) said it's reached a deal to buy Perseon (Salt Lake City, UT; no SBIR) for $10.6 million in a deal that will take the publicly traded Perseon private. ... Galil, which makes needles that deliver super-chilled gas to freeze and destroy cancer tumors, said in its announcement that the acquisition of Perseon is contingent on Galil raising $26 million in new debt and equity. ... Perseon also specializes in cancer-destroying tech, but it uses microwave heat therapy. [Mark Reilly, Minneapolis / St. Paul Business Journal, Oct 27, 15]

Persimmon Technologies (Wakefield, MA)

Persimmon Technologies (Wakefield, MA; no SBIR, founded 2010) has added $1.5 million to a round of investment first announced more than a year ago .... provides vacuum robotics for the semiconductor, flat-panel display and solar markets [Don Seiffert, Boston Business Journal, Mar 4. 14]

The CEO of Persimmon Technologies (Wakefield, MA; no SBIR) says that a $5.8 million round of Series B funding will go toward development of its hybrid-field motor technology as well as expansion of its manufacturing facility for vacuum robotics.[Don Seiffert, , Boston Business Journal, Jan 14, 13]

Persimmon Technologies (Wakefield, MA; no SBIR, founded 2010) which provides motor technology and robotics for the semiconductor, solar, LED and flat-panel display equipment markets, received a $500,000 Phase II NSF SBIR to develop soft magnetic material for use in electric motors. ... In March, received $2 million in equity financing, [Don Seiffert, Mass High Tech, Nov 30, 12]

Persimmon Technologies (Wakefield, MA; no SBIR, founded 2010) which provides direct drive vacuum robotics, has received $2 million in equity financing, according the federal documents. ... [company's] website says it is the developer, manufacturer, and distributor of atmospheric and vacuum robotics, vacuum modules, and automation systems for a range of industries, including semiconductor, data storage, LED, OLED, solar and flat panel display equipment markets. Its goal is to be the largest vacuum robotics company serving the semiconductor, LED and solar markets by 2020. [Don Seiffert, Mass High Tech, Mar 21, 12]

PersonalBee

Technorati agreed to acquire fledgling startup Personal Bee [which] developed a service for people to collect and publish news, information, and entertainment. [RedHerring.com, Apr 13]

Personalis (Menlo Park, CA)

Personalis (Menlo Park, CA; no SBIR), a startup that provides exome and genome sequencing and interpretation, has completed a $33 million Series C financing round. ... will use the funding to scale up operations. [Gina Hall, Silicon Valley Business Journal, Jan 13, 15]

Personalis (Menlo Park, CA; no SBIR) , a startup that provides exome and genome sequencing and interpretation, raised $22 million in Series B funding. .... brings the total raised to more than $42 million. .... to expand its commercial team further, including in Asia. .... The company said that since its first customer purchase 13 months ago it has received more than $14 million in orders to sequence and analyse more than 7,000 human samples. [Cromwell Schubarth, Silicon Valley Business Journal, Oct 6, 13]

Personal Genome Diagnostics (Baltimore, MD)

Labcorp, a leading global life sciences company, announced that it has entered into a definitive agreement to acquire Personal Genome Diagnostics (PGDx), (Baltimore MD; $900K SBIR) a leader in cancer genomic with a portfolio of comprehensive liquid biopsy tissue-based products. ... Labcorp will pay $450M in cash at closing and up to an additional $125 million on achieving future performance milestones [Labcorp press release, Dec 23, 2021]

Personal Genome Diagnostics (Baltimore, MD; $900K SBIR) has agreed to be acquired by [Labcorp] one of the world's largest life sciences companies in a deal that could pay up to $575 million. [Holden Wilen, Baltimore Inno, Dec 23, 21]

Personal Genome Diagnostics (Baltimore, MD; $1M SBIR) looks to raise $3.5M following FDA clearance for cancer diagnostics tech [Morgan Eichensehr, Baltimore Business Journal, May 27, 20]

No happy early morning in America. The U.S. economy could take the better part of a decade to fully recover from the coronavirus pandemic and related shutdowns. [Congressional Budget Office, Jun 1, 20]

Personal Genome Diagnostics [PGDx] (Baltimore, MD; $900K SBIR, founded 2010) developing in vitro diagnostic (IVD) genome testing, or tests that can be used to analyze the DNA of tumors, to cancer patients worldwide raised $42M. [Morgan Eichensehr, Baltimore Business Journal, Oct 5, 18] total previous funding $99M [crunchbase.com]

Personal Genome Diagnostics (Baltimore, MD; no SBIR, founded 2010) cancer diagnostics company raised $75 million [led by Bristol-Myers-Squib] to expand access to genomic testing for cancer patients. [company press release, Jan 3, 18]

Personal Genome Diagnostics (Baltimore, MD; no SBIR, 21 employees) raised $4.32 million [Series A] ... Using gene research from Johns Hopkins University, Personal Genome Diagnostics analyzes the DNA of tumors to better diagnose cancer. The company in May released its newest test, ImmunoSelect-R, which will be used to develop cancer therapies that stimulate and strengthen the patient’s immune system to fight cancer. [Sarah Gantz, Baltimore Business Journal, Jun 5, 15]

Personal Genome Diagnostics (Baltimore, MD; no SBIR, launched in 2010 and has 19 employees) closed a $2.8 million fundraising round to help propel the firms research into tumor DNA. ... is commercializing Johns Hopkins gene research to use as tests that can help evaluate tumors during cancer treatment. .... recently launched its first commercially available test, METDetectTM, which is a less invasive alternative to a tumor biopsy. [Sarah Gantz, Baltimore Business Journal, Apr 3, 14]

Pervasis Therapeutics (Cambridge, MA)

Pervasis Therapeutics (Cambridge, MA; no SBIR) raised $10 million out of a $17 million third round of financing. ... focuses on creating cell-based compounds and devices. It is also exploring technology in non-vascular applications, such as bone and joint repair, wound healing and inflammation. [Julie Donnelly, Mass High Tech, Sep 16, 09]

Pervasis Therapeutics (Cambridge, MA; no SBIR) secured $9.75M in additional financing. ...focuses on regenerative cell-based therapies and devices [Boston Globe, Jan 16]

Pervasis Therapeutics (Cambridge, MA; no SBIR), developer of cell-based therapies and devices, reports it has nabbed a $9.8M tranche of Series B financing ... founded 2004 [Mass High Tech, Jan 15]

Pervasive (San Diego, CA)

a new semiconductor startup, courtesy of venture funding from the Bay Area. Pervasive, (San Diego, CA; no SBIR) a fabless semiconductor design company that is focused on smart grid applications, raised $6 million from investors, according to a recent filing with securities regulators. [Bruce Bigelow, signonsandiego.com, Jun 17, 10]

Petra Pharma (NYC,NY)

Seattle’s Accelerator Corp. made its long-awaited splash in New York last week with its first Manhattan biotech startup, Petra Pharma (NYC, NY; no SBIR). Now here comes Lodo Therapeutics (NYC, NY; no SBIR), Accelerator’s second startup, right in Petra’s wake [with $17M]. Lodo didn’t get the big $48 million round that Petra did last week. But the startup, built around the work of Rockefeller University researcher Sean Brady, got a respectable $17 million Series A round and, what’s more, some of that money comes from The Bill & Melinda Gates Foundation—which has over the past few years increasingly sought to back biotech startups that align with its mission of improving global health. [Ben Fidler, xconomy.com, Jan 10, 16]

Pfenex (San Diego, CA)

Pfenex (San Diego, CA; no SBIR), an early-stage biotech specializing in biosimilars, aims to price its stock at $12 to $14 a share in an IPO that could arrive next week, according to a regulatory filing. Pfenex was spun out of Dow Chemical, currently its largest shareholder, to advance technology that uses a fluorescing microbe in a fermentation process to make a variety of protein biotherapeutics, including drugs, vaccines, and diagnostic reagents. [Alex Lash, xconomy.com, Jul 10, 14]

Pfenex (San Diego, CA; no SBIR, founded 2009), a Dow Chemical spinoff developing a drug for retinal diseases, filed with the SEC Thursday to raise $74.8 million in [IPO] .... Pfenex's technology was originally developed at Mycogen (San Diego, CA; no SBIR), biotech later purchased by Dow. [Bradley Fikes, utsandiego.com, Jun 5, 14]

Elevation Pharmaceuticals (San Diego, CA; no SBIR, founded 2008) startup developing aerosol-based treatments for respiratory diseases, said it has raised a tranched $30 million in Series A venture funding. It’s a sizable round for the [San Diego] life sciences community, but other recent fundings have come close. Last month, VentiRx (no SBIR) raised $25 million, Pfenex (no SBIR) got $24 million, and Zogenix (no SBIR) got $20 million. [Bruce Bigelow, signonsandiego.com, Mar 8, 10]

Pharmacyclics (Sunnyvale, CA)

U.S.-China biotech Xynomic Pharma has raised additional funding to take an HDAC inhibitor in-licensed last year into seven new cancer trials. The company hasn’t revealed the amount of the series B financing but says it will be enough to start trials of abexinostat—originally developed by Pharmacyclics (Sunnyvale, CA; one SBIR) - in blood cancers and solid tumors over the next 12 months. It will also fund initial clinical testing of XP-102, a pan-RAF inhibitor licensed from Boehringer Ingelheim in a $502 million deal last November, in colorectal cancer and melanoma. [Phil Taylor, Fierce Biotech, Jun 1, 18]

Pharmacyclics up 17% [Feb 25, 15]

Pharmacyclics (Sunnyvale, CA; one SBIR, market cap $9.3B) up 16% [Jan 13, 15]

Pharmacyclics (one SBIR) up 15% [Jul 29, 14]

More capitalism competition - for new ideas. How J&J and Dr. Lebowitz homed in on the California prospect and recruited its maker, Pharmacyclics (Sunnyvale, CA; one SBIR in 1995, market cap $10B) reflects a shift in how big drug companies find new medicines. .... the scouting kicked into higher gear. J&J scientists would get to know counterparts at companies on their Bullseye charts, building relationships at medical meetings and other venues. Sometimes, a J&J scientist might talk with a prospect for months—even years—before raising the issue of a deal. .... its drug hunters flew to Europe to woo the drug [daratumumab]'s [Danish maker. .... in 2013, it bought Aragon Pharmaceuticals (no SBIR), which has a potential prostate-cancer treatment that is in clinical trials. [Jonathan Rockoff, Wall Street Journal, Mar 9, 14]

A step toward European approval of the blood cancer drug Imbruvica will net Pharmacyclics (one SBIR in the 1990s) a $50 million payment from partner Johnson & Johnson. .... on top of $60 million that Pharmacyclics, led by CEO Robert Duggan, earned from Janssen Biotech Inc. when the Food and Drug Administration last week approved Imbruvica for mantle cell lymphoma patients previously treated with other drugs. The company received another $75 million from Janssen Biotech in September, when the FDA accepted Imbruvica's application. [Ron Leuty, San Francisco Business Times, Nov 20, 13]

Pharmacyclics up 12% [Jun 10, 13]

With a promising drug that could be an alternative to chemotherapy, Pharmacyclics (Sunnyvale, CA; one SBIR in 1995) has seen a meteoric rise. [Diana Samuels, Silicon Valley / San Jose Business Journal, Nov 23, 12]

Pharmacyclics (Sunnyvale, CA; one SBIR two decades ago) has seen its stock quadruple from the beginning of this year. The company has boomed on growing evidence that supports its new drug for blood cancers, ibrutinib, which is designed to selectively block a molecular target called Bruton’s tyrosine kinase (Btk). [Luke Timmerman, xconomy.com, Jul 9 ,12]

Pharmacyclics up 17% [Feb 13, 21]

Pharmacyclics up 17% [Feb 10, 12]

Pharmacyclics up 13% [Feb 9, 12]

Pharmacyclics down 15% [Dec 9, 11]

Pharmacyclics down 12% [Aug 4, 11]

Pharmacyclics up 11% [Jun 10, 10]

Pharmacyclics up 12% [May 10, 10]

Pharmacyclics down 14% [May 7, 10]

Pharmacyclics up 14% after announcing data from two preclinical studies. [Apr 18, 07]

Hope for FDA reconsideration of Pharmacyclics case had a bad day as the stock dropped 11%.[Apr 10, 07]

Pharmacyclics up 15% after asking the FDA that its new drug application for a cancer treatment be filed over protest. [Apr 5, 07]

Pharmacyclics dropped 37% after announcing that the FDA rejected a marketing application for the company's drug to treat lung cancer that has spread to the brain. [Feb 21, 07]

PharmaJet (Golden, CO)

[FDA] OK'd the use of PharmaJet (Golden, CO; no SBIR) needle-free injectors for flu shots, giving the company its best chance to break into the domestic market for vaccine delivery. ... the first FDA approval for a needle-free injection for a flu virus vaccine, freeing PharmaJet to create a market among the 150 million people who get flu vaccinations annually in the U.S. [Greg Avery, Denver Business Journal, Aug 19, 14]

PharmAkea Therapeutics (San Diego, CA)

PharmAkea Therapeutics (San Diego, CA; no SBIR) raised $45 million from venture capital and biotech investors. ..... to develop drugs for cancer and fibrotic diseases. ...... Celgene is contributing $35 million of the total [Bradley Fikes, utsandiego.com, Oct 18, 13]

Pharmasphere (Boston, MA)

[Massachusetts] has rescinded $360,000 in tax credits to a fledgling biotechnology company PharmaSphere (Boston, MA; no SBIR) that misled officials about the size of its workforce, the first time such an award has been revoked. ... has been struggling to raise the $6.5 million in private financing it needs for the project, has yet to receive any of the promised public money. ... claimed on the application that it had 11 to 50 employees. The company later acknowledged it never had those workers. [Todd Wallack, Boston Globe, Dec 25, 10]

Pharmasset

OnCore Biopharma (Doylestown, PA; no SBIR) biopharmaceutical company seeking to develop a cure for hepatitis B, is merging with Tekmira Pharmaceuticals (Canada) .... founded in 2012 by the group at Pharmasset (led by Mike Sofia) that developed Sovaldi, a drug now used as part of a combination therapy to cure hepatitis C. Pharmasset was acquired by Gilead Sciences (NASDAQ: GILD) for $11.5 billion in early 2012. ... will focus on developing a "curative regimen" for hepatitis B patients by combining multiple therapeutic approaches. [John George, Philadelphia Business Journal, Jan 12, 15]

Later this year [FDA] is expected to approve a new pill that can cure hepatitis C—a chronic infection that afflicts about 170 million people worldwide and annually kills 350,000 people, including 15,000 in the U.S.—faster and with fewer side effects than current remedies [for $84000 per case]. ... Pharmasset (Princeton, NJ; $2M SBIR in Georgia 2000-2003, founded 1998) had been looking at a group of drugs known as nucleotide analogues, which met some of these criteria, since the mid-2000s. ... Researchers then ran into a few big biochemical problems. ... Michael Sofia, then at Pharmasset, solved the problems by adding two compounds known as esters to the analogue. ... The new formulation was named sofosbuvir in Sofia's honor; the company was purchased, in 2011, by Gilead for $11 billion. [Jessica Wapner, Scientific American, Aug 19, 14]

Gilead announced a roughly $10.4 billion deal to buy Pharmasset (Princeton, NJ; $2M SBIR 2000-2003 in Georgia),[up 85%] a company that doesn’t yet have meaningful revenue but is developing treatments for hepatitis C.[Shira Ovida, Wall Street Journal, Nov 21. 11] HHS has another big econonmic SBIR story. Would that the other agenices could be so smart in picking techologies and companies with a future.

Pharmasset down 12% [Nov 4, 11]

Pharmasset up 15% [Aug 9, 11]

Pharmasset up 10% [Jun 8, 11] on encouraging clinical data, it plans to test its hepatitis C treatment PSI-197 as a stand-alone therapy. Pharmasset is currently testing PSI-197 in combination with peginterferon and ribavirin, two standard treatments for the chronic liver disease. [MarketWatch, Jun 8]

Pharmasset up 12% [Apr 5, 11]

Pharmasset up 10% [Mar 31, 11]

Pharmasset up 24% [Mar 7, 11]

Pharmasset up 10% [Mar 16, 10]

Pharmasset down 10% [Apr 30, 09]

Pharmasset up 11% [Apr 29, 09]

Pharmasset down 10% [Apr 20, 09] stopped development of Clevudine for hepatitis B in the wake of side effects in long-term users in South Korea, where it already is sold. [Wall Street Journal, Apr 21]

Pharmasset up 10% [Apr 8, 09]

Pharmasset up 11% [Mar 26, 09]

Pharmasset up 12% [Mar 17, 09]

Pharmasset up 14% [Mar 23, 09]

Pharmasset up 12% [Mar 12, 09]

Pharmasset up 15% [Mar 3, 09]

Pharmasset down 19% [Feb 25, 09]

Pharmasset up 15% [Oct 16, 08]

Pharmasset up 15% [Oct 14, 08]

Pharmasset up 26% [Oct 13, 08]

Pharmasset down 12% [Oct 10, 08]

Pharmasset up 10% [Mar 13, 08]

Pharmasset up 17% [Jan 16, 08]

Pharmasset up 12%. [Jan 15, 08]

Pharmasset up 33% [Jan 8, 08] after the company announced positive data from a short-term early stage study on its hepatitis C candidate, R7128

Pharmasset rose 14% after saying it will receive a $7.5M payment from Roche for a collaboration on hepatitis C treatment research

Pharmasset which IPO'd Apr 27,07 is holding its price. 14 HHS SBIR Phase 1s over $100K.

PharmAthene (Annapolis, MD)

PharmAthene (Annapolis, MD; no SBIR) a clinical-stage bio-defense company, announced it has scrapped a planned merger with Theraclone Sciences (Seattle, WA; no SBIR) .... days after Theraclone disclosed that the Biomedical Advanced Research and Development Authority (BARDA) had declined to fund clinical trials for one of its product candidates [Bill Flook, Baltimore Business Journal, Dec 2, 13]

Theraclone Sciences (Seattle, WA; no SBIR, 34 employees) plans to combine with a publicly traded biotech PharmAthene (Annapolis, MD; no SBIR, 50 employees) in a merger of equals ... Theraclone is developing disease-specific antibodies to fight cancer and serious infectious diseases, while PharmAthene is a biodefense company focused on anthrax and chemical nerve agents. [Seattle Times, Aug 1, 13]

Biodefense company PharmAthene (Annapolis, MD; no SBIR) could get $100 million in damages following a decision by the Delaware Supreme Court that Siga Technologies acted in bad faith by backing out of a proposed licensing agreement for its smallpox treatment medication to be used in response to a biochemical attack, the Daily Record reported. [Baltimore Business Journal, May 30, 13]

PharmatrophiX (Chapel Hill,NC)

PharmatrophiX (Chapel Hill,NC; no SBIR, founded 2005), a small drug developer working toward therapies for Alzheimer’s disease, recently raised more than $5 million of a $9.5 million round.[Jason deBruyn, Triangle Business Journal, Jul 18, 14]

PhaseBio Pharmaceuticals (Malvern, PA)

PhaseBio Pharmaceuticals (Malvern, PA; $3.5M SBIR) filed for chapter 11 bankruptcy protection weeks after being sued for breach of contract by a Blackstone Inc. portfolio company. The chapter 11 filing follows the breakdown in a three-year partnership between PhaseBio and Blackstone’s SFJ Pharmaceuticals X Ltd. to develop Bentracimab, which helps prevent major bleeding for patients on a blood thinner. [Jodi Xu Klein and Becky Yerak, Wall Street Journal, Oct 24, 2022]

PhaseBio had already shown its Brilinta reversal agent could work in healthy volunteers, but now the biotech has the phase 3 data to back up the therapy's use in patients who are in an emergency situation. [Emmy Lucas, Fierce Biotech, Nov 15, 2021]

PhaseBio (Malvern, PA; $3.6M SBIR) announced iachieved its primary endpoint and topline data from its Phase 2b clinical trial of bentracimab, which was conducted in healthy, older volunteers 50-80 years old. [company press release Nov 3, 21]

PhaseBio Pharma (Malvern PA; $3.6M SBIR) is signing a manufacturing partner for its Brilinta reversal agent as it ushers the drug through phase 3 and, it hopes, FDA approval. [Amirah Al Idrus, Fierce Biotech, Mar 11, 21]

TransEnterixup 38% [Feb 10, 21]

PhaseBio Pharmaceuticals up 17% [Jul 17, 20]

Phasebio Pharma up 36% [May 28, 20] receives clearance of IND application from U.S. FDA under Coronavirus Treatment Acceleration Program (CTAP) "VANGARD" trial will assess the efficacy and safety of PB1046 in hospitalized COVID-19 patients at high risk for rapid clinical deterioration and acute respiratory distress syndrome Based on FDA feedback, PhaseBio believes that positive, clearly interpretable and clinically meaningful trial results may enable PhaseBio to submit a Biologics License Application [company press release, May 27, 30]

PhaseBio Pharma up 26% [Apr 14, 20]

PhaseBio Pharmaceuticals up 30% [Dec 19, 19]

Phase Bio up 24% [Sep 25, 19] announced the completion of its Phase 2a clinical trial of PB2452. Full data from the trial are planned to be presented at an upcoming medical congress. In the trial, PB2452 achieved immediate and sustained reversal of ticagrelor in older (ages 50-64) and elderly (ages 65-80) subjects on dual antiplatelet therapy of ticagrelor and low-dose aspirin. PB2452 was generally well tolerated, with only minor adverse events reported. [company press release, Sep 24, 19]

Phase BioPharma down 19% [Sep 6, 19]

PhaseBio Pharmaceuticals down 15% [Sep 3, 19]

PhaseBio Pharma up 17% [Aug 28, 19]

PhaseBio Pharma down 11% [Apr 10, 19]

PhaseBio Pharma up 16% [Apr 9, 19]

PhaseBio Pharma up 17% [Apr 8, 19]

Phase Bio Pharma up 30% [Apr 1, 19]

Phase Bio Pharma up 67% [Mar 18, 19]

PhaseBio Pharma down 16% [Dec 19, 18]

PhaseBio Pharma up 18% [Dec 6, 18]

PhaseBio Pharmaceuticals (Malvern, PA; no SBIR, founded 2002) focused on the development and commercialization of novel therapies for orphan diseases, with an initial focus on cardiopulmonary disorders, announced the completion of a $34 million Series D financing [company press release, Sep 5, 18] total funding $140M [crunchbase.com]

PhaseBio Pharmaceuticals (Malvern, PA; no SBIR) developing therapies for the treatment of orphan diseases, today announced that the Company has been awarded a $2.8 million [NIH] Fast Track SBIR to support the clinical development of PB1046, a first-in-class, sustained-release vasoactive intestinal peptide (VIP) analogue, in patients with pulmonary arterial hypertension (PAH). [company press release, Feb 27, 18]

PhaseBio Pharmaceuticals (Malvern, PA; no SBIR) developing therapies for the treatment of orphan diseases, today announced that the Company has secured $15.6 million in funds to support the clinical advancement of its expanded pipeline. [company press release, Nov 29, 17]

PhaseBio Pharmaceuticals (Malvern, PA; no SBIR), a clinical-stage biopharmaceutical company developing therapies for the treatment of orphan diseases, announced that the Company has entered an exclusive, worldwide license agreement with MedImmune, the global biologics research and development arm of AstraZeneca, for PB2452 (formerly MEDI2452), a Phase 1-ready reversal agent for ticagrelor. [company press release, Nov 28, 17]

PhaseBio Pharmaceuticals (Malvern, PA; no SBIR) biopharmaceutical company working on a once-weekly insulin treatment for diabetics, raised $40 million [series C financing... led by AstraZeneca] in a private stock sale. ... to conduct mid-stage clinical testing of its once-weekly insulin treatment, PE0139, in patients with type-2 diabetes. [John George, Philadelphia Business Journal, Mar 12, 15]

PhaseBio Pharmaceuticals (Durham, NC; no SBIR) raised $25 million in a series B round of financing, the company announced ... developing therapies based on its proprietary technology with proteins that can be used to enhance the delivery of therapeutic drugs. [Triangle Business Journal, Jan 7, 10]

PhaseBio Pharmaceuticals (Malvern, PA; no SBIR) entered into a deal giving the exclusive rights to its drug-delivery technology for use in treating cancer to Duke University. PhaseBio retained development and commercialization rights to all other applications of its elastin-like polypetide [ELP] technology platform. [John George, Philadelphia Business Journal, Mar 25, 16]

PhaseBio Pharmaceuticals (Morrisville, NC; no SBIR) has raised about $8 million to date in two rounds of financing [Triangle Business Journal, Nov 13, 09]

Phase Bioscience (Durham,NC)

Phase Bioscience (Durham NC: $200K SBIR)raised $6.6M in its most recent round of financing. [Raleigh News&Observer, Oct 25]

Phase Genomics (Seattle, WA)

Phase Genomics (Seattle, WA; $7.7M SBIR) landing $2.5 million in new grant money ... will help the company target acute myeloid leukemia and colorectal cancer with its genome sequencing technology [Rick Morgan, Seattle Inno, Aug 9, 2023]

PhaseRx (Seattle, WA)

PhaseRx sold to Swiss buyer in bankruptcy case; went public in May 2016 and filed for Chapter 11 bankruptcy protection in December 2017 [Casey Coombs, Puget Sound Business Journal, Feb 5, 18]

PhaseRX (Seattle, WA; no SBIR, IPO 2016) filed for bamkruptcy [Seattle Times, Dec 12, 17]

PhaseRx up 14% [May 26, 16]

PhaseRx (Seattle, WA; no SBIR) filed for IPO [Seattle Times, Apr 18, 16] biotechnology company focused on developing mRNA therapeutics to treat orphan liver diseases [company website]

PhaseRx (Seattle, WA; no SBIR) got a $1.5M venture round ....developing therapies via sIRNA technologies. [xconomy.com,Dec 26, 12]

Phoenix Analysis and Design Technologies (Tempe, AZ)

Phoenix Analysis and Design Technologies (PADT) (Tempe, AZ; $4.5M prior SBIR) announced NASA has awarded a $755,000 Phase II STTR to collaborate with Arizona State University (ASU) and Kennesaw State University (KSU, Georgia) to enable the development of stronger and lighter structures for space exploration. ... to develop a software tool for designing, virtually testing and optimizing strong, lightweight lattice structures for aerospace vehicles. The result will be a commercial software product that PADT plans to market. [company press release, Dec 10, 19] How nicely utilitarian and presumably low tech risk in the hands of experienced engineers. The Congresscritter will no doubt applaud as innovation is whatever the company and the federal agency say it is.

Phenomix Sciences (Rochester,MN)

A Mayo Clinic early stage startup focused on personalizing chronic disease treatment has launched its seed round. Phenomix Sciences (Rochester, MN; no SBIR) is seeking $1 million so that it can commercialize its current core product: a new clinical test for obesity. The test analyzes metabolomic and DNO biomarkers to determine what kind of obesity a patient has, and thereby result in more effective weight loss treatments. [Amanda Ostuni, Twin Cities Business, November 29,18]

Phigenix (Atlanta, GA)

Phigenix (Atlanta, GA; no SBIR) biotech plans to raise $10.5 million, according to [SEC] filing ... uses molecular therapeutics that target the immune system to prevent and fight prostate cancer. The company is developing diagnostic tests which may detect prostate abnormalities at the pre-malignant state years before the onset of cancer, according to its website [Urvaksh Karkaria, Atlanta Business Chronicle, Aug 19, 15]

Phio Pharmaceuticals (Marlborough MA)

Phio Pharmaceuticals (Marlborough MA; no SBIR) down 57% [Feb 11, 20], developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL(TM)) therapeutic platform, announced the pricing of an underwritten public offering [to raise $8M] [company press release, Feb 11, 20]

Phoenix Molecular Designs (San Diego, CA)

Phoenix Molecular Designs (San Diego, CA; no SBIR), a biotech developing kinase inhibitors to treat cancer, has brought in an undisclosed amount of financingâ€”boosting its total seed funding raised to $12 million [Melissa Fassbender, xconomy.com, Nov 26, 19]

Phoenix (formerly Phoenix Nuclear Labs, Monona, WI)

Phoenix (formerly Phoenix Nuclear Labs, Monona, WI; no SBIR, founded 2005) said it inked a $4 million contract with the US Army to demonstrate neutron-based imaging technologies that could be used to help inspect large, complex munitions, according to a press release. The Madison-area company previously was awarded Army contracts in 2014 and 2016 worth a combined $6.6 million. [Jeff Engel, xconomy.com. May 6, 19]

Phoenix Biotechnology (San Antonio, TX)

Phoenix Biotechnology (San Antonio, TX; no SBIR) which has been developing a plant-based drug to treat Alzheimer’s for more than a decade, is looking for help in promoting its therapy because it is running out of time and money. The biotech company published findings in 2016 that showed that its drug may be able to produce an antioxidant response in the brain and may stimulate a protein related to memory and learning. [Angela Shah, xconomy.com, May 1, 17]

Phoenix Nuclear Labs (Monona, WI)

Phoenix Nuclear Labs (Monona, WI; $1.2M SBIR) announced it has been awarded multiple contracts by the U.S. Army totaling $3.6 million [to] build an advanced neutron radiography system to detect defective munitions and demonstrate the ability to use their neutron generators to detect and identify concealed explosive threats. [company press release, Aug 2, 16] Phoenix grew out of technology that medical physicist Paul DeLuca created in the 1970s and 1980s at the University of Wisconsin-Madison, but has developed its own intellectual property, he said. ... Now the company has potential to develop into a "highly viable, $100 million a year in sales company," he said. [Kathleen Gallagher, Milwaukee Journal Sentinel, Aug 2, 16]

Phoenix Nuclear Labs (Madison, WI, $1M SBIR) raised $790K ... makes particle acceleration and neutron generation systems. Its customers include companies in the neutron radiography and materials processing industries. [Milwaukee Journal Sentinel, Jan 7, 16]

Phoenix Nuclear Labs (Monona, WI; $900K SBIR) maker of neutron generator technology, said it has converted $3.2 million of debt financing from 10 investors into equity. That financing includes $2 million the company raised in November [Kathleen Gallagher, Milwaukee Journal Sentinel, Mar 12, 15]

Phoenix Nuclear Labs (Monona, WI; $900K SBIR, founded 2005) maker of neutron generator technology, said it has raised $2 million from outside investors. ... In February, the company signed what it said was its first large-scale commercial contract, which has it supplying a thermal neutron generation system to Ultra Electronics Holdings, a British maker of control systems. Phoenix spun out Shine Medical Technologies (no SBIR) in 2010. [Kathleen Gallagher, Milwaukee Journal Sentinel, Nov 24, 14]

Phoenix Nuclear Labs (Monona, WI; $900K SBIR) announced today that it has been awarded a one-year, $3 million contract by the U.S. Army to build an advanced neutron radiography unit. The neutron imaging system will be used for the nondestructive inspection of munitions, pyrotechnics and other critical defense components. ... an upgraded, second-generation version of a similar system that it delivered to Picatinny Arsenal [NJ] in 2013. ... The PNL neutron radiography platform is the first system capable of bringing neutron radiography out of an R&D environment and into a production setting, similar to industrial X-ray systems. [company press release, Oct 6, 14]

Phoenix Nuclear Labs (Monona, WI; no SBIR) said it has completed a $590,500 round of equity fundraising to continue developing its particle accelerator technology. ... is collaborating with Shine Medical Technologies and the Morgridge Institute for Research to develop a new process for producing molybdenum-99, a medical isotope used in medical imaging procedures. [Milwaukee Journal Sentinel, May 21]

Phoenix Science (Chelmsford, MA)

Phoenix Science & Technology (Chelmsford MA) got a $15M Phase III Navy SBIR for more development of pulsed light and acoustic devices for for ultraviolet water treatment and for paint stripping of naval vessels. [Mass High Tech, Aug 26] Navy mainline takes advantage of sole-source rules for SBIR awardees to ease its contract administration. It means juicy contracts for the good (Navy likes them) companies. The one downside to that policy is that Navy will favor companies ready for large contracts for Phase 1 and 2. Phoenix has at at least $3.5M of Navy SBIR since 1995

Phononic Devices (Raleigh, NC)

Phononic (RTP, NC; no SBIR, founded 2009) has patented new solid-state cooling and refrigeration technology that will replace older refrigeration systems. This new Phononics solid-state semiconductor technology has enabled Phononics to enter a broad new range of consumer and business products. The company has received almost $90 million in outside funding to date. [Raleigh News & Observer, Mar 3, 16]

Phononic Devices (Durham, NC; no SBIR) raised $5.5 million in its second equity round. .... develops advanced thermoelectric devices designed to efficiently manage and monetize heat, including coolers and generators, and has received $3 million in government seed funding. [Lauren Ohnesorge, Triangle Business Journal, Dec 20, 12]

The White House held up a small [17 employees] company as an example of the success of its policy. Phononic Devices (Raleigh, NC; no SBIR) scored $3 million from the U.S. Department of Energy two years ago and earlier this year netted $12 million in private investment. ... develops semiconductor devices that capture and recover waste heat and could tap a rich source of energy. [John Murawski, Raleigh News & Observer, Aug 31, 11]

Phononic Devices (Raleigh, NC; no SBIR) startup that makes miniature electronic heat pumps has scored $10 million in venture capital to create prototypes of its product for demonstration to potential customers. ... with 10 employees at its Centennial Campus office, plans to hire up to 20 scientists and engineers in the next 18 months as it ramps up production of its thermodynamic devices, CEO Anthony Atti said. The 2-year-old company is developing a product designed at Oklahoma University to replace conventional equipment that removes heat from computer and refrigeration components. In the past two years, Phononic won a prestigious $3 million grant from the U.S. Department of Energy and $2 million in venture capital. The first $5 million went into research, development and design. The latest round of venture financing will pay for further testing and assembly of prototypes. [John Murawski, Raleigh News & Observer, Feb 24, 11]

Photobit (Pasadena, CA)

Photobit Acquired. Photobit (Pasadena, CA) was quietly acquired by Micron Technology in Micron's run at the emerging CMOS image sensor market. No price reported. eNews says at least 20 chipmakers are believed to be producing or developing CMOS image sensors, though no single supplier is considered entrenched.. Photobit, a JPL spinoff acquired key patents to the JPL technology and some government contracts, especially SBIR from (then) BMDO , Then it needed deep pockets volume manufacturing capacity, and the know-how to optimize a process technology for cost and performance. Enter Micron, which claims that combining Photobit's IP with its process expertise will enable high resolution in a small pixel size to significantly reduce chip size, cost, and power consumption, Frost & Sullivan estimated the 2001 image sensor market, including CCDs, at about $1 billion.

Photolitec (Buffalo, NY)

Photolitec LLC (Buffalo, NY; no SBIR), a spin-off from Roswell Park Cancer Institute, finalized a new $2 million investment from an Indian pharmaceutical company AMI Organics should be the final boost needed ... to begin clinical trials and commercialize its specialized photosensitive compounds, which kill cancer cells when exposed to light through photodynamic therapy (PDT). ... Additional private funding for Photolitec's work included a $5 million investment from Zhejiang Hisun Pharmaceutical Co. Ltd., a Chinese pharmaceutical group, which made its final payment last year.
Zhejiang Hisun retains licensing rights for China, Taiwan, Hong Kong and Singapore; while AMI will control licensing for the U.S., Canada, Europe and India. [Tracey Drury, Buffalo Business First, Mar 3, 15]

PhotoMedex (Montgomeryville, PA)

medical-device developer MELA Sciences (Irvington, NY; $3M SBIR as Electro-optical Sciences) that recently acquired a local company’s laser skin care technology is planning to relocate its headquarters to Montgomery County [PA]. The move is a result of an agreement to purchase PhotoMedex (Horsham, PA; no SBIR)’s Xtrac and Vtrac laser devices used to treat psoriasis and other skin disorders, for $42.5 million. [John George, Philadelphia Business Journal, Jul 15, 15] PhotoMedex is a global skin health company providing aesthetic solutions to dermatologists, professional aestheticians and consumers. [company website]

PhotoMedex (Montgomeryville, PA; no SBIR) has raised $2.7 million in a private stock placement. ... develops proprietary excimer laser and fiber optic systems for the treatment of skin disorders [John George, Philadelphia Business Journal, Oct 23, 09]

PhotoniCare (Champaign, IL)

PhotoniCare (Champaign, IL; $4M prior SBIR) startup making ear imaging technology raised $5.2 million in a Series A round In addition to the funding, PhotoniCare also received a $2.1 million [NIH] Phase II SBIR [which] brings PhotoniCare’s total funding to more than $12 million, according to Crunchbase. [Chicago Inno, Oct 1, 20]

PhotoniCare (Champaign, IL; $4M SBIR) dedicated to revolutionizing healthcare by providing physicians with better diagnostic tools, announced an oversubscribed $5.2 million Series A financing [to] expand PhotoniCare’s executive team, ramp up manufacturing, execute on the company’s sales and marketing plan, fuel artificial intelligence development to enable real-time decision support for the TOMi Scope, and expand reimbursement activities and customer support [company press release, Sep 3, 20]

Photonics Innovations (Birmingham, AL)

Laser systems maker IPG Photonics(Oxford, MA, founded 1990; no SBIR) has acquired Photonics Innovations (Birmingham, AL; one SBIR) a maker of active and passive laser materials and tunable lasers.[Mass High Tech, Jan 26, 10]

Photon-X (Huntsville, AL)

Lucidux LLC (Providence, RI; no SBIR), a startup that makes 3-D imaging technology for surgery and other medical applications, has received $250,000 in funding from the Slater Technology Fund, a non-profit corporation that works like a venture capital firm ... founded in 2011, is developing its technology with corporate partner, Photon-X (Huntsville, AL; $6M SBIR) The real-time, three-dimensional imaging of internal organs and tissues uses software-enhanced presentation and can be used by surgeons during procedures such as laparoscopy and arthroscopy. The company says it can highlight diseased tissue, allowing surgeons to remove it without damaging healthy tissue nearby. [Don Seiffert, Mass High Tech, Jul 30, 12]

PhotoSonix Medical (Ambler, PA)

PhotoSonix Medical (Ambler, PA; founded 2014) is developing a treatment for dermal diseases generated by bacterial biofilm, such as acne. Biofilms, which make treatment extremely difficult, shield bacteria from attack by both drugs and the immune system, often inducing a chronic inflammatory response. Photosonix's product, CLENS, will cut through biofilm by combining both ultrasound and violet light to kill underlying biofilm bacteria. [Lauren Hertzler, Philadelphia Business Journal, Jan 16, 15] investors Ben Franklin Technology Partners

PhotoThera (Carlsbad, CA)

Dr. Jackson Streeter once held the ultimate cool job. In the mid-1990s he was the first medical doctor to be a pilot in the elite U.S. Navy Fighter Weapons School, more commonly known as TOPGUN ... he gave it all up in May, 1997, to start a company, PhotoThera (Carlsbad CA; no SBIR), built around an unlikely laser therapy he learned about from an obscure Hungarian medical journal. ... His device, called NeuroThera, is still in clinical trials, but it is gaining respect from stroke specialists and once-skeptical venture capitalists. ...managed to drum up $750,000 in financing from Hamilton BioVentures and California Technology Ventures in 2001, in part by crashing a Goldman Sachs investment meeting in San Diego. Positive data in animals helped him raise an additional $4.35 M, then $19 M more, and finally in 2006, $30.5 M. [Catherine Arnst, Business Week, Nov 19]

Photronics (Brookfield, CT)

Photronics (Brookfield CT; no SBIR) up 12% [Nov 29, 17] quarterly profits up

Photronics (Brookfield, CT; no SBIR) reports it plans to raise more than $85 million in a public stock offering ... to repay some of its outstanding bank loans ... imaging technology company [Mass High Tech, Sep 11, 09]

Phoundry Pharmaceuticals (Research Triangle Park, NC)

"that GSK was downsizing really helped accelerate our company,” says Paul Feldman, the CEO of newly formed Phoundry Pharmaceuticals (Research Triangle Park, NC) a drug developer ... this group of six made up one-fifth of GSK’s Enteroendocrine Discovery Performance Unit, which was caught up as part of the downsizing GSK announced late last year. ... the group took their six years of work with them, including huge amounts of data, more than five semitrailers in equipment, two top assets that could one day treat metabolic diseases and the institutional knowledge to create intellectual property. In return, they agreed to give GSK a royalty of 2 percent on net sales if those two assets become marketable drugs. ... raised $500,000 and plans a second tranche of another $500,000 in the coming months [Jason deBruyn, Triangle Business Journal, Aug 18, 15]

Phraxis (St Paul, MN)

Phraxis (St Paul, MN; no SBIR, founded 2008), developing solutions, offers InterGraft, a percutaneously delivered arterio-venous shunt that provides a non-surgical approachfor patients who need vascular access to enable hemodialysis, raised $5.6M in a venture round ... prior funding $2.3M [crunchbase.com, Mar 11, 19].

Phrixus Pharmaceuticals (Ann Arbor, MI)

After showing some early promise in treating European patients, Phrixus Pharmaceuticals (Ann Arbor, MI, $900K SBIR) a startup developing drugs to treat cardiac and respiratory problems in young males with Duchenne muscular dystrophy, is preparing to launch U.S. clinical trials early next year. ... Described by Phrixus as “a molecular band-aid,” Carmeseal was initially developed in the 1990s to treat heart attacks. Repurposed as Carmeseal-MD, the drug is infused into the bloodstream, where it finds microscopic tears in the heart muscle and binds to them. [Sarah Schmid Stevenson, xconomy.com, Oct 16, 17]

Phurnace Software

Phurnace Software (Austin, TX; no SBIR),18-month-old company, which sells software that accelerates the deployment of Java applications, completed its $5 million first round of venture backing. [Austin American-Statesman, Jul 21]

Two Austin startups,30 Second Software Inc. and Phurnace Software Inc., have received venture capital infusions. 30 Second Software, founded by Austin entrepreneur Dave Sikora, has raised $2.9 million from two corporate investors, to develop mobile commerce technology and services. Phurnace, which won the 2006 University of Texas MOOT Corp business-plan competition, received $1.3 million [from] a Texas-based venture fund affiliated with Draper Fisher Jurvetson. [Austin American-Statesman, Sep 3]

PhylloTech (Middleton, WI)

Six Madison [WI]-area tech startups are receiving grants from the SBIR Advance program, a collaboration between the Wisconsin Economic Development Corp. and the UW System Administration's Center for Technology Commercialization, to grow their businesses. Onexio Biosystems, Madison $75K, Equipment used to quickly screen potential drug compounds during the drug development process. Pyran, Madison $75K: Using wood and crop waste to make a key chemical used to manufacture paints and plastics; Stem Pharm, Fitchburg, $75K: Biomaterials for cell and tissue manufacturing; NCD Technologies, Madison $100K: Diamond and diamond-like coatings for medical devices and other industries. PhylloTech, Middleton $100K: A process to engineer plants to produce proteins that will help them resist agricultural diseases. [Judy Newman, Wisconsin State Journal, Mar 27, 19]

Phylonix (Cambridge, MA)

A Fish for All Seasons. Phylonix Pharmaceuticals (Cambridge, MA; $8M HHS zebrafish SBIR) got a two-year EPA contract for up to $4.3M to explore the use of zebrafish as a screening tool.

Doing Its Thing. NSF handed Phylonix a $500K Phase 2 SBIR to assess possible toxic effects of chemicals on the development of human organs and tissues using tests performed in zebrafish. The company calls itself a Contract Research Organization providing in vivo zebrafish assays.

Phylos Bioscience (Portland, OR)

Phylos Bioscience, (Portland, OR; no SBIR) which is mapping the cannabis genome, has raised $250,000 in equity, according to [SEC] filing with the U.S. Securities and Exchange Commission. ... could raise another $1.75 million, according to their filing. .... collaborating with a half-dozen research universities to uncover the plant's biology. [Elizabeth Hayes, Portland Business Journal, Feb 3, 15] Not exactly a market-failure situation, and therefore no need for government subsidy.

Physcient (Durham, NC)

Physcient (Durham, NC; $700K SBIR) is gearing up to re-invent the way doctors perform surgery. Co-founder and CEO Hugh Crenshaw and team are tackling blunt dissection, a surgical standard that has been largely unchanged for decades. [Amanda Jones Hoyle, Triangle Business Journal, Sep 6, 13]

Physical Optics (Torrance, CA)

Mercury Systems has agreed to purchase defense systems integrator Physical Optics (Torrance, CA; a three-decade top SBIR consumer of about $420M) for approximately $310M in cash to expand the former's global avionics and missions systems portfolio. [Brenda Marie Rivers, GovConWire, Dec 8, 20] POC founded and operated by a Polish couple w PhDs from Warsaw Univ.

Ceradyne got $436M in government contracts in 2006, says fedspending.org's database. Physical Optics $21M.

Loving Experience. Scientific Systems (Woburn,MA; $50M+ SBIR) won a NASA JPL Phase 2 SBIR for Distributed Formation State Estimation Algorithms Under Resource and Multi-Tasking Constraints. Creare (Hanover NH; $120M SBIR) won four NASA JPL Phase 2 SBIRs. Intelligent Automation (Rockville MD; $100M SBIR) won three NASA JPL Phase 2 SBIRs. Physical Optics (Torrance, CA; $200M SBIR) won one NASA JPL Phase 2 SBIR. Radiation Monitoring Devices (Watertown, MA; $90M SBIR) won one NASA JPL Phase 2 SBIR. Etc, etc, etc. A zillion start-ups all over America got letters saying there was not enough money to nurture their ideas.

Physical Optics (Torrance, CA), still a private firm after 15 years of SBIR and 322 Phase 1s through 1998 (if the SBA database is current) spun off its fourth subsidiary to focus on commercial products" But SBIR cheerleaders should ask why POC hasn't had a BMDO Phase 2 since 1994 alongside its tons of military service awards. It did have three Phase 2s from DOE last year.

POC's website claims POC’s rapid growth has been achieved through a successful commercialization strategy based on in-house manufacturing, corporate alliances, licensing and joint ventures. POC also has a long and successful history of converting technologies developed under Federal SBIR programs into commercial products. This conversion has been accomplished using multimillion dollar venture capital investments, and strong banking relationships and allows us to capitalize on both commercial & government growth opportunities. With our unique expertise, $10 million in assets, and a strong growth record, POC is well positioned to become a major player in the rapidly growing optoelectronic markets. You may notice that the website has little useful data (it's a private corporation) by which anyone could evaluate whether SBIR was getting its money's worth. POC has managed over the years of SBIR to never go public despite being in a hot industry.

Physical Sciences (Andover, MA)

Physical Sciences, a huge consumer of SBIR, bought Q-Peak to get Q-Peak's solid-state laser systems which would complement and support PSI's activities in laser applications.

Lucent signs cascade-laser sales deal. US-based technology-development company Physical Sciences Inc. (PSI) has signed a deal with Lucent Technologies to develop and sell gas sensors that are based on quantum cascade lasers (QCL). PSI says that, with prototype sensors already under development, the devices will be available for delivery by the middle of the year. The QCL sources operate between 5 and 12 µm, which corresponds to the fingerprint molecular-absorption region of many common and pollutant gases. PSI has also licensed patents and technologies from Gemfire, based in California, which has developed periodically poled lithium niobate crystals to convert laser emissions in the visible and near-infrared into the 2 to 4.5 µm region. Gas sensors for water-vapour and hydrocarbon detection that are based on these sources are also under development at PSI.Together with the QCL-based sensors, PSI will be able to cover the spectral range from the visible through to the far-infrared.

Alan Gelb of Physical Sciences Inc (Andover, MA) got a BMDO Phase 2 for a versatile, charge-free atom beam tool for semiconductor processing. The tool uses PSI's proprietary microwave-driven plasma beam technology..... In the Phase II program, the oxygen beam will be developed into a processing tool capable of meeting the uniformity and cleanliness requirements for the 300 mm wafer fab. Addtionally, chlorine atom and CF4/02 beams will be generated, characterized and demonstrated for metal and chamber cleaning applications. The proposed program will be carried out in collaboration with a major equipment manufacturer to assure the development of a commercial tool. . How nice an oxygen beam! Alan Gelb and PSI got the first SDIO Phase 2 in 1986 for ... an oxygen beam. Wonder what PSI has done in the intervening decade about commercializing its beam technology? Ask CEO Bob Weiss why he wants more and biger SBIR with all the present management schemes (without co-investment) that he so often taps. What is PSI's ROI for all that government investment? Maybe holding his feet to a co-investment fire was the only way to force realistic proposals.

PhysioGenix (Wauwatosa, WI)

start-ups in the drug field within the Milwaukee 7 economic development region suggests another strategic direction for the regional economy. Those new ventures come as Concordia University of Wisconsin mounts an impressive campaign to build a new pharmacy school in southeastern Wisconsin, possibly in downtown Milwaukee. ... New ventures in the emerging drug-making concentration: MPP Group (no SBIR)a venture headed by serial entrepreneur Frank Langley that is building drugs aimed at alcoholism. James Cook, a University of Wisconsin-Milwaukee researcher, developed the compounds. Neuro Amp (no SBIR),a spin-off from PhysioGenix (Wauwatosa, WI; $3M SBIR) that is aiming at diseases of the central nervous system and Alzheimer's. Promentis (no SBIR), a collaboration between Marquette University's David Baker and UWM researchers and former Schwarz Pharma managers who are targeting schizophrenia and central nervous system disorders. Cytometix (no SBIR), a 2004 start-up headed by Lane Brostrom that is developing drugs for the treatment of pain and asthma. Endece (no SBIR), a 2006 Mequon start-up headed by James Yarger that is developing compounds for treating cancer, sepsis, learning and memory. [John Torinus, Milwaukee Journal Sentinel, Jan 31, 09]

PhysioGenix (Wauwatosa, WI; $3.5M SBIR) which sells pre-clinical services to drug companies, said it plans to spin off a subsidiary that will attempt to create drugs out of compounds developed at the University of Wisconsin-Milwaukee [Kathleen Gallagher, Milwaukee Journal Sentinel, Jan 18, 09]

PhysioSonics (Seattle, WA)

PhysioSonics, (Seattle, WA; no SBIR) a University of Washington spinout company that's developing an ultrasound device to monitor blood flow in the brain, has raised $2 million in funding to move toward commercialization of its first product. [Puget Sound Business Journal, Jun 24, 09]

PhytoTech (Monmouth Junction, NJ)

A Real Industrial Plant PhytoTech (Monmouth Junction, NJ) is on the verge of parlaying one SBIR into an industry. Whereas most companies bleat that environmental technology is too much potential and too little immediate earnings prospects (and therefore needful of government succor), last week it filed for an IPO to raise $11M for the "bio-technology" of using metal-loving plants to capture metals from the soil. PhytoTech has one 1997 Army SBIR to absorb uranium from Army-contaminated ranges. The same hyper-uptake principle would work also for hydroponic culture to remove metals from flowing water. One warning: don't eat the leaves. In late 1994, the company raised more than $3 million US in private placement venture capital. Of this, $1.1M was committed to Rutgers for research to be conducted. Field trials have been conducted in Chernobyl, Ukraine, in Sheffield, England, and in Trenton, NJ.

PhytoTech's market success is likely to depend on three things: the bureaucracy of getting government to buy such a product, the economics of finding better uses (like concentrating trace metals for pharmaceutical supplements), and the general market attitude to biotech companies. Michael Gianturco (financial pundit) [Bloomberg Personal, May 98] says biotech is where digital was in the 1970s. That is, stocks are unpredictable and therefore dangerous, a situation where the best thing about this sector is also the worst That alone scares conservative investors and bureaucrats. Gianturco also notes more optimistically that Molecular biology is to the second half of the 20th century what physics was to the first half: a springboard for a torrent of widely used commercial applications.The SBIR deciders MAY note the potential or they may just simply use the technology for cleanup as a pure service contract. Their imaginations can be put to the test.

Picolight (Boulder, CO)

Trilumina (Albuquerque, NM; no SBIR, founded 2010) announced this week it was expanding its Albuquerque footprint [Collin Krabbe, Albuquerque Business Journal, May 25, 18] delivers a VCSEL technology platform capable of low-cost, small form facto and high power illumination for laser radar (LiDAR) and 3D-Sensing. [company website] Sounds like an outgrowth of VCSEL developed by Jack Jewell's 1980s team at Bell Labs, then funded with some SBIR to Jewell's firms Photonics Research (became Vixel), and Picolight. Jewell is now a consultant claiming 72 issued US patents and 150 publications [https://www.linkedin.com/in/jack-jewell-a1149410]

Picolight (Boulder, CO) did a cross-licensing deal with Honeywell for its “oxide confined” VCSELs. Picolight started life in 1996 with an BMDO SBIR, got seven Phase 2 SBIRs 1997-2000 and now employs 100 people. Companies like Picolight, with entrepreneurs like Jack Jewell, and products like the next generation VCSELs make the perfect SBIR start-up situation.

Picolight's 100 employees testify that the company has made exemplar use of a little SBIR money and a wad of venture capital sine starting up in 1995. Its latest news is that it made the first 1310nm transceivers out of its signature product - VCSELs. Six Phase 2 SBIRs in the late nineties was all the government R&D help he needed. It is actually founder Jack Jewell's second such rise to success, having pulled the same trick after starting Vixel in 1991.If there was ever a poster child for SBIR, Jack makes the ideal candidate on the basis of getting somewhere with an infant technology an only a little bit of government money. $5M of SBIR attracted $80M of private investment which by its nature expects a high ROI which in turn requires really large sales volume. If the technology really works in the marketplace - no small trick - the return to the government in corporate income taxes alone will be among the largest ROI government ever gets from intruding in the marketplace. The stories that the federal agencies tell of sales volume by SBIR companies is small potatoes to ROIs like Jack Jewell's. But Jack will have to get his reward from the private market because the government is disinterested in adjusting its SBIR to bet on more Jack Jewells

Picolight (Boulder, CO) raised another $27M of venture capital to keep its 120 employees developing transceiver subsystems for short-reach (1-meter to 20-kilometer) optical-networking connections. That makes $80M raised since 1996. Picolight’s specialty is the Vertical Cavity Surface Emitting Laser (VCSEL) deriving from Jack Jewell's work first at Bell Labs, then at his co-founded Vixel before he founded Picolight. Both Vixel and Picolight got their funding starts from SDIO/BMDO's SBIR, back when BMDO cared about co-investment and entrepreneurs

Picolight (Boulder, CO) says it's part of a 14 company initiative for a next generation 10GB pluggable fiberoptic transceiver. And as soon as Nortel and Lucent and Corning pick themselves out of the overbuilding cellar, .... [fact from Laser Focus World, Jun01]

Picolight (Boulder, CO) took down $10.8M in VC funding in the fall of 1999, says Photonics Spectra Apr00. Picolight is the second child of Jack Jewell who first co-founded Vixel.. He got both started with SBIR from BMDO, Vixel in 1991 and Picolight in 1996. PS calls it a manufacturer of VCSEL devices. Vixel went public in 1999 but is presently languishing well below its first trading range.

Picolight $3.5M Jack Jewell closed a $3.5M investment in two-year old Picolight (Boulder, CO) to develop the next generation of VCSELs. That funding on the top of three BMDO Phase 2 SBIRs brings his capital influx to about $8M. Jack tells how he got the first $250K to match the Fast Track $1M: One night a stranger knocked at his door up a long track from the road in the mountains above Boulder looking for Jack's wife who had published a scientific article on x-ray lithography. Her address was on the paper byline. He was interested in investing in it until Tanya said that it was really long term stuff but "by the way have you heard about Jack's new company?"

Picolight's VCSELs Light Up. Having won a BMDO Fast Track as a deserved reward for attracting private capital to a BMDO technology - next generation VCSELs - Picolight (Boulder, CO) also won two regular-way Phase 2 awards, also with rewards for new capital. Of course, from BMDO they are not just a handout of an R&D contract. They require an escalating match rate by private capital as both the technology and the company mature. BMDO did the same thing for the first company Jack Jewell founded - now Vixel Corp - which has raised tens of millions to go into full scale production. From the FT which had 4:1 (BMDO to private), the second has 2.5:1, and the third 0.7:1. BMDO also holds out the idea of expanding the amount if Picolight finds investors. BMDO's message: if you can't find investors </b>in your technology as it technically matures, you're kidding yourself about its potential in which case we will cut our losses.

Picolight Fast Track. A DOD Fast Track award is on its way to Picolight (Boulder, CO) for a shot at the next generation of vertical cavity surface emitting lasers, manufacturable oxide-defined VCSELs, that would dramatically upgrade instruments such as CD and DVD pickups, datacom transmitters, barcode scanners, printers, gas sensors and telecom 1.3 micron transmitters. Since Picolight just got started by Jack Jewell, one of the founders of Vixel (Broomfield, CO) and an alumnus of Bell Labs, it qualified for a 4:1 match of whatever third party cash it could recruit. Such recruiting is rarely easy for the kind of new technology that BMDO favors. (BMDO knows it cannot reach its technology dreams with safe incremental advances to present technology and thus bets on some risky stuff that VCs avoid.)

Vixel (and Jewell) got started with a BMDO (then SDIO) SBIR in 1991 and has since raised more than $30M to get a VCSEL industry rolling. Jewell said on a 1994 BMDO SBIR video that his dream was "to walk into a consumer electronics store and see his products on every shelf";. Jewell now has a two-way play in VCSELs: he wins if Vixel sells a zillion of today's VCSELs and/or if Picolight sells a zillion of tomorrow's VCSELs. He's basically betting that his new venture will overtake his first venture. He has to decide which to hope for: Vixel's establishing a market whose next generation Picolight can exploit faster than Vixel can OR Picolight's leafrogging Vixel straight into a second generation technology before the first even recovers its investments. BMDO and Jewell win either way. He's probably hoping more for the latter because the capital raising and the multiple founders of Vixel well diluted his equity share. Still, even a small percent of a giant win makes him a winning entrepreneur. If he's economically rational and capitalistic, he'll root for the biggest pile of money

Jack's dreams can also be inferred from his November 1991 Scientific American article Microlasers in which Vixel is called by its first name, Photonics Research Inc. Jon Baron, DOD's Fast Track champion says that 75% of all Fast Track awards have gone to 4:1 matches that can only be had by first time Phase 2 winners under 10 employees.

Picometrix (Ann Arbor, MI)

Advanced Photonix up 10% [Oct 23, 07] after announcing that its subsidiary, Picometrix, has received a follow-on $750K AF Phase II SBIR for further non-destructive testing (NDT) application development involving the testing of radomes for defects such as delaminations and water intrusion utilizing the T-Ray 4000 terahertz system platform. [company press release] Picometrix started life in 1992 with an SDIO SBIR when Steve Williamson got fed up with his university's handling of patenting his work.

Picometrix (Ann Arbor MI) got some national press [Business Week, Apr 11] for trying to develop a terahertz people scanner. Pico started life (as Picotronix) with 1992 SBIR from SDIO for Steve Williamson's launch from the cozy but bureaucratic university lab situation, and has had six Phase 2s to help along its commercial ventures in super-fast lasers. I didn't have to talk too hard to Steve to convince him that he was great SBIR material of the mettle I was looking for in the high-tech days of Star Wars. It calls itself a leading supplier of high-speed optical receivers and ultrafast instrumentation since 1992. Recently it said it was being bought for $12M by Advanced Photonix, another 1980s SDIO-SBIR winner. Co-founder Rob Risser said the firm has been profitable every year of its existence except the IT crash years of 2002 and 2003. Half a million profit in 2004 on $7.5M revenue. [facts from Scott Anderson, The Ann Arbor News, Mar 25, 05]

Pixelligent (Baltimore, MD)

Pixelligent (Baltimore, MD; $6.5M SBIR) announced that it has secured $38 million in non-dilutive growth capital backed by its intellectual property portfolio. [company press release, Nov 3, 2022]

Pixelligent (Baltimore, MD;$7M SBIR) announced a $1.9M grant from the [DOEnergy) Advanced Manufacturing Office (AMO) to fund a program titled “Rapid and Efficient Deposition of Metal Oxide Coatings for Bearings and Gears in Harsh Environments.” The grant follows an earlier award of $1.5M in 2020. [company press release, Sep 8, 2022]

PLx Pharma

PLx Pharma up 18% [Jul 20, 21]

PLx Pharma up 27% [Jul 13, 21] announced that three stock-keeping units ("SKUs") of VAZALORE, the first and only U.S. Food and Drug Administration ("FDA") approved liquid-filled aspirin capsules, will be available in over 4,500 Walmart stores across the United States in mid-August. [company press release, Jul 13, 21]

PIC Therapeutics ((Boston, MA)

PIC Therapeutics (Boston, MA; no SBIR) a biotechnology company focused on transforming the treatment of cancer though the selective modulation of oncogene translation, closed a $5M Series Seed round of preferred equity funding [to] accelerate our program focusing on allosteric regulation of eIF4E via an innovative drug development platform designed to produce early proof of concept in advance of the clinic.”. [company press release, Apr 15, 20]

Plastomics (St. Louis, MO)

Plastomics (St. Louis, MO; $200K SBIR) biotech startup, plans to advance its crop improvement technology after raising $7.1 million. [St Louis Inno, Nathan Rubbelke, Nov 16, 2021[

Plexxikon (South San Francisco, CA)

Daiichi Sankyo is shutting down (PDF) its Plexxikon (South San Francisco, CA; $300K SBIR in 2003) R&D operation in South San Francisco. More than 10 years after buying the biotech for $805 million upfront, Daiichi has decided to drop the 60-employee operation to focus investment on three antibody-drug conjugates (ADCs). [Nick Paul Taylor, Fierce Biotech, Jan 12, 22]

PolyMedica (Wakefield, MA)

PolyMedica (Wakefield, MA; 2 Phase 1 SBIRs), provider of products for diabetics, has agreed to be acquired by a giant pharmacy benefits manager, Medco Health Solutions for about $1.5 B cash.

PolyMedix (Radnor, PA)

PolyMedix (Radnor, PA; $5.7M SBIR, founded 2002) facing a $6.8 million loan payment, filed for Bankruptcy Court protection, according to [SEC] documents [John George, Philadelphia Business Jounral, Apr 2, 13]

Polymedix (Radnor, PA; $8.5M SBIR) CEO, sent a letter to shareholders stating, “PolyMedix continues to work with its financial advisers on a financing transaction or other strategic transaction to fund the continued clinical development of brilacidin and its technology platform.” Brilacidin, formerly known as PMX-30063, is an experimental antibiotic compound. [John George, Philadelphia Business Journal, Beb 7, 13]

PolyMedix (Radnor, PA; $8M SBIR) said it has stopped enrollment in two clinical trials for its new drug candidate PMX-60056 because of observations of reductions in blood pressure in some study patients. [John George, Philadelphia Business Journal, May 10, 12]

PolyMedix (Radnor, PA; $4.2M SBIR) and the University of Massachusetts received a $750,000 [Army STTR] contract ... to conduct further testing on [multidrug resistant biofilm-embedded bacteria ]antimicrobial compounds [John George, Philadelphia Business Journal, Nov 16, 10] raised $20M in stock offering Nov 09

PolyMedix (Radnor, PA; $4.5m SBIR) received a $986,000 phase-II NIH grant to support the company’s development of antimicrobial compounds to treat a mouth infection. [John George, Philadelphia Business Journal, Sep 30 , 10]

PolyMedix (Radnor, PA; $3.6M SBIR) announced a public equity offering of up to $21 million. ... for development of an antibiotic and a heparin antagonist [Philadelphia Business Journal, Nov 11, 09]

PolymerPlus (Valley View, OH)

Peak Nanosystems subsidiary PolymerPlus (Valley View, OH; $2.5M SBIR), a military material R&D company that was acquired by Peak in April, landed a $5 million five-year contract from the U.S. Army to develop plastics that can be used in military armor and transportation, in a partnership with Case Western Reserve University and the Army Combat Capabilities Development Command’s Army Research Laboratory. [Kevin Cummings, North Texas Inno, Oct 1, 20]

Polymer Technology Systems (Indianapolis, IN)

Polymer Technology Systems (Indianapolis, IN; no SBIR), a diagnostic medical device maker, won Innovation of the Year for a line of products to rapidly determine cholesterol rates and other levels in blood. The Mira Awards are sponsored by Techpoint. The private company founded in 1992 has sales representatives and/or distributors worldwide.[Indianapolis Star, May 19]

Polynoma (San Diego, CA)

Polynoma (San Diego, CA; no SBIR, fewer than ten employees) a tiny biotech has launched a Phase 3 trial of a vaccine against melanoma, the most dangerous form of skin cancer. ... different because it includes hundreds of antigens, molecules that provoke an immune response, taken from three lines of melanoma cells, [CEO] Hopper said. ... largely bankrolled by Cheong Kong Group, Hong Kong-based conglomerate [Bradley Fikes, utsandiego.com, Jan. 13, 2015]

PolyNova (Long Island, NY)

After a few years fine-tuning its investment strategy, Accelerate Long Island has seeded its first group of startups. The nonprofit organization and the Long Island Emerging Technologies Fund announced plans to put $500,000 into five Long Island, NY-based biotech and cleantech startups: Goddard Labs, Green Sulfcrete, PolyNova, SynchroPET, and Traverse Biosciences. [Ben Fidler, xconomy.com, Jun 9, 14] None had SBIR.

PolyPlus (Berkeley, CA)

PolyPlus Battery (Berkeley, CA; one 1999 SBIR) has landed a nearly $9 million investment from the U.S. Department of Energy to scale up production of new kinds of batteries..... will ramp up production of advanced lithium-air, lithium-water and lithium-sulfur batteries.... to produce the batteries at factory scale, ... to extend the driving range of electric vehicles.[George Avalos, Oakland Tribune, Jun 12, 12] founded 1991 ... 27 employees including 7 PhDs [company website] Why government money for what should be an ROI investment? faces one big technical problem: Its lithium-air battery can be recharged just 40 to 50 times, vs. thousands of times for traditional lithium-ion batteries [Alexandra Dean, Bloomberg Business Week, Apr 5, 12] DOE is desparately pushing efficient batteries for the political dream of a nationwide adoption of electric autos in the windstorm of private market resistance.

ARPA-E Awards. The administration announced $106M in ARPA-E stimulus awards. Small biz winners: Ginkgo BioWorks (Boston, MA; one SBIR) $6M primary; OPX Biotech (no SBIR) $6M primary; Logos Tech (Arlington, VA; $2M SBIR) secondary;Sion Power (Tucson, AZ; $250K SBIR) $5M primary; ReVolt Tech (no SBIR) $5M primary; PolyPlus Battery (Berkeley, CA; one SBIR) $5M; Pellion Tech (no SBIR) $3.2M primary; A123 Systems secondary, twice; Planar Energy Devices (no SBIR) $4M; Maxpower (Harleysville, PA; $9M SBIR) secondary; NanoLab (Newton, MA; $5M SBIR) secondary; Codexis (no SBIR) $4.6M; Nexant (no SBIR) secondary.

PolyPlus (Berkeley, CA; $100K SBIR a decade ago) is developing lightweight, high-energy batteries that can use the surrounding air as a cathode. is partnering with a manufacturing firm to develop single-use lithium metal-air batteries for the government, and it expects these batteries to be on the market within a few years. The company also has rechargeable lithium metal-air batteries in the early stages of development that could eventually power electric vehicles that can go for longer in between charges. [Katherine Bourzac, MIT Tech Review, Jun 26, 09]

PolyRemedy

PolyRemedy (no SBIR) said that it closed a $20 million Series C financing. ... focused on integrated wound management systems. [Boston Globe, Jun 7, 11]

Polysciences (Warrington, PA)

Polysciences (Warrington, PA; $200K SBIR long ago) raised $4 million in a debt offering completed Wednesday, according to [SEC] documents ... maker of laboratory products and specialty monomers/polymers for microscopy, histology, biotechnology, electronics and other industrial applications. ... founded in 1961, last month opened an office in Taiwan to expand its global presence. [John George, Philadelphia Business Journal, Oct 20, 11]

Polystor

UltraCell (Livermore, CA; $800K SBIR) will get $1 million from the state of Ohio to help move more of its manufacturing operations to the Dayton region. .. has production operations in the area, recently landed a $3 million contract [funded by stimulus dollars] with the USAF to develop portable fuel cells for use by soldiers in the field. ... raised $3.8 million in venture funding to help expand operations at its facility in Dayton. ... has raised $30 million total since it was started in 2002 [Dayton Business Journal, Dec 18, 09] launched with technology licensed from Lawrence Livermore National Laboratories ... [In 2007] it planned to invest $74M in the Dayton operation. The state has promised $15.2M in loans, grants and tax credits. [Dayton Business Journal, May 15, 07] portfolio.com lists James Kaschmitter as Chairman & CEO. Kaschmitter had a battery firm Polystor ($500K SBIR in 1996)and founded PowerStor (no SBIR) in 1997 as a spin-off from PolyStor [allbusiness.com, Dec 99].

Wha'ppen Polystor? The story is simple and heart-warming for government R&D types. Polystor started life with a DARPA contract that allowed the founder to skip out of Livermore Labs (which was looking for ways to de-populate). A BMDO Phase 2 SBIR followed which induced a British company to toss in money which led to a mass production Army contract in 1999 plus $9.5M from the Advanced Battery Consortium and an ATP grant. PolyStor was the first Li-ion battery producer in the United States and the first to use a nickel cobalt oxide cathode that delivers the highest capacity and energy density in the industry, says Branscom et al. In winter 2001 the firm employed roughly 150 people, with a staff of 35 in research and development. In 2002, Polystor ceased operations. Sweet story ends. Which suggests several hard questions for the government advocates: 1) Why did all that government money not produce a sustainable economic winner? ; 2) Is the battery powered vehicle still a government pipe-dream?; 3) Did the government ever ask whether that technology at that price could survive in a competitive market place especially in a company nurtured by government handout?; 4) How much government money is too much?

POP Biotechnologies (Buffalo, NY)

POP Biotechnologies (Buffalo, NY; $900K SBIR, founded 2015) a preclinical stage biotech developing next-generation drug and vaccines products, announces that it has entered an agreement to receive a [$3 million] equity investment from South Korean vaccine manufacturer Eubiologics Co., Ltd. in conjunction with the establishment of a joint venture, EUPOP Life Sciences. [company press release, July, 2020]

Portola Pharmaceuticals (San Diego, CA)

Portola Pharma (SOUTH SAN FRANCISCO, CA; $700K SBR) up 130% [May 5,20] Alexion Pharmaceuticals announced it would spend $1.4 billion to acquire Portola Pharmaceuticals, which sells a medicine called Andexxa used to stop life-threatening bleeding in patients who have been given certain anticoagulants. [Josh Nathan-Kazis, Barron's May 5, 20]

Potola Pharma down 19% [Feb 27, 20] reported financial results for the fourth quarter and full year

Portola Pharm up 14% [Dec 31, 18]

Portola Pharma up 21% [Nov 8, 18]

Portola Pharma down 18% [Aug 9, 18] reported a net loss of $106M

Portola Pharmaceuticals won FDA approval for andexanet alfa (Andexxa), a drug that reverses the effect of blood thinners in cases of life-threatening bleeding. The approval also sets the company up for a $100 million payment under a royalty financing agreement the company signed last year. [Frank Vinluan, xconomy.com, May 11, 18]

Portola Pharma up 26% [May 4, 18] announced that [FDA] approved Andexxa(R) [coagulation factor Xa (recombinant), inactivated-zhzo], the first and only antidote indicated for patients treated with rivaroxaban and apixaban, when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding. [company press release, May 4, 18]

Portola Pharma down 25% [Mar 1, 18] "2017 was a year of significant achievement for Portola, highlighted by the FDA approval of our first medicine, Bevyxxa, and the regulatory application for FDA approval of our breakthrough-designated Factor Xa-inhibitor antidote, AndexXa," said [CEO] Bill Lis and nearly double net loss [company press release, Feb 28, 18]

Portola Pharma up 11% [Dec 26, 17]

Portola Pharma up 47% [Jun 23,17]

Portola Pharma up 13% [May 9,17]

Portola Pharma up 34% [Dec 23, 16] announced that [FDA] accepted Portola's New Drug Application (NDA) granting priority review for betrixaban, an oral, once-daily Factor Xa inhibitor anticoagulant, for extended-duration prophylaxis of venous thromboembolism (VTE) in acute medically ill patients with risk factors for VTE. [company press release, Dec 23, 16]

Portola Pharma down 13% [Nov 8, 16]

Portola Pharmaceuticals (South San Francisco, CA; $500K SBIR) said the FDA needs more information to make an approval decision about andexanet alfa (AndexXa), an emergency drug that reverses the effect of blood thinners. [Alex Lash, xconomy.com, Aug 19, 16]

Vertex Pharmaceuticals said one of the four Phase 3 trials testing the experimental cystic fibrosis drug VX-661 with ivacaftor (Kalydeco) failed and is being shut down. The combination is meant to improve upon Vertex’s approved pairing of CF drugs ivacaftor-lumacaftor (Orkambi), and Vertex is testing it in a variety of genetic subsets of CF patients. Data from the other three trials should come in late 2016 or early 2017. [Alex Lash, xconomy.com, Aug 19, 16]

Portola Pharma down 15% [Aug 18, 16]

Portola Pharmaceuticals down 29% [Mar 24, 16] said late-stage data showed its oral anticoagulant was not superior to an injectable standard therapy in preventing blood clots in acutely ill patients. [Reuters, Mar 24, 16]

Portola Pharmaceuticals took an important step toward its first drug approval with its experimental antidote for blood-thinning drugs passing a key clinical study, according to early results. ... said it would file for [FDA] approval of the drug, known as andexanet alfa, by the end of this year. Portola last year won the FDA's "breakthrough therapy" designation for the drug, which could accelerate its trip through the regulatory agency's approval process. [Ron Leuty, San Francisco Business Times, Apr 8, 15]

Portola Pharma up 10% [Feb 13, 15]

Portola Pharma (S San Francisco, CA; $500K SBIR) up 12% [Feb 6, 15]

Portola Pharma down 10% [Oct 2, 14]

Portola Pharma ($500K SBIR) up 16% [Oct 1, 14]

Portola Pharmaceuticals (South San Francisco, CA; $500K SBIR) made a deal with Daiichi Sankyo for late-stage clinical testing of a drug for people taking anticoagulants — the company's third such deal with new-generation blood-thinning drugs in the past two years. .... now has collaborations in Phase III clinical trials with all the major manufacturers of so-called Factor Xa inhibitors. [Steven E.F. Brown, San Francisco Business Times, Jul 7, 14]

Portola Pharma (S San Francisco, CA; $500K SBIR) down 10% [Jul 7,14]

Portola Pharmaceuticals (South San Francisco, CA; $500K SBIR) started enrolling patients in a late-stage clinical trial of a treatment for major bleeding in patients taking common anticoagulants. [Steven E.F. Brown, San Francisco Business Times, May 13, 14]

Portola Pharma up 12% [Oct 16, 13]

Portola Pharma down 13% [Oct 8, 13]

Portola Pharma up 13% [Sep 5, 13]

Portola Pharma (South San Francisco, CA; $500K SBIR) up 10% [Jun 27, 13]

Portola Pharmaceuticals IPO expected to raise $100M. [Ron Leuty, San Francisco Business Times, May 14, 13]

Portola Pharma (South San Francisco, CA; $500K SBIR) up 12% [May 28, 13]

Accumetrics (San Diego, CA; no SBIR) develops, manufactures, and markets the VerifyNow® System, a comprehensive suite of tests for the assessment of platelet response to antiplatelet therapies. ... signed an agreement with Portola Pharmaceuticals, (South San Francisco, CA; $500K SBIR) to develop and supply the VerifyNow System and VerifyNow Tests for use in clinical trials. [Accumetrics company press release] has raised $24 million from investors since 2009 .. employs 70 people [signonsandiego.com, Mar 2, 11]

Poseida Therapeutics (San Diego, CA)

Poseida Therapeutics down 31% [Aug 19, 20] A Phase 1 trial testing a Poseida Therapeutics cell therapy in men with prostate cancer is on hold after a patient enrolled in the study died of liver failure nearly three weeks after receiving the treatment. [Sarah de Crescenzo, xconomy.com, Aug 18, 20]

Poseida Therapeutics (San Diego, CA; no SBIR, founded 2015), a clinical-stage biopharmaceutical company leveraging proprietary non-viral gene engineering technologies to create life-saving therapeutics, today announced closing of a Series C financing round, raising $142 million led by a $75 million equity investment from Novartis Pharma AG [company press release, Apr 22, 19] prior funding $85M [crunchbse.com]

Poseida Therapeutics (San Diego, CA; no SBIR) filed for [IPO] to raise up to $115 million, .... working on a form of personalized immunotherapy for the treatment of cancer called CAR-T, or chimeric antigen receptor T cell therapy, with hopes to address some the current limitations of current CAR-T therapies. [MarketWatch, Jan 4, 19]

Possis Medical (Minneapolis, MN)

Possis Medical (Minneapolis, MN; $250K SBIR) up 35% [Feb 11, 08] as it sold itself to Bayer for $344M.

Pothole Pros (Waldorf, MD)

Fifteen university research teams from Maryland will receive a total of $4.1 million to work with local companies to turn their research into products that could one day be sold on the commercial market. .... MIPS will contribute $1.8 million and private companies will contribute $2.8 million. The companies: A&G Pharmaceutical (Columbia, MD; no SBIR), Rehabtics LLC (Baltimore, MD; no SBIR) High Impact Environmental (Church Hill, MD; no SBIR), Birich Technologies (Towson, MD; no SBIR), Earth Networks (Germantown, MD; no SBIR), Fiberight (Halethorpe, MD; no SBIR), CoolCAD Electronics (College Park,MD $1.6M SBIR), XChanger Companies (Annapolis, MD; no SBIR), Remedium Technologies (College Park, MD; no SBIR), Pothole Pros LLC (Waldorf, MD; no SBIR), Hoopers Island Oyster Aquaculture (Fishers Creek, MD; no SBIR), Metompkin Seafood (Crisfield, MD; no SBIR) GreatGrow Maryland LLC (Rock Hall, MD; no SBIR), vCalc (Hagerstown, MD; SBIR), Shore Thing Shellfish (Tall Timbers, MD; no SBIR). ($114,094) [Sarah Gantz, Baltimore Business Journal, Feb 26, 14]

PowerGenix (San Diego, CA)

in hybrid vehicles like the Toyota Prius and the Ford Focus. When they're stopped, so are their engines. When the driver presses down on the accelerator, powerful batteries start the engine and move the car Dan Squiller, chief executive of Scripps Ranch-based battery maker PowerGenix (no SBIR), is betting that technology will spread to other cars too, as it has in Europe. ... a good match for the nickel-zinc rechargeable batteries PowerGenix has been developing over the last decade. [Onell Soto, signonsandiego.com, May 25, 11]

Army's venture venture. The Army's VC (OnPoint Tech) current investment portfolio : A123 Systems (Boston, MA; $750K SBIR, IPO 2009) advanced Lithium-Ion based cells for rechargeable battery packs; Atraverda (UK) advanced bi-polar battery electrodes for rechargeable batteries; Integrated Fuel Cell Technologies (Burlingto MA; no SBIR) next generation fuel cell systems for portable devices; Nanosolar (Palo Alto, CA; $1.7M SBIR) thin-film solar technology for roll-to-roll printing of solar cells on flexible substrates, PowerGenix (San Diego, CA; no SBIR) next-generation rechargeable batteries; Power Precise (Herndon, VA; no SBIR) a fabless semiconductor company specializing in battery management devices; Ultra Cell (Livermore, CA; no SBIR) integrated fuel cell systems; Zinc Matrix Power (Santa Barbara, CA; no SBIR) high-performance rechargeable alkaline battery technology for commercial and military markets; Akermin (St Louis, MO; no SBIR) portable fuel cells based on its proprietary “Stabilized Enzyme Biofuel Cell” SEBC™ technology; Superprotonic (Pasadena CA; $200K SBIR) solid acid fuel cell. [defense-ventures.com] No surprise that a VC, even one doing it for the government, sees tech opportunity much different than does Army SBIR. I note that the three outside trustees (of five trustees) of OnPoint are a DOD political appointee, and entrepreneur/attorney, and Paul Gompers from Harvard Business School who with Josh Lerner publish a lot of venture research. Lerner did a lot of SBIR study until, I presume, he gave up on SBIR's ever being anything but a political handout.

PowerGenix (San Diego, CA; no SBIR; founded Y2K) is still a pip-squeak, having raised only $61 million from venture capitalists and praying for revenue of $10 million this year. ... In December it began selling its AA rechargeable nickel-zinc batteries in Ritz Camera stores. It now has agreements to deliver $70 million worth of its batteries over the next three years to makers of power tools, garden tools and electric scooters and bicycles; shipping starts this fall. The attraction: Zinc is plentiful, nontoxic, recyclable and enables production of batteries with a high rate of discharge. ... Says Lux Research Senior Analyst Ying Wu, "PowerGenix is the cheaper option, for now, and it has strong performance." But if the price of lithium-ion cells drops, Wu says, PowerGenix will be challenged. [Kerry Dolan, Forbes, May 11]

inc Power. PowerGenix (San Diego, CA) landed a $17M round of financing in November ... For the past few years, PowerGenix has been developing a battery that it says is as much as 75% lighter, 30% smaller and 10 times as powerful as existing nickel-cadmium or nickel-metal hydride batteries. [Wall Street Journal, Jan 29, 07] No SBIRs yet.

Powerlight (Berkeley CA)

Powerlight, of Berkeley, CA, a large venture-backed solar installer, ..just won a contract to help build the world's largest solar photovoltaic power project: a 11-megawatt solar power plant in Serpa, Portugal. [Apr 29, 06]

Power Precise Solutions (Herndon, VA)

Army's venture venture. The Army's VC (OnPoint Tech) current investment portfolio : A123 Systems (Boston, MA; $750K SBIR, IPO 2009) advanced Lithium-Ion based cells for rechargeable battery packs; Atraverda (UK) advanced bi-polar battery electrodes for rechargeable batteries; Integrated Fuel Cell Technologies (Burlington MA; no SBIR) next generation fuel cell systems for portable devices; Nanosolar (Palo Alto, CA; $1.7M SBIR) thin-film solar technology for roll-to-roll printing of solar cells on flexible substrates, PowerGenix (San Diego, CA; no SBIR) next-generation rechargeable batteries; Power Precise (Herndon, VA; no SBIR) a fabless semiconductor company specializing in battery management devices; Ultra Cell (Livermore, CA; no SBIR) integrated fuel cell systems; Zinc Matrix Power (Santa Barbara, CA; no SBIR) high-performance rechargeable alkaline battery technology for commercial and military markets; Akermin (St Louis, MO; no SBIR) portable fuel cells based on its proprietary “Stabilized Enzyme Biofuel Cell” SEBC™ technology; Superprotonic (Pasadena CA; $200K SBIR) solid acid fuel cell. [defense-ventures.com] No surprise that a VC, even one doing it for the government, sees tech opportunity much different than does Army SBIR. I note that the three outside trustees (of five trustees) of OnPoint are a DOD political appointee, and entrepreneur/attorney, and Paul Gompers from Harvard Business School who with Josh Lerner publish a lot of venture research. Lerner did a lot of SBIR study until, I presume, he gave up on SBIR's ever being anything but a political handout.

The Army is about to start using technology that measures the remaining power in batteries, developed by Herndon, Va.-based PowerPrecise Solutions, which received an investment from [Army VC] OnPoint in March 2004. The Army expects to save $65 million a year with the new product. It has put $61.8 million into the fund since Congress mandated its creation in the fiscal 2002 Defense Appropriations Act. .. The other Army "VC" investments: higher power density fuel cell system based on generating hydrogen from highly concentrated methanol for use in portable electronics (UltraCell); advanced rechargeable batteries based on silver zinc (Zinc Matrix Power);thin-film solar technology (Nanosolar). [Kimberly Palmer, GovExec, May 15]

PowerVision (Belmont, CA)

Medical device company PowerVision (Belmont, CA; no SBIR) raised $10 million to complete a $30 million Series D funding. ... developed an implantable lens that restores vision at all distances for people with cataracts and presbyopia. The lens mimics a healthy eye’s natural process of changing shape and adjusting focus. .... to complete patient enrollment in its ongoing lens study, which is expect to close by the end of the year, and help launch a new study next year. [Sarah Drake, Silicon Valley Business Journal, Jun 17, 14]

PowerVision (Belmont, CA; no SBIR) that is developing a new kind of lens for the eye closed on $24 million in financing by several backers, including Medtronic ... is developing an an intraocular lens, which is implanted in the eye. The idea is to restore the eye’s ability to adjust its focus. The company will use the funds to expand its research and development efforts and for a clinical trial in Europe. None of its products are as-yet approved for sale. [Janet Moore, Minneapolis Star Tribune, Jul 15, 11]

Pozen (Chapel Hill, NC)

A small Chapel Hill (NC) drug maker is teaming up with one of the world's largest pharmaceutical companies to create a painkiller that would neutralize a nagging side effect: stomach ulcers. As part of the deal, Pozen would receive up to $375M in payments and bonuses from AstraZeneca, which is based in London. If the drug wins U.S. regulatory approval for patient use, Pozen also stands to earn even more in sales royalties through 2023. The company's stock jumped nearly 40% on Wednesday's news. Pozen, a 10-year-old company with 35 employees, is demonstrating a talent coveted by many drug startups in the Triangle: attracting major corporate firepower to back experimental medicines. [Raleigh News and Observer, Aug 3] No SBIR record.

PQ Bypass (Sunnyvale, CA)

PQ Bypass (Sunnyvale, CA; no SBIR, founded 2009) has gathered $60 million in equity financing to move forward with its minimally invasive technology for treating long blockages in leg arteries caused by peripheral artery disease. [company press release, Jan 8, 19] prior funding $10M [crunchbase.com]

Prairie Technologies (Middleton, WI)

scientific equipment maker Bruker has acquired Prairie Technologies (Middleton, WI; $5.3M SBIR, 30-employees) that makes high-tech microscopes for an undisclosed amount. Bruker said that the acquisition will expand Bruker’s Nano Surfaces Division’s existing life science atomic force microscopy (Bio-AFM) systems [Don Seiffert, Boston Business Journal, Sep 13, 13]

Pranalytica (Santa Monica, CA)

Pranalytica (Santa Monica, CA; $500K SBIR) started as a developer of sensors for analyzing human breath for disease, but is now leading the quest to make small lasers that can knock down antiaircraft missiles. ... [Founder] At age 60, C. Kumar N. Patel had a resume of accomplishments few scientists could match. In a span of four decades, Patel invented the carbon dioxide laser, which revolutionized manufacturing and surgical procedures, obtained 38 patents and ran the physics and engineering departments at Bell Labs, a premier research operation historically attached to AT&T ... left the relative comfort of academia, tapped his life savings and started a tiny technology company .... Amid the rising concern about terrorists using chemical weapons, the Pentagon began looking for reliable, portable devices that could be used to detect chemical agents and explosives. Patel's technology looked promising. In 2004, the Defense Department awarded the company a $13-million grant. ... Since that 2008 breakthrough with the anti-missile laser, Pranalytica has grown to 15 employees. [Peter Pae, Los Angeles Times, Jan 26,09]

Praxis Biotechnology (Albany, NY)

Praxis Biotechnology (Albany, NY; no SBIR) startup recently won $50,000 at FuzeHub's commercialization competition. ... is developing a medication to reduce inflammation associated with rosacea without affecting the rest of the body. [Madison Iszler, Albany Times-Union, Nov 17, 17]

Precipio (New Haven, CT)

Precipio (New Haven, CT; no SBIR) down 21% [Jun 17, 19]

Precision Biopsy (Aurora, CO)

Precision Biopsy (Aurora, CO; no SBIR) biotech working on alternative prostate cancer biopsy procedures, said it's raised $33.6 million in new financing. ... [to] "accelerate commercial expansion of (its) ClariCore biopsy system, designed to provide accurate real-time classification of prostate tissue during biopsy procedures, and its Focal Therapy program which seeks to provide targeted localized therapy to reduce complications and improve outcomes." [Ben Miller, Denver Business Journal, Oct 5, 15]

Allied Minds, a Boston-based investment firm specializing in early-stage university ventures, has partnered with the University of Colorado to establish Precision Biopsy LLC, which is developing an optical biopsy needle to be used in diagnosis of prostate cancer. [Denver Post, Jul 16, 08]

Precision BioSciences (Research Triangle Park, NC)

Precision Biosciences down 16% [Apr 3, 20]

Precision Biosciences up 18% [Dec 20, 19]

Precision Biosciences (Durham, NC; $500K SBIR) down 52% [Dec 9, 19] announced updated interim clinical data from the ongoing Phase 1 trial of its lead investigational off-the-shelf (allogeneic) chimeric antigen receptor (CAR) T cell therapy candidate, PBCAR0191 [company press release, Dec 9, 19]

Precision Biosciences (RESEARCH TRIANGLE PARK, NC; $500K SBIR) up 25% [Nov 14, 19]

Precision BioSciences (Durham, NC; no SBIR) raising $126 million [IPO]. ... proprietary technology ARCUS reprograms a gene-editing enzyme called I-Crel, which is found in algae. [Frank Vinluan, xconomy.com, Mar 28, 19]

Precision BioSciences (Durham, NC; $500K SBIR, 130 employees) files plans for $100 million IPO. [Raleigh News & Observer, Mar 4, 19]

Gilead Sciences is partnering with Precision Biosciences (Durham, NC; $500K SBIR, founded 2006 ) that has used its proprietary gene-editing platform to develop products for both agriculture and human health. No upfront payments were disclosed, but if the alliance results in commercialized drugs, Precision stands to gain up to $445 million in milestone payments and royalties. [Frank Vinluan, xconomy.com, Sep 12, 18] Precision total funding $136M [crunchbase.com]

Precision BioSciences (Durham, NC; $500K SBIR, founded 2006) raised $110 million series B round. ... sets the genome editing specialist up to take its lead, off-the-shelf CAR-T therapy into clinical trials. [Nick Paul Taylor, Fierce Biotech, Jun 26, 2018] total funding $136M [crunchbase.com]

Fresh off a deal [with Baxalta] that could ultimately be worth $1.6 billion, Precision BioSciences will look to more than double its headcount this year. [Jason deBruyn,Triangle Business Journal, Apr 7, 16]

Baxalta, a global biopharmaceutical leader, and Precision BioSciences (Durham, NC; $500K SBIR), the genome editing company, announced a global collaboration to develop a broad series of allogeneic chimeric antigen receptor (CAR) T cell therapies directed towards areas of major unmet need in multiple cancers. .... Precision BioSciences will receive an upfront payment of $105 million from Baxalta, with additional option fees, developmental, clinical, regulatory, and sales milestones, potentially totaling up to $1.6 billion, in addition to royalties on worldwide sales. [joint companies press release, Feb 25, 16] Baxalta is a recent spin-off from Baxter International.

Precision BioSciences (Durham, NC; $500K SBIR) a Duke University spinout announced Monday it raised $25.6 million [Series A financing] to continue its work. ... to very precisely change the human genome. ... The possibility of altering human DNA carries so much upside that some scientists have begun to imagine a health care world so changed that it would hardly be recognizable by today’s standards. However, the scientific advances also cause some concern. [Jason deBruyn, Triangle Business Journal, May 11, 15]

NIST TIP winners $22 million in funding for nine research projects targeting innovative manufacturing technologies in fields ranging from biopharmaceuticals and electronics to renewable energy sources and energy storage: Isogenis (Aurora, CO; $4.8M SBIR); ActaCell, (Austin,TX; no SBIR); Engineered BioPharmaceuticals (Manchester, CT; no SBIR); Arsenal Medical (Watertown, MA; no SBIR); Kent Displays (Kent, OH; $2.6M SBIR); Precision BioSciences (Research Triangle Park, NC; $340K SBIR); Ginkgo BioWorks (Boston, MA; one SBIR); Sinmat (Gainesville, FL; $4.4M SBIR); Polyera (Skokie, IL; no SBIR).

Precision for Medicine (Chevy Chase, MD)

Biotech Precision for Medicine (Chevy Chase, MD, no SBIR) ranked #10 in VC funding for 2013 at $150 million , and the top collector for non-software/Internet firms. [Bruce Bigelow, xconomy.com, Jan 17, 13]

Precision Genome Engineering (Seattle, WA)

Precision Genome Engineering (Seattle, WA; no SBIR) or Pregenen, has been purchased by Bluebird bio ... Former Pregenen shareholders are also eligible to receive up to $135 million if certain clinical and commercial milestones are achieved. ... Pregenen is a recognized leader in the development and reprogramming of novel Homing Endonuclease and MegaTAL based enzymes that provide a highly specific and efficient way to silence, edit, or insert genetic components,” said Pregenen co-founder Dr. Andrew Scharenberg, in a statement. [Ben Miller, Puget Sound Business Journal, Jul 1, 14]

Precision Ocular Metrology (Albuquerque, NM)

Medical device startup Precision Ocular Metrology (Albuquerque, NM; no SBIR, founded 2012) [focused on mapping the topography of the eyes] is not only debuting a new product in the Albuquerque market, but is also keeping its headquarters here — a move that will create 10 new jobs in the coming months. ... the company benefited from the New Mexico Angel Investment Tax Credit, which allows accredited investors that file a New Mexico tax return to take a tax credit up to $25,000 in exchange for investing in local companies whose focus is high-tech or manufacturing. [Sal Christ, Albuquerque Business First, Oct 5, 15]

Precision Optics (Gardner,MA)

Precision Optics (Gardner, MA; $400K SBIR two decades ago) has formed a deal with Intuitive Surgical Operations Inc., a surgical robotics firm in California, bringing $2.5 million to Precision Optics. ... said it plans to continue pursuing its technology outside of medical robotics, focusing on its Lenslock endoscopes, Microprecision optical elements and handheld stereoendoscopes. [Michelle Lang, Mass High Tech, Aug 5, 11]

Precision Optics (Gardner, MA; $500K SBIR) sold its optical filter line to a New Jersey company for $250,000 and a three-year royalty agreement [Mass High Tech, Jan 22, 08]

Precision Optics which had a sliver of HHS SBIR money in the late 80s is in danger of de-listing for lack of $1 stock price for 30 days.

Precision Optics, a bit HHS SBIR played in the late 80s, raised another $5M in a rights offering to buy the $1.30 stock at $1

Precision Therapeutics (Pittsburgh,PA)

The recapitalization of Precision Therapeutics (Pittsburgh, PA; no SBIR, founded 1995) that transformed the life sciences company into Helomics caps a 20-year saga that illustrates just about every fundraising vehicle deployed in the region. Starting with high-net-worth individuals, the company landed a who's who of Pittsburgh business funders ... That gave way to venture capital rounds, led at first by local firms and then some of the largest national institutional investors. [Patty Tascarella, Pittsburgh Business Times, Nov 21, 14] dedicated to personalized cancer care. Precision offers a portfolio of products developed to help guide physicians and patients with difficult clinical decisions throughout the cancer care continuum. ... first commercial test, ChemoFx®, is a proprietary chemoresponse marker which helps improve patient outcomes by supporting physicians in the selection of effective treatments for women with gynecologic cancer. [company website]

West Penn Allegheny Health System, found that a test developed by Precision Therapeutics (Pittsburgh, PA; no SBIR) can show who will mostly likely not respond to platinum-based chemotherapy for ovarian cancer, a standard approach in treating the disease. More important, test results can be available before treatment begins. ..... began marketing the test in 2006, the company’s first and primary product, spokeswoman Pam Ranallo said. Krivak’s study is the first to demonstrate the product’s value before treatment begins. Platinum-based agents are the standard of care in treating ovarian cancer [Kris Mamula, Pittsburgh Business Times, Jul 11, 13]

Precision Virologics (St. Louis, MO)

Precision Virologics (St. Louis, MO; no SBIR) announced a $500,000 investment from Oncolys BioPharma, a publicly traded Japanese company focusing on the development of novel viral-based biologics for the treatment of cancer and serious infectious diseases. This investment signals global interest in the [company], which is developing biologically targeted vaccines for emerging infectious diseases, including Zika and Chikungunya. The half-million-dollar investment is the second major milestone in one week for Precision. Last Tuesday, the biotech company announced its entrance into a license agreement with the Office of Technology Management, the tech transfer arm of Washington University. [Washington University press release, Mar 31, 17]

Precisive Surgical (Seattle, WA)

Startup Carlsmed (San Diego, CA; no SBIR) and startup spine imaging system company Precisive Surgical (Seattle, WA; no SBIR) have completed a merger to develop a personalized surgical workflow platform [which] will combine clinical intelligence, advanced image recognition, and 3D printing to enable earlier surgical intervention delivering personalized implants to patients with complex, multi-level spinal alignment deviation, according to Carlsmed. [Nancy Crotti,medicaldesignandoutsourcing.com, Jul 19, 19]

Predictive Biosciences (Lexington, MA)

Predictive Biosciences (Lexington, MA; no SBIR) announced the completion of a $25 million Series C round of growth capital financing. ... describes itself as a commercial stage, fully-integrated developer of novel molecular diagnostic cancer assays and a provider of anatomic pathology laboratory products and services [Boston Globe, Jun 16, 10]

Predictive Biosciences (Lexington, MA; no SBIR) closed on a $21.75 million Series B financing to fund clinical trials for its oncology testing assays. The -based firm stated it would use the capital to develop its urine-based test that can detect the presence of cancer. The firm plans to launch a multi-center clinical trial for patients with recurring bladder cancer in 2009. A portion of the money will also be used to establish a new independent laboratory. [Mass High Tech, Oct 16, 08]

Pregmama (Gaithersburg, MD)

The Maryland Technology Development Corp. (Tedco) has invested $1.1 million in 14 state startups.The grants were made through the organization's Technology Commercialization Fund. ... toward advancing the each company's technology and product commercialization efforts. Common Curriculum LLC, Diagnostic Biochips Inc. and Firejack Inc. were each awarded $100,000. • Authentik Solutions LLC; Brain Sentry LLC; Clear Guide Medical LLC; ConverGene LLC; Cordex Systems LLC; Pregmama LLC; SameGrain, Inc; TimberRock Energy Solutions, Inc. and Vasoptic Medical, Inc. each received $75,000. • Magpie Sensing LLC was awarded $74,990 • Weinberg Medical Physics LLC received $60,000 [Baltimore Business Journal, Jul 19, 13]

Prellis Biologics (San Francisco, CA)

Prellis Biologics (San Francisco, CA; no SBIR, founded 2016) assembled $8.7 million in new funding alongside positive news from the first transplantation of its vascular tissue scaffolds. is building human tissues for drug development, and ultimately, developing human organs for transplantation. [Conor Hale, Fierce Biotech, Jul 31, 19] prior funding $10M [crunchbase.com]

Presage Biosciences (Seattle, WA)

Presage Biosciences (Seattle, WA; no SBIR) has been named one of FierceBiotech ’s “Fierce 15” of 2013. ... a spinoff company of the Fred Hutchinson Cancer Research Center .... patented a novel method for simultaneously analyzing multiple cancer drug candidates and drug combinations within a single tumor while that tumor is still in a patient. .... FierceBiotech evaluates hundreds of private companies from around the world each year before selecting the 15 it considers the most innovative, creative and promising. The other Fierce 14 are: Acetylon Pharmaceuticals; AnaptysBio; CytomX (Santa Barbara, CA; $500K SBIR); FibroGen (South San Francisco, CA; $1.3M SBIR); Immunocore; Jounce Therapeutics; Kala Pharmaceuticals; MacroGenics (Rockville, MD; $2.6M SBIR) ; Moderna Therapeutics; Nimbus Discovery; Scioderm; Ultragenyx; UniQure; and Visterra. [Valerie Bauman, Puget Sound Business Journal , Sep 24]

Presage Biosciences (Seattle, WA; no SBIR) said in a regulatory filing that it has raised $1.6M of an equity financing that could be worth as much as $10.5 million over time. Presage, a spinoff from the Fred Hutchinson Cancer Research Center, has some cool technology for helping separate the winners from the losers in the early stages of drug development. It has previously raised at least $4 million [Luke Timmerman, xconomy.com, Aug11, 11]

Presidio Pharmaceuticals (San Francisco, CA)

BioCryst Pharmaceuticals is buying Presidio Pharmaceuticals (San Francisco, CA; no SBIR) for $101 million in stock.... in a bid to achieve together what neither company has been able to do alone: produce new treatments for the debilitating hepatitis C infection that afflicts 170 million people worldwide..... despite more than $200 million spent on research and development. [John Murawski, Raleigh News & Observer, Oct 19, 12]

Pressure BioSciences (South Easton, MA)

Precision BioSciences (Durham, NC; $500K SBIR), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUSÂ® genome editing platform, announced that the Company will regain full rights and all data it generated for the in vivo chronic hepatitis B virus (HBV) program developed under its 2018 collaboration agreement with Gilead Sciences. ... Gilead funded the research and development and was responsible for the clinical development and commercialization of potential therapies. [company press release, Jul 10, 20]

Pressure BioSciences (South Easton, MA; $3M SBIR) a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, cosmeceuticals, nutraceuticals, and food & beverage industries, announced its intention to change the corporation's name to Availa Bio upon completion of the acquisitions and merger of Cannaworx, Inc. and SkinScience Labs, Inc. with PBI. [company press release, May 5, 20]

Pressure BioSciences (South Easton, MA, one SBIR), a 2009 Larta NIH-CAP company focused on the development of novel instruments and solutions to the error prone nature of biological sample preparation, has recently entered in to a distribution agreement with Netherlands-based LA Biosystems BV to market and sell their instruments in Belgium, the Netherlands, and Luxembourg. This follows on the coattails of a collaboration with the Henry C. Lee Institute of Forensic Science and international co-marketing and distribution agreements with KeraFAST LLC (USA), Digilab Inc. (USA), OROBOROS (Austria) and IUL Instruments GmbH (Germany). [LARTAVox, Mar 21, 12]

Pressure BioSciences (South Easton, MA; one SBIR) completed an $800,000 private placement ... to support commercialization of its Pressure Cycling Technology platform, which uses rapid cycles of hydrostatic pressure between ambient and ultra high levels to control biomolecular interactions. [Michelle Lang, Mass High Tech, Feb 9, 12]

On the heels of receiving $112,000 in loans from three of its investors, Pressure BioSciences (South Easton, MA; one SBIR) was awarded [$650K DOD SBIR] ... help fund the development of an automated, high-throughput, high-pressure system, including instruments and consumables, for safe and accurate processing of pathogenic organisms such as viruses and bacteria. [Lori Valigra, Mass High Tech, Oct 14, 11]

Pressure BioSciences(South Easton, MA; one SBIR) was awarded a $649,498 [SBIR] grant from the U.S. Department of Defense.... will help fund the development of an automated, high-throughput, high-pressure system, including instruments and consumables, for safe and accurate processing of pathogenic organisms such as viruses and bacteria. The system will be based on the company’s pressure cycling technology, which uses rapid cycles of hydrostatic pressure between ambient and ultra high levels to control biomolecular interactions. ... a substantial portion of the remaining development costs of a new system aimed at the sample preparation market. He estimated the size of that market at $6 billion, including approximately 80,000 laboratories and 500,000 researchers worldwide. [Lori Valigra, Mass High Tech, Oct 14, 11] Sounds an awful lot like merely reducing business risk for a working technology which competes with private capital and enters the territory of corporate welofare. Ah well, DOD likes certainty in its spending.

Pressure Biosciences (no SBIR) has pulled in $1.2 million through a combination of equity, warrants and securities. [Mass High Tech, Dec 4, 09]

Pressure BioSciences (South Easton, MA; no SBIR) sold about $1.16 million in stock and warrants, as a first tranche of a $2.5 million private placement. [Mass High Tech, Nov 19, 09]

Pressure BioSciences (South Easton, MA; no SBIR, 27 employees) has announced restructuring steps, including a 40 percent reduction in workforce, closing of a research facility in Rockville, Md., and widespread cost reductions ... will focus on Pressure Cycling Technology (PCT) for the mass spectrometry market, as well as the biological sample preparation market. Other company projects not related to the new strategy will be terminated. [Mass High Tech, Dec 2, 08]

PreTalen (Dayton, OH)

PreTalen (Beavercreek, OH; $2.3M SBIR, founded 2007) announce their recent award of the Agile Cyber Technology II (ACT II) contract [with] a ceiling value of $950M [company press release May 8, 18] announce that they have teamed up with LinQuest Corporation to serve the Joint Navigation Warfare Center ( JNWC) on a $99M contract, awarded by the United States Strategic Command. [company press release Mar 12, 18] claims 87% growth rate since 2007 with doubling in 2017. [company website] SBIRs sounds like standard analysis service for AF GPS navigation systems, but then SBIR innovation is in the eye of the beholder since the federal agency has full control of its definitions.

PreTalen Ltd. (Dayton, OH; at least $300K SBIR) was recently awarded a nearly $24 million contract for research and development with the Air Force Research Laboratory at Wright-Patterson Air Force Base. [Dayton Busines Journal, Jan 2, 17] Read USAF SBIR success story report.

Prevail Therapeutics (New York, NY)

Prevail Thera up 17% [Sep 12, 19]

Prevail Therapeutics (New York, NY; no SBIR) announced the pricing of its [IPO] to raise $125 million [company press relese, Jun 19, 19] developing disease-modifying gene therapies to prevail against neurodegenerative diseases [company website]

Prevail Therapeutics (New York, NY; no SBIR) is eyeing a $100 million IPO to continue development of gene therapies to treat neurodegenerative disorders. The company’s lead program, PR001, is an experimental treatment for Parkinson’s disease in patients who have a particular genetic mutation. says in its prospectus that the drug is also being developed to treat the neurological effects of Gaucher disease, an enzyme deficiency disorder. [Frank Vinluan, xconomy.com, May 28, 19]

Prevail Therapeutics (New York, NY; too soon for SBIR, founded 2017) developing gene therapies for patients with Parkinson’s disease and other neurodegenerative diseases, announced a $75 million Series A financing ... is pioneering the development of gene therapies with a goal of addressing the underlying disease process in Parkinson’s disease and other neurodegenerative disorders. [company press release, Mar 8,18]

Prevencio (Kirkland; WA)

Prevencio (Kirkland; WA; no SBIR) announced the successful results of a new heart disease test, which will enable the company to continue raising its $20 million Series C funding ... “With the successful presentation of clinical data of the HART CAD test at the European Society of Cardiology scientific sessions. [Casey Coombs, Puget Sound Business Journal, Sep 8, 16]

Preventice (Minneapolis, MN)

Regulators cleared [startup] Preventice ( Minneapolis, MN; no SBIR) remote heart-monitoring device for sale in Europe, the company announced .... pairs a smartphone with a device about the size of a pager in a single kit. Patients stick the device on their chests and the smartphone collects data, which physicians review after a set period of monitoring. ..... partnered with Mayo Clinic to develop the product. [Katherine Grayson, Minneapolis / St Paul Business Journal, Oct 9, 13]

Prevention Pharmaceuticals (New Haven, CT)

Prevention Pharmaceuticals (New Haven, CT; no SBIR) has sold $650,000 of a $2 million securities offering, through a combination of debt, options and warrants .... to introduce an OTC zinc-salts heartburn gel cap called Acid-Fix that is based on technology out of Yale University [Lori Valigra, Mass High Tech, Jan 13, 11]

Prieto Battery (Fort Collins, CO)

startup Prieto Battery (Fort Collins, CO; no SBIR), spun out of Colorado State University, has succeeded in producing what founder Amy Prieto calls “the first true 3-D battery that can be charged and discharged, and that will hold a charge”—in other words, that fills the basic requirements of a conventional battery. 3-D batteries could be cheaper to make, faster to charge, safer, smaller, and less environmentally toxic than conventional batteries. [Richard Martin, technologyreview.com, Oct 26, 15]

Primary Data (Los Altos, CA)

Even the best. Primary Data (Los Altos, CA; no SBIR) is reportedly the latest highly touted and well-funded Silicon Valley tech company to go bust, despite raising $100 million and having Apple co-founder Steve Wozniak as its "chief scientist." The company's website is dead and it hasn't immediately responded to requests [Silicon Valley Business Journal, Jan 22, 18]

Primera Biosystems (Mansfield, MA)

Primera Biosystems (Mansfield, MA; no SBIR) reports it has closed on a $20 million Series C round of financing, ... a molecular diagnostics company developing a proprietary nucleic acid analysis system [Mass High Tech, Sep 21, 09]

Molecular diagnostics company Primera Biosystems(Mansfield, MA; no SBIR) closed on a $21M Series B financing led by a British investment firm ... has operated quietly since it closed an $11M Series A financing in 2005. [Mass High Tech, Jan 8, 08]/p>

Primordial (St Paul, MN)

Primordial (St Paul, MN; $1M SBIR) which makes software that helps vehicles navigate off-road terrain, has landed a $2.9 million military contract. .... has received more than $10 million in military funding to develop the product since launching in 2002. [Katharine Grayson, Minneapolis / St Paul Business Journal, Nov 15, 12] Sounds like the Army found a product it likes and is using SBIR money for the final engineering. Legal, but.

PrimorigenBiosciences

Primorigen Biosciences got a Phase I SBIR grant of $362,714 from NIH. The grant allows the Madison biotech company to compete for an additional $1.6 million grant in the future, company executives said. Primorigen is developing new antibodies and other products for cell therapy research. ... will accelerate Primorigen’s development of a new protein detection test to support cell research on Type I diabetes, the company said. [Milwaukee Journal-Sentinel, Sep 4, 08]

Primus Power (Hayward, CA)

Primus Power (Hayward, CA; no SBIR) raised $20 million for a new round .... from [South African] strategic investor Anglo American Platinum [John Sailors, San Francisco Business Times, Feb 5, 14]

Princeton Satellite Systems (Plainsboro, NJ)

Reaching for the stars. Princeton Satellite Systems (Plainsboro, NJ; $7M SBIR) was selected for two NASA STTRs on their new topic, T2.01-9960, Advanced Nuclear Propulsion! Our research institution partner is Princeton Plasma Physics Laboratory. Our proposals were featured in NASA’s official press release! Here is a quote: High temperature superconducting coils for a future fusion reaction space engine. These coils are needed for the magnetic field that allows the engine to operate safely. Nuclear fusion reactions are what power our sun and other stars, and an engine based on this technology would revolutionize space flight. [company press release, Jun 6, 17]

Principia Biopharma (South San Francisco, CA)

Principia Biopharma (South San Francisco, CA; no SBIR, founded 2008) filed [IPO] to raise up to $86.3 million to carry its lead asset into phase 3. The company's BTK inhibitor is currently in phase 2 trials for the autoimmune skin disease pemphigus and is also being developed for immune thrombocytopenic purpura (ITP), a bleeding disorder. .... licensed a different BTK inhibitor, PRN2246, to Sanofi in November. This one is in development for multiple sclerosis and has been shown to cross the blood-brain barrier, opening the door to use in other neurological disorders. Principia picked up $40 million upfront and stands to reap up to $765 million in milestone payments. [Amirah Al Idrus, Fierce Biotech, Aug 19, 18] total funding $89M [crunchbase.com]

Principia Biopharma (South San Francisco, CA; no SBIR) raised $50 million in a Series B round aimed at pushing its experimental drugs against autoimmune diseases and cancer into clinical trials. .... raised $40 million in 2011 .... noted three drugs in its portfolio: An oral drug that inhibits BTK, or Bruton’s tyrosine kinase, an enzyme that is required for signaling B cell receptors that can lead to proliferation and survival of cancer cells in the blood. Principia said the drug could be used against cancer and autoimmune diseases; An oral inhibitor of FGFR, or fibroblast growth factor receptors, that can slow the progression of solid tumors, and; A drug tackling autoimmune and inflammatory diseases by blocking the path of IL-17, which is produced by cells that respond to a breach of the immune system. IL-17, which scientists believe plays a role in multiple sclerosis, rheumatoid arthritis and other conditions, activates cells that produce more of a certain type of small proteins, called cytokines, that promote inflammation. [Ron Leuty, San Francisco Business Times, Apr 22, 14]

Prism Solar Technologies (Lake Katrine, NY)

solar-power startups in particular have seen a three-year surge, from a low of no venture investment in the third quarter of 2005 to a high of more than half a billion dollars in the second quarter of this year. CaliSolar (Sunnyvale, CA; no SBIR) $13M; Wakonda Technologies (Fairport, NY; $200K SBIR) $9M; Prism Solar Technologies (Lake Katrine, NY; no SBIR) $9M. [Dean Takahashi, MIT Tech Review, S/O 08]

Procept BioRobotics (Redwood Shores, CA)

Medical-device startup Procept BioRobotics (Redwood Shores, CA; no SBIR, founded 2009) raised $42 million to treat prostate issues. ... has raised $43.6 million to date. ... to develop a surgical product for trans-urethral resection of prostate tissue ... for a limited commercial launch of AquaBeam in targeted international markets [Gina Hall, Silicon Valley Business Journal, Jul 7, 15]

ProCertus BioPharm (Madison, WI)

Other [Wisconsin] companies the MoneyTree report showed raising venture funding in the second quarter were: Aquarius Technologies (Port Washington, WI; no SBIR) developer of wastewater treatment technologies, $4 million; NeuWave Medical (Madison, WI; no SBIR) medical device company, $2.63 million; ProCertus BioPharm (Madison, WI; $1.6M SBIR) drug developer, $1.7 million; and Zurex Pharma (Madison, WI; no SBIR) drug developer, $1 million. [Kathleen Gallagher, Milwaukee Journal Sentinel, Jul 19, 11]

ProCertus BioPharm< (Madison, WI; $1.6M SBIR) has raised $1.7 million to fund clinical trials to determine whether its products can safely help cancer patients avoid side effects of radiation and chemotherapy. ... ProCertus' products are applied to skin or the inside of the mouth minutes before cancer therapy to protect cells that will be exposed to chemotherapy and radiation. [Kathleen Gallagher, Milwaukee Journal Sentinel, Apr 5, 11]

ProCertus BioPharm (Madison, WI; $1.6M SBIR), developing drugs to protect cancer patients from common chemotherapy and radiation side effects will announce Tuesday it has raised $2.1 million. ... has also started enrolling patients in a clinical trial to determine whether its DermX product prevents burns caused by radiation therapy, said Paul Weiss, the company's acting chief executive officer. .... ProCertus licenses its technology from the Wisconsin Alumni Research Foundation. The company raised $2.3 million in 2007. [Kathleen Gallagher, Milwaukee Journal Sentinel, Jun 30, 09]

div class="pharma">

Processa Pharmaceuticals (Hanover, MD)

biotech Processa Pharmaceuticals (Hanover, MD; no SBIR, founded 2009) raising $8 million [Morgan Eichensehr,Baltimore Business Journal, May 22, 18] total funding $2.5M [crunchbase.com] lead product, PCS499, will be investigated for the treatment of Necrobiosis Lipoidica, a necrotizing skin condition, caused by several pathophysiological changes. [company website]

Proclara Biosciences (formerly NeuroPhage Pharmaceuticals (Cambridge, MA)

Despite a litany of high profile failures among drugs to fight Alzheimer’s disease, biotechs and pharma companies continue to pour billions of dollars into the fight. The latest firm to get a financial boost is a startup from , that until today has been known as Neurophage Pharmaceuticals (Cambridge, MA; no SBIR). .... has raised $47 million from current backer Merieux Development and a group of high net worth individuals, and changed its name to Proclara Biosciences. [Ben Fidler, xconomy.com, Sep 7, 16]

Procyrion (Houston,TX)

Procyrion (Houston, TX; no SBIR) medical device company, raised $5.15 million of what is expected to be a $10 million raise, according to [SEC] filing ... manufactures a booster pump for the heart that is less stressful than surgery. [Joe Martin, Houston Business Journal, Jul 14, 15]

Fannin Innovation Studio (Houston, TX) currently has 10 portfolio companies, which include Procyrion (Houston, TX; no SBIR), a medtech device startup that makes Aortix, a thinner-than-a-pencil circulatory support pump implanted in the aorta through the femoral artery via a catheter. [Angela Shah, xconomy.com, Feb 11, 15]

Profectus BioSciences (Baltimore,MD)

Profectus BioSciences (Baltimore, MD; $2.4M SBIR) received a $9.5 million DOD grant for a phase 1 clinical trial of its Ebola vaccine. ... Profectus' fourth this year — all for work developing and manufacturing Ebola vaccines. The new grant brings the company's total funding up to at least $49.8 million. ... new grant will support a clinical trial of Profectus' VesiculoVax, a vaccine for Ebola Zaire, a common strain of the deadly virus [Sarah Gantz, Baltimore Business Journal, Oct 31, 14]

Profectus BioSciences (Baltimore, MD; $1M SBIR) was awarded a total of $6.25 million in funds from the [NIH]. ...includes three SBIR grants totaling $2.9 million. ... develops vaccines for chronic viral diseases ... grants are in addition to $4.4 million the company recently secured. Those funds included an SBIR grant of $3.1 million ... an HIV and cancer research company, is a spinout from the Institute of Human Virology formed to commercialize research spearheaded by Dr. Robert C. Gallo, the famed AIDS co-discoverer who oversees the institute. [Emily Mullen, Baltimore Business Journal, Oct 7, 10]

Progenics Pharmaceuticals (Tarrytown, NY)

Lantheus Holdings, a leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, and Progenics Pharmaceuticals, (Tarrytown, NY; $34M SBIR) an oncology company developing innovative medicines and artificial intelligence to find, fight and follow cancer, announced a definitive agreement for Lantheus to acquire Progenics in an all-stock transaction. [joint companies press release, Oct 2, 19]

Progenics Pharma up 17% [Aug 22, 19]

Progenics Pharma down 16% [Aug 12, 9]

Progenics Pharma down 18% [Sep 13, 18]

Progenics Pharma down 10% [Mar 23, 18]

Progenics Pharma up 15% [Mar 8, 18]

Progenics Pharma up 10% [Dec 13, 17]

Progenics Pharma up 11% [Sep 18, 17]

Progenics Pharma up 12% [Aug 28, 17]

Progenics Pharma down 15% [Aug 9, 17]

Progenics Pharma down 13% [May 4, 17] reported wider loss [company press release, May 4, 17]

Progenetics Pharma up 10% [Feb 16,17]

Progenics Pharma up 10% [Nov 8, 16]

Progenics Pharm up 11% [Sep 30, 16]

Progenics Pharma up 24% [Jul 20, 16]

Progenics Pharma down 10% [Mar 15,16]

Progenics Pharmaup 18% [Feb 16, 16]

Progenics Pharma up 11% [Oct 23,15]

Progenics down 11% [Jul 29,15]

Progenics Pharma up 14% [Jun 30, 15]

Progenics Pharma down 11% [Jun 24, 15]

Progenics Pharma up 10% [May 6,15]

Progenics Pharma up 17% [Nov 7, 14]

Salix Pharmaceuticals announced that federal regulators have signaled they will approve its drug Relistor for treatment of chronic pain in non-cancer patients. ... will not require Salix and its partner Progenics Pharmaceuticals to submit additional data as part of its new drug application. [David Bracken, Raleigh News & Observer, Jul 14, 14]

Progenics Pharma up 16% [Jan 30, 14]

Progenics Pharma down 27% [Jan 29, 14]

Progenics Pharma up 10% [Nov 21, 13]

Progenics Pharma down 10% [Sep 16, 13]

Progenics Pharma up 12% [Jul 11, 13]

Progenics Pharma down 11% [Jun 20, 13]

Progenics Pharma up 31% [Jun 11, 12] said a [FDA] advisory committee will review Salix's opioid-induced constipation treatment in patients with chronic pain, after Salix formally appealed the FDA's response on the drug last year. [Wall Street Journal, Jun 11]

Progenics Pharma down 14% [May 1, 13]

Progenics Pharma up 29% [Mar 15, 13]

Progenics Pharma (Tarrytown, NY; $34M SBIR, until 2007) up10% [Mar 7, 13]

Progenics Pharma down 50% [Jul 30, 12]

Progenics Pharma up 31% [Dec 20, 11] after [Progenics and Salix] said a late-stage study for an expanded use of the constipation treatment Relistor yielded positive results. [AP, Dec 20]

Progenics Pharma up 21% [Nov 30, 11]

Progenics Pharmaup 15% [Oct 4, 11]

Progenics Pharma up 10% [Aug 29, 11]

Progenics Pharma up 11% [Aug 15, 11]

Progenics Pharmaup 12% [Aug 11, 11]

Progenics Pharma up 16% [Aug 9, 11]

Progenics Pharma down 11% [Aug 4, 11]

Progenics Pharma up 11% [Sep 22, 10]

Progenics Pharma up 13% [Jul 21, 10]

Progenics Pharma down 10% [Jul 16, 10]

Progenics Pharma up 11% [May 26, 10]

Progenics Pharma up 12% [May 12, 10]

Progenics Pharma up 11% [Nov 16, 09]

Progenics Pharma down 11% [Jun 22, 09]

Progenics Pharma down 12% [Apr 20, 09]

Progenics Pharma up 14% [Mar 26, 09]

Progenics Pharma up 11% [Mar 23, 09]

Progenics Pharma up 14% [Mar 12, 09]

Progenics Pharma down 21% [Dec 1, 08] On a stock bloodbath day

Progenics Pharma down 11% [Nov 14, 08]

Progenix Pharma down 10% [Oct 22, 08]

Progenics Pharma up 11% [Oct 13, 08]

Progenics Pharmaceuticals which dropped more than 60% when its lead drug, Relistor, failed a phase 3 trial last month for postoperative ileus, a constipation-like condition that follows abdominal surgery. Then the stock jumped more than 30% in the other direction yesterday after the drug was recommended for approval in the European Union for treating opioid-induced constipation (OIC), and is trading up another 26% today after the FDA approved it last night. In fact Progenics has roughly tripled since I said investors had overreacted to the failed drug study. [motleyfool.com, Apr 25, 08]

Progenics Pharmaceuticals up 22%, topped the list of Biggest Percentage Price Gainers on the Nasdaq. Wall Street Journal, Apr 22]

Progenics Pharmaceutical up 19% after the company said its Relistor constipation drug was approved for sale in Canada. [AP, Apr 1, 08]

Progenics Pharmaceuticals down 63% after the company and its partner Wyeth said their constipation drug failed a late-stage clinical trial. [AP, Mar 12, 08]

Progenics Pharmaceuticals up 10% [Jan 8, 08]

Progenity (San Diego, CA)

Venture Capital investments in San Diego 3Q2016. Ostendo Technologies (Carlsbad, CA; one SBIR) $42 million; Tealium ( San Diego; no SBIR) $35 million ; Singlera Genomics (San Diego, CA; no SBIR) $20 million; Avelas Biosciences (San Diego, CA; no SBIR) $20 million ; Fortis Therapeutics (San Diego, CA; no SBIR) $18 million ; Histogen (San Diego, CA; no SBIR) $16 million ; Medsphere Systems (Carlsbad, CA; no SBIR) $15 million; CellSavers (San Diego, CA; no SBIR) $15 million; Progenity (San Diego, CA; no SBIR) $12 million; AristaMD (San Diego, CA; no SBIR) $11 million. [Bruce Bigelow, xconomy.com, Oct 11, 16]

Progeny Systems (Washington, DC)

Progeny Systems (Washington, DC; 271 SBIR awards for something like $90M] landed a potential four-year, $303.1M contract to produce MK54 Mod 1 lightweight torpedo kits and provide complementary test tools, spares and technical services for the U.S. Navy and foreign military sales customers. [Nichols Martin, GovCon Wire, Aug 23, 18] Its SBIRs sound like ordinary engineering with little technical risk for which both the DOD and the contractor will surely claim worthy innovation. One award "developed a social media analytics toolkit." Work will be in Utah, Pennsylvania, and Virginia. Where's the problem when both parties got what they wanted? It depends on the innovation value of the SBIR Phase 2 proposals that just missed acceptance but there is no public mechanism for asking that question when the agency has sole autonomy for picking winners.

Prologic

Efficient Ears. On average, companies generated roughly $28 in earmark revenue for every dollar they spent lobbying. By any standard, that's a hefty ratio: The companies in the Standard & Poor's 500-stock index brought in just $17.52 in revenues for every dollar of capital expenditure in 2006. ... Says Keith Ashdown, chief investigator for the watchdog group Taxpayers for Common Sense: "The lion's share of these projects is about politics and jobs, rather than real needs." [Business Week, Sep 17] The earmark efficiency champ is an SBIR company, Scientific Research (Atlanta GA and others; about $15M SBIR), that got $344 in earmarked funds per dollar of political "investment".Other SBIR investors: Isothermal Systems (KY and WA; $2M SBIR) at $221 per lobbying dollar; Prologic (Fairmont WV; $2M SBIR) at $133 per dollar; Trex Enterprises (San Diego CA; $7M SBIR) at $116 per dollar. From an efficiency viewpoint, politicians make a good investment. You just have to learn how to kiss frogs.

Promedior (Malvern, PA)

Promedior (Lexington, MA; no SBIR, founded 2012, 10 employees) says its drug to treat a rare bone marrow disease known as myelofibrosis can reverse the disease and allow patients to start producing blood normally again. The company presented results of the first part of a Phase 2 trial of PRM-151 .... most recent investment came in 2012, a $22 million round that brought the company's total to $65 million, according to federal filings. [Don Seiffert, Boston Business Journal, Dec 9, 14]

Promedior (no SBIR), a biotechnology company relocating here from [Malvern, PA], has opened new office and lab space in Lexington, ... looking to develop treatments for fibrosis, and it said it has raised a total of $65 million in funding to date.... In a statement, Bruhn said: “We were attracted to the unique resources of the Massachusetts life sciences industry, which includes the full complement of world class companies involved in drug development along with highly innovative government initiatives that support biotechnology companies. [Chris Reidy, Boston Globe, Dec 17, 12] Live better where your industry thrives.

Promedior (Malvern, PA. no SBIR) raised $21.5 million in a first closing of a series D round of venture capital financing [John George, Philadelphia Business Journal, Mar 7, 12]

Promega (Madison, WI)

Promega (Madison, WI; $3.7M SBIR) has signed a licensing agreement with MilliporeSigma, the U.S. life sciences business of German pharmaceutical and chemical company Merck KGaA. The agreement allows Promega to use MilliporeSigma’s genome-editing technology to create research products and services. [Katherine Davis, WiscInno, Jan 2, 20]

The Scientist strives annually to identify the latest and greatest tools, technologies, and techniques to hit the life-science landscape. This year’s selection includes Quanterix (Lexington, MA; $200K SBIR) brought its Simoa biomarker detection technology to the lab bench, launching the compact SR-X system; Promega (Madison, WI; $5M SBIR) new protein detection system excels at measuring protein levels across the cell; and Dharmacon (Lafayette, CO; $1.6M SBIR) launched on the market in June 2017, instead provides users with an arrayed library of synthetic crRNA guides with a “one-well-per-gene” format, allowing for a much subtler assay. [The Scientist, Nov 30, 17] .

Reversed. The U.S. Court of Appeals affirmed a Wisconsin judge’s decision to overturn a verdict awarding $52 million in damages to Promega [Fitchburg, WI; $4M SBIR) , according to Life Sciences Intellectual Property Review, a trade publication. Promega, which manufactures reagents and other life sciences research tools, had earlier brought suit against Life Technologies, a business unit of Waltham, MA-based Thermo Fisher Scientific (NYSE: TMO). Promega claimed in the lawsuit that Life Technologies infringed on a U.S. patent when the company supplied a plant in London with an enzyme meant to be combined with other components to make DNA analysis kits. [Jeff Buchanan, xconomy.com, Nov 20, 17]

Promega (Madison, WI; $5M SBIR in 1990s) said it plans to seek FDA approval for one of its products for the first time. The product—a test that doctors would use to make decisions around diagnosing and treating patients with colorectal cancer—has been in use since 2004, but has only been used as a lab-developed test (and therefore is not subject to the same FDA oversight as other diagnostics). [Jeff Buchanan, xconomy.com, Jul 12, 17]

The U.S. Supreme Court ruled against Promega in a patent case the lab supplies maker had brought against Life Technologies, a business unit of Thermo Fisher Scientific the [AP] reported. Promega filed suit claiming that Life Technologies infringed on a U.S. patent when the company supplied a plant in London with an enzyme meant to be combined with other components to make DNA analysis kits. [Jeff Buchanan, xconomy.com, Mar 7, 17]

The Supreme Court sided with Life Technologies in a patent infringement case that limits the international reach of U.S. patent laws. The justices ruled unanimously on Wednesday that the company’s shipment of a single part of a patented invention for assembly in another country did not violate patent laws. Life Technologies supplied an enzyme used in DNA analysis kits to a plant in London and combined it with several other components to make kits sold worldwide. Promega (Madison, WI; $5M SBIR) sued, arguing that the kits infringed a U.S. patent. [AP, Feb 22, 17]

Representatives of a global investment banking firm are calling shareholders of Promega (Madison, WI; $5M SBIR, founded 1978) [maker of biotech research tools] to say an investor group's $625-a-share offer is lower than comparable transactions in the industry, a shareholder told the Journal Sentinel ... "Promega is one of the stars of the tech story in Wisconsin," said Don Layden, a Milwaukee lawyer who is not connected with the situation. [Kathleen Gallagher, Milwaukee Journal Sentinel, Oct 13, 15]

Promentis Pharma (Milwaukee, WI)

Promentis Pharmaceuticals (Milwaukee, WI; $500K SBI) announced that it has commenced a Phase 1 single ascending dose study for its lead compound, SXC-2023. Promentis is developing SXC-2023 and other compounds that engage System xc-, a central nervous system (CNS) target addressing glutamatergic imbalance and oxidative stress, to treat obsessive-compulsive and related disorders, substance-related and addictive disorders and other neuropsychiatric disorders. SXC-2023 has demonstrated a compelling profile across a range of non-clinical studies. [company website, Nov 20, 17]

Promentis Pharmaceuticals (Milwaukee, WI; $500K SBIR) that is developing drugs to treat schizophrenia and other psychiatric disorders, has raised an additional $17.2 million from investors, bringing the total in its third round of financing to $26 million. [Guy Boulton, Milwaukee Journal Sentinel, Mar 29, 17]

Promentis Pharmaceuticals (Milwaukee, WI; $500K SBIR, founded 2007) developing compounds for the treatment of schizophrenia and other central nervous system disorders, has raised $8.7 million in equity funding, according to [SEC] filing ... said it is developing compounds aimed at modifying brain chemistry by targeting the glutamate system, which is critical to transmitting signals in the brain. Promentis previously raised $2.9 million of venture capital in 2014. [Kathleen Gallagher, Milwaukee Journal Sentinel, Oct 10, 16]

Promentis Pharmaceuticals (Bayside, WI; $500K SBIR) developing drugs that modify brain chemistry to treat central nervous system (CNS) disorders, inked an exclusive licensing deal this month with the University of Montana. The two have been research partners for about five years [Jeff Engel, xconomy.com, Feb 12, 15]

Promentis Pharmaceuticals (Milwaukee, WI; $500K SBIR, founded 2007, three full-time employees) that is developing drugs to treat schizophrenia and other central nervous system disorders, has raised $2.9 million from investors, company executives said. .... developing compounds aimed at modifying brain chemistry by targeting the glutamate system, which is critical to transmitting signals in the brain. The company will use the money to bring two of the compounds into clinical trials for humans, said Chad E. Beyer, president and chief executive officer. The funding provides the "financial bandwidth" to get the two compounds into clinical trials within the next two years, Beyer said. .... exclusively licensed its original technology from Marquette University and the University of Wisconsin-Milwaukee. ... In 2012, it received a $1.8 million [NIH] award [Kathleen Gallagher, Milwaukee Journal Sentinel, Jan 16, 14]

Chad E. Beyer, the former head of neurochemistry at Wyeth Pharmaceuticals, has been named [CEO] at Promentis Pharmaceuticals (Milwaukee, WI; $500K SBIR) drug development start-up. [Milwaukee Journal Sentinel, Jul 25, 13]

Promentis Pharmaceuticals (Milwaukee, WI; $500K SBIR) developing drugs to treat schizophrenia and other central nervous system disorders said Thursday it has raised $1.94 million from investors. [Kathleen Gallagher, Milwaukee Journal Sentinel, Feb 26, 10]

Promentis Pharmaceuticals (Milwaukee, WI; $500K SBIR; founded 2006) will receive a $250,000 Technology Venture Fund loan from the state Department of Commerce to continue development of pharmaceuticals that treat psychiatric, behavioral and neurological disorders. ... initially focused on the development of a new class of antipsychotic medications for the treatment of schizophrenia. [Business Journal of Milwaukee, Feb 11, 10]

start-ups in the drug field within the Milwaukee 7 economic development region suggests another strategic direction for the regional economy. Those new ventures come as Concordia University of Wisconsin mounts an impressive campaign to build a new pharmacy school in southeastern Wisconsin, possibly in downtown Milwaukee. ... New ventures in the emerging drug-making concentration: MPP Group (no SBIR),a venture headed by serial entrepreneur Frank Langley that is building drugs aimed at alcoholism. James Cook, a University of Wisconsin-Milwaukee researcher, developed the compounds. Neuro Amp (no SBIR),a spin-off from PhysioGenix (Wauwatosa, WI; $3M SBIR) that is aiming at diseases of the central nervous system and Alzheimer's. Promentis (no SBIR), collaboration between Marquette University's David Baker and UWM researchers and former Schwarz Pharma managers who are targeting schizophrenia and central nervous system disorders. Cytometix (no SBIR),a 2004 start-up headed by Lane Brostrom that is developing drugs for the treatment of pain and asthma. Endece (no SBIR),a 2006 Mequon start-up headed by James Yarger that is developing compounds for treating cancer, sepsis, learning and memory. [John Torinus, Milwaukee Journal Sentinel, Jan 31, 09]

Prometheus (Sharon, MA)

Prometheus (Sharon, MA; $8M SBIR) has upsized its IPO, positioning it to reel in $190 million to bankroll clinical development of an anti-TL1A monoclonal antibody in IBD. [ Nick Paul Taylor, Fierce Biotech, Mar 12, 21 ]

Prometheus Laboratories (San Diego, CA)

Eight years after biotech Prometheus Laboratories (San Diego, CA; $400K SBIR) was acquired by Nestlé Health Science, the diagnostic business has been sold again, this time to a little-known biotech called Precision IBD {San Diego, CA; no SBIR) that plans to lay off approximately a quarter of Prometheus’s workforce. [Sarah de Crescenzo, xconomy.com. Jul 11, 19]

PROMISS Diagnostics (Wauwatosa, WI)

PROMISS Diagnostics (Milwaukee, WI; no SBIR, founded 2017), developing an early-detection ovarian cancer test, has raised $400,000 in a seed round of funding, the company announced. PROMISS Diagnostics is a venture-stage biotech company that develops bio-analytical solutions to assist physicians in improving women’s health outcomes. [Milwaukee BizTimes, Apr 29, 20]

PROMISS Diagnostics (Wauwatosa, WI; no SBIR), a startup that is developing a noninvasive, commercialized screening test for ovarian cancer that uses a machine learning algorithm to distinguish between a benign and malignant mass, has closed on $400,000 in capital to further develop its screening test. [WiscInno, Jan 12, 20]

Pronutria formerly Essentient (Cambridge, MA)

Pronutria (Cambridge, MA; no SBIR) said it's raised $12.25 million in new funding and launched two clinical trials for its novel nutrient products that can treat diseases. ... formerly named Essentient, founded in 2011 .... emerged from stealth mode in November, with details about its ProNutrein products and its $10.8 million in Series A funding [Kyle Alspach, Boston Business Journal, Feb 14, 14]

Pronutria, (formerly Essentient, Cambridge, MA; no SBIR) unveiled details about its funding from founder Flagship Ventures and its plans to offer novel nutrient products that can treat diseases. .... disclosed that it raised $10.8 million in Series A funding during [past two years] .... company says its ProNutrein products are naturally occurring, orally consumed pure protein products that "trigger pharmacological effects through precise and reproducible delivery of specific amino acids." [Kyle Alspach, Boston Business Journal, Oct 22, 13]

Propagenix (Rockville, MD)

Maryland Technology Development Corp approved awards of $8.5 million to 29 new stem cell research projects. The for-profit firms each receiving over $1M are: TissueGene (Rockville, MD; $100K SBIR), Longeveron LLC (Miami, FL; no SBIR), MaxCyte (Gaithersburg, MD; $1M SBIR), Propagenix (Rockville, MD; no SBIR), Seraxis (Germantown, MD; no SBIR), and 3Dnamics (Germantown, MD; no SBIR). [Morgan Eichensehr, Baltimore Business Journal, May 16, 17]

Pro-Pharmaceuticals

Pro-Pharmaceuticals has closed a $6 million private placement [Mass High Tech, May 12, 10]

Propeller Health (Madison, WI)

Propeller Health (Madison, WI; no SBIR) announced that it received FDA clearance to market a sensor it has developed for use with Ellipta, a dry powder inhaler made by the U.K.-based pharmaceutical giant GlaxoSmithKline. .... PH makes Internet-connected inhalers and sensors designed to help patients with asthma and chronic obstructive pulmonary disease. [Jeff Buchanan, xconomy.com, Nov 8, 16]

Propeller Health (Madison, WI; no SBIR) said it’s partnered with the U.K.-based Vectura Group to develop a connected dry powder inhaler for patients with asthma and chronic obstructive pulmonary disease (COPD). The two groups will initially work to develop an add-on sensor for one of the inhalers that Vectura currently sells. The announcement comes on the heels of partnerships Propeller has forged or expanded with Boehringer Ingelheim (Germany), Aptar Pharma (Crystal Lake, IL; no SBIR), and GlaxoSmithKline (U.K.) during the past six months. GSK’s Ellipta inhaler is also of the dry powder variety, as opposed to other types like soft mist and metered-dose. [Jeff Buchanan, xconomy.com, May 31, 16]

Propulsive Wing (Syracuse, NY)

Most Innovative Technology ... at the 10th Annual SmartStart UNYTECH Venture Forum–– Propulsive Wing, (Syracuse, NY; no SBIR) developing an unmanned aerial vehicle (UAV) platform. [Business Review (Albany), May 19, 10]

ProstaGene (Wynnewood, PA)

ProstaGene (Wynnewood, PA; no SBIR) raised $400,000 from private investors to support commercialization of a gene-based test to help guide prostate cancer treatment. [John George. Philadelphia Business Journal, May 3, 16]

Protagonist Therapeutics (Menlo Park,CA)

Protagonist Therapeutics (Newark, CA; $3.2M SBIR) down 19% {Jul 3, 2023] announced positive topline results from the Phase 2b FRONTIER 1 clinical trial evaluating the oral interleukin-23 receptor (IL-23R) antagonist JNJ-2113 (formerly PN-235) in adult patients with moderate-to-severe plaque psoriasis (PsO)[i] presented at World Congress of Dermatology in Singapore. [company press release, Jul 4, 2023]

Protagonist Therapeutics (Newark, CA; $3.2M SBIR) up 52% [Mar 7, 2023] announced positive topline results from its collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) , in the FRONTIER 1 Phase 2b clinical trial evaluating the oral Interleukin-23 receptor (IL-23R) antagonist peptide JNJ-2113 in patients with moderate-to-severe plaque psoriasis. [company press release, Mar 7, 2023]

Protagonist Therapeutics (Newark, CA; $3.3M SBIR) down 50% [Apr 26, 22] announced topline results from the Phase 2 IDEAL study evaluating PN-943 in patients with moderate-to-severe ulcerative colitis (UC). [company press release, Apr 25, 22]

Protagonist Therapeutics (Newark CA; $3.2M SBIR) down 22% [Apr 22]

Protagonist Therapeutics (Newark, CA; $3.2M SBIR) up 84% [May 8, 20] announced initial data from the ongoing Phase 2 study of PTG-300 in patients with polycythemia vera. The current results demonstrate that treatment with PTG-300 at individualized doses ranging from 10 mg to 80 mg for up to 28 weeks provided dose-related control of hematocrit levels and eliminated the need for phlebotomy in all six out of six patients that received the dosing as per protocol. [company press release, May 7, 20]

Protagonist Thera up 16% [Sep 27, 16]

Protagonist Therapeutics (Milpitas, CA; two SBIRs) IPO raised $90 million. .... is working on oral drugs to treat inflammatory bowel disease. [Cromwell Schubarth, Silicon Valley Business Journal, Aug 11, 16]

Protagonist Therapeutics (Milpitas, CA; one prior SBIR) set targets for its upcoming IPO in which it hopes to raise up to $87.2 million. [Cromwell Schubarth, Silicon Valley Business Journal, Aug 1, 16] [won Phase 1 SBIR] that supports preclinical research aimed at discovering and optimizing lead molecules as novel peptide mimetics of the natural hepcidin hormone. Protagonist aims to develop these mimetics as potential injectable treatments for iron overload disorders, such as beta-thalassemia and hereditary hemochromatosis. [company press release, Jul 28, 16] announced the closing of a $40 million Series C financing [company press release, Aug 10, 15]

Protagonist Therapeutics (Milpitas, CA; no SBIR, founded 2001) filed plans to raise up to $75 million in IPO. .... develops drugs that treat colon diseases. .... has raised $67 million since it was founded [Cromwell Schubarth, Silicon Valley Business Journal, Jul 11, 16]

In its second round of venture funding, Protagonist Therapeutics (Menlo Park, CA; no SBIR) raised $14 million.
... to develop alternatives to biologic and small molecule drugs using new technology called disulfide-rich peptide, or DRP. Johnson & Johnson Development Corp. led the round [Stephen EF Brown, San Francisco Business Times, Jun 4, 13]

Protein Foundry (Milwaukee, WI)

Protein Foundry LLC (Milwaukee, WI; no prior SBIR), a Medical College of Wisconsin spin-off that makes specialty biochemical compounds for researchers, said it has received a $250,000 [NIH SBIR] grant. ... to develop a safe and efficient method for delivering therapeutic proteins into nerve cells [Kathleen Gallagher, Milwaukee Journal Sentinel, Oct 14, 15] manufactures recombinant proteins for biomedical research [company website]

Protein Sciences (Meriden,CT)

Flublok, a flu vaccine made from cells rather than egg protein, is now available at Target pharmacies as its developer, Protein Sciences (Meriden, CT; $1.3M SBIR) seeks to broaden sales in the upcoming flu season. ... the vaccine is now in 6,000 stores [Mara Lee, Hartford Courant, Sep 23, 15]

Protein Sciences (Meriden, CT; $1.6M SBIR) says its Flublok vaccine has been granted 12 years of regulatory exclusivity by [FDA] ... company's flu vaccine uses recombinant DNA to produce the proteins that form its active ingredients. Other flu vaccines rely on active influenza strains, grown in chicken eggs or in cell-based cultures, to synthesize the necessary proteins. [ZACH MELVIN, Hartford Courant, Jun 4, 15]

[FDA] licensed Protein Sciences (Meriden, CT; $1.5M SBIR) Pearl River, N.Y., manufacturing plant for production of its flagship influenza vaccine, Flublok. [Brian Dowling, Hartford Courant, May 13, 15]

Protein Sciences (Meriden, CT; $1.4M SBIR, 130 employees) is two months away from testing a vaccine for Ebola. ... [CEO] Manon Cox said Protein Sciences plans to deliver samples to [NIH] for testing in December. She and U.S. Rep. Rosa DeLauro said the vaccine could be available for medical workers or members of the U.S. military early next year. ... gets most of its business from a new flu vaccine that entered the market two years ago ... Work on the vaccine is mostly self-funded at this point, the company said [Brian Dowling, Hartford Courant, Oct 6, 14] When urgent demand strikes, SBIR's structure makes it of little value. But regular government has the capacity and organization to do almost anything in an emergency, a point usually overlooked by the small government crowd that cries "liberty" as a screen for wanting lower taxes.

Protein Sciences (Meriden, CT; $1.4M SBIR) announced a major distribution agreement that will .... make Flublok available to people through its more than 230 clinics nationwide and to employers that arrange their vaccination clinics through the company. ... vaccine is produced differently from traditional flu vaccines [as] the company makes a genetic copy of the virus, and from that makes large quantities of the influenza virus protein, the main ingredient of most inactivated flu vaccines. [Brian Dowling, Hartford Courant, Aug 20, 14]

Protein Sciences (Meriden, CT; $1.4M SBIR) is negotiating an incentive deal that could bring 100 or more jobs to its Meriden [CT] complex, even as the maker of a breakthrough flu vaccine readies a manufacturing plant in New York's Rockland County. [Dan Haar, Hartford Courant, Dec 17, 13]

Protein Sciences (Meridan, CT; $1.4M SBIR) skirted bankruptcy, fought off a hostile takeover bid, spent three years angling for a sorely-needed government contract, and survived a four-year dialogue with the FDA before winning approval this year for the first influenza vaccine made with genetic engineering and without eggs. [Bernadette Tansey, xconomy.com, Mar 11, 13]

Protein Sciences (Meriden, CT; $1.4M SBIR) is investing millions of dollars in a new manufacturing facility for its flu vaccine — in Rockland County, N.Y. [Dan Haar, Hartford Courant, Dec 4, 12]

Protein Sciences facing possible bankruptcy and liquidation has been awarded a $35 million federal [HHS] contract to develop a faster way to make vaccines for pandemic influenza. ... But only a day earlier, creditors filed a petition in federal bankruptcy court seeking to force Protein Sciences into bankruptcy and liquidation, saying they were owed $11.7 million. Almost all of that money is owed to Emergent BioSolutions, a vaccine company in Rockville, Md., that lent Protein Sciences $10 million last year in advance of the pending acquisition of virtually all the assets of Protein Sciences by Emergent. The acquisition deal fell apart, and Emergent sued Protein Sciences and its top executives, accusing them of fraud and breach of agreements. [Andrew Pollack, New York Times, Jun 23]

Protein Sciences claimed breach of contract in cancelling its sale to Emergent BioSolutions which counter-claimed thatProtein Sciences had no legal right to end the deal on its own, calling the claims "baseless." [Wash Post, Jul 30, 08]

Protein Sciences (Meriden, CT; $900K SBIR) came out slugging, saying a lawsuit by its merger partner was an attempt to cripple the maker of a next-generation flu vaccine, forcing it into bankruptcy so it could be bought more cheaply. Emergent BioSolutions is backing out on millions of dollars in loans that it agreed to make as part of a merger agreement in May, Protein Sciences said in a press release. The loans are critical to keeping the cash-strapped company afloat while it pursues licensing and further work on its FluBlok vaccine. [Kenneth Gosselin, Hartford Courant, Jul 11, 08]

Emergent BioSolutions, in a push to diversify beyond its biodefense business, plans to announce today that it is buying Protein Sciences (Meriden, CT; $900K SBIR), a maker of a next-generation flu vaccine that federal regulators have put on a fast track to approval. for $75M [Kendra Marr, Washington Post, May 27]

ProteinSimple (formerly Cell Biosciences) (Santa Clara, CA )

Startup Unchained Labs (Pleasanton, CA; no SBIR) pulled in $25 million in a Series A financing. ... started by Tim Harkness, who built Santa Clara protein analysis technology company ProteinSimple. That company sought to raise $86.3 million in an initial public offering last year, before its $300 million acquisition in August by Minneapolis-based Techne Corp ... Unchained Labs sees itself as a life sciences tools company. It plans to buy businesses and product lines, starting with the recent acquisition of Optim, an analytical instrument designed to help drug developers measure protein stability and, as a result, poor drug candidates early in the development process. [Ron Leuty, San Francisco Business Times, Feb 12, 15]

Techne (which does business as Bio-Techne) has agreed to buy protein-analysis technology maker ProteinSimple (Santa Clara, CA; no SBIR) for $300 million in cash, the company announced ... filed in May to raise up to $86.25 million in an IPO but has apparently decided that it was better off being acquired than going public. ... changed its name from Cell Biosciences in 2011 [Katharine Grayson, Minneapolis / St. Paul Business Journal, Jun 18, 14]

ProteinSimple (Santa Clara, CA; no SBIR) (formerly Cell Biosciences) bioscience company that has created protein analysis tools to help researchers understand the role of proteins in disease, has filed for an IPO with the intent to raise $86.25 million ..... [said the money] may be used for actions including "the acquisition of other products, businesses or technologies, although we currently have no commitments or agreements relating to any of these types of transactions.” [Silicon Valley Business Journal, May 2, 14]

Proteon Therapeutics (Waltham, MA)

Proteon Thera (Waltham. MA; $250K SBIR in Kansas) down 75% [Dec 13, 16] announced that its first Phase 3 clinical trial with investigational vonapanitase, PATENCY-1, did not meet its primary endpoint of improved primary unassisted patency compared to placebo (p=0.254). However, the top-line results for the trial's secondary endpoint suggested that vonapanitase may improve secondary patency compared to placebo (p=0.048). [company press release, Dec 13, 16]

Proteon Thera down 12% [Nov 3, 16]

Proteon Thera up 12% [Jun 27, 16]

Proteon Thera down 12% [May 6, 16]

Proteon Thera down 14% [Feb 22, 16]

Proteon Thera down 10% [Oct 23,15]

Proteon Thera down 13% [Aug 7, 15]

Proteon Thera down 10% [Jul 6, 15]

Proteon Thera down 10% [Jul 2, 15]

Proteon Thera up 17% [May 15, 15]

Proteon Thera (Kansas City, MO; $250K SBIR) down 12% [May 14, 15]

Proteon Thera ($200K SBIR)down 12% [Apr 20,15]

Proteon Thera ($250K SBIR) up 18% [Apr 8,15]

Proteon Thera (Kansas City, MO; two SBIRs) up 15% [Dec 9, 14]

Proteon Thera (Kansas City, MO; $250K SBIR) down 10% [Dec 3, 14]

Proteon Therapeutics (Kansas City, MO; $250K SBIR), a developer of drugs for kidney and vascular disease, has brought in another $15.2 million in equity- and options-based funding says an SEC filing [Erin Kutz, xconomy.com, Aug 12, 11]

Proteon Therapeutics (Waltham, MA (research in KC); $200K SBIR) has received an additional $12 million in venture capital. ... developing a blood vessel-dilating drug candidate [Kansas City Business Journal, May 28, 09]

Biopharmaceutical startup Proteon Therapeutics (Waltham, MA; $250K SBIR) has completed a $38 million Series B equity financing deal and has signed a deal with Novartis worth a potential half billion dollars [Mass High Tech, Mar 5]

Proteon Therapeutics (Waltham, MA and KC, MO; 2 SBIRs) reports it has been awarded a patent by the European Patent Office covering the use of a class of proteins known as elastase, for dilating arteries and veins in humans.

Biopharmaceutical company Proteon Therapeutics (Waltham, MA; two Phase 1SBIRs) has locked up $12M financing following last year's $19M. ... to advance its first product candidate, PRT-201, into human clinical studies in both hemodialysis vascular access and peripheral arterial disease [Mass High Tech, Sep 6, 07]

Proteostasis Therapeutics

Proteostasis Thera down 28% [Oct 24, 18] priced a public offering to raise $74M. [company press release, Oct 23, 18]

Proteostasis Thera down 23% [Oct 19, 18] after more than quadrupled after the company had disclosed positive preliminary results from a study testing an in-house, two-drug combination for cystic fibrosis. [Ben Fidler, xconomy.com, Oct 19, 18]

Protostasis Thera up 12% [Jun 15, 18]

Proteostasis Therapeutics down 38% [Jun 7, 18]

Data released looks to have eased a potential threat to Vertex Pharmaceuticals’ burgeoning cystic fibrosis franchise,[as] Proteostasis Therapeutics released data from a 49-patient Phase 1 study testing its experimental cystic fibrosis drug, PTI-801, in combination with Vertex’s FDA-approved CF drug ivacaftor/lumacaftor (Orkambi). Proteostasis pointed to statistically significant changes [that] didn’t lead to a statistically significant improvement in lung function—the gold standard for a CF drug’s effectiveness—over Orkambi and a placebo [Ben Fidler, xconomy.com, Jun 7, 18]

Protostesis Thera up 10down 11% [May 30, 18]

Proteostasis Thera down 26% [Mar 20, 18]

Proteostasis Thera up 54% [Mar 13, 18] announced that [FDA] has granted Breakthrough Therapy Designation for PTI-428, the Company's cystic fibrosis transmembrane conductance regulator (CFTR) amplifier. [company press release, Mar 12, 18]

Proteostasis Thera up 14% [Mar 9, 18]

Protoeostasis Thera up 10% [Feb 12, 18]

Proteostasis Thera down 31% [Feb 1,18]

Proteostasis Thera down 12% [Jan 16, 18]

Proteostasis Therapeutics up 13% [Dec 22, 17]

Proteostasis Therapeutics up 12% [Dec 19, 17]

Proteostasis Therapeutics down 10% [Dec 18, 17]

Proteostasis Therapeutics down 14% [Dec 14, 17]

Marinus Pharma up 10% [Dec 13, 17]

Proteostasis Therapeutics down 11% [Dec 13, 17]

Proteostasis Therapeutics (Cambridge, MA; no SBIR, founded 2006, 71 employees, IPO 2016, market cap $59M) up 161% [Dec 12, 17], a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, announced positive study results across all three of the company's CF pipeline programs. .... has formed a collaboration with Astellas Pharma (Japan). to research and identify therapies targeting the Unfolded Protein Response (UPR) pathway [company press release, Dec 12, 17] also announced that it intends to offer and sell 7,000,000 common shares

Proteostasis Therapeutics (Cambridge, MA; no SBIR) raised $50 million in an IPO despite a tough environment for biotech and even IPOs in general. The bad news: Proteostasis had to significantly discount its deal to raise that money. It sold 6.25 million shares at $8 apiece, well below its projections. [Ben Fidler, xconomy.com, Feb 11, 16] developing novel therapeutics that regulate protein homeostasis to improve outcomes for patients with orphan and protein processing diseases, today announced that it has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for PTI-428, an investigational oral treatment for cystic fibrosis (CF). [company press release, Feb 1, 16]

Proteostasis Therapeutics (Cambridge, MA; no SBIR) has added to its three-year-old Series A funding, boosting it from a planned $5 million to taking $70.6 million of what is now a planned $81.8 million round ... developer of a drug discovery platform aimed at developing therapeutics based on small molecules for Parkinson’s disease, Huntington’s disease, multiple sclerosis, amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease. [Rodney Brown, Mass High Tech, Jun 2, 11]

David Pendergast, the former CEO who led Transkaryotic Therapies through its sale to Shire Pharmaceutical Group, has helped new startup Proteostasis Therapeutics (no SBIR) raise $45 M in its first round, the company said. Proteostasis was founded on the research of Jeffrey Kelley of the Scripps Research Institute in California and Susan Lindquist of the Whitehead Institute for Biomedical Research at MIT. [Mass High Tech, Aug 25]

Proteotech

In Washington state’s biotech cluster, 83 local biotech companies were awarded grants worth a combined $34 million, Adaptive TCR, AVI Biopharma, Omeros, Proteotech, and Trubion Pharmaceuticals and 78 others. [Luke Timmerman, Seattle Times, Nov 3] Most were $245K, a little money for almost everyone. Too little money to make a big swing in effect. Just politics.

Proteus Biomedical (Redwood City, CA)

It’s hard to find a better example of how technology is revolutionizing patient care than the tiny edible sensor Proteus Biomedical (Redwood City, CA; no SBIR) plans to begin selling this fall in the UK. When the grain-of-sand-sized sensor is integrated into a drug tablet or capsule and activated by stomach fluid, it signals when the medicine was taken to a patch on the patient’s body. Then the patch relays the information along with the person’s heart rate and other medical details to a caregiver’s phone – all without a visit to the doctor. [Steve Johnson, San Jose Mercury News, Mar 26, 12]

Proteus Biomedical (Redwood, CA; no SBIR) a seven-year-old start-up, that is working on "smart pills" — internal sensors that monitor a person's health ... has lined up more than $60 million in funding and will concentrate for now on designing smart pills that monitor mechanical and electrical devices, as opposed to, say, blood chemistry. [Josh Quittner, Time, Dec 15, 08]

A system that monitors pill taking and its effects is being engineered by a Silicon Valley startup. The technology consists of pills that report when they've been taken, and sensors that monitor the body's responses. The company behind the technology, Proteus Biomedical, (Redwood City, CA; no SBIR), calls its technology the Raisin system. George Savage, Proteus's cofounder and a former ER physician, says that the company was motivated by the fact that so many medical problems stem from drug compliance problems. According to Savage, 40 percent of hospital readmissions for heart failure happen because patients fail to take their medications properly. [Michael Chorost, MIT Tech Review, Mar 20]

Proteus Digital Health (Redwood City, CA)

data from mobile and wearable devices could chart the student’s vital signs and sleep and activity patterns and compare them to a “sociability index” so as to suggest whether he or she is entering a manic or depressed stage, thus enabling earlier intervention when needed. That is the vision that Proteus Digital Health (Redwood City, CA; no SBIR, founded 2001) is refining, and for which it disclosed raising another $120 million from unidentified investors. .... Before the latest funding round, Proteus had raised about $200 million, Thomspon said. [Patrick Hoge, San Francisco Business Times, Jun 2, 14]

Proteus Digital Health (Redwood City, CA; no SBIR) pioneering the use of ingested sensors in health care, has raised a $62.5 million Series F round of capital ... The total Proteus has raised since 2003 is now more than $150 million, the company said. [Patrick Hoge, San Francisco Business Times, May 2, 13]

Protez Pharmaceuticals (Malvern, PA)

Novartis AG< purchased Protez Pharmaceuticals(Malvern, PA; no SBIR) a developer of antibiotics, this week for $400 M cash. [Pittsburgh Business Times, Jun 6]

Prothena

Elan Corp. spinout Prothena (no SBIR) will take an experimental drug aimed at a rare protein-misfolding disease into a late-stage clinical trial, the company said ... Elan seeded Prothena with $125 million, but the company now has about $300 million in the bank, said Chief Scientific Officer Gene Kinney. Now Prothena is ready to take NEOD-001 into the late-stage trial. [Ron Leuty, San Francisco Business Times, Dec 2, 14]

ProThera Biologics (Providence, RI)

ProThera Biologics (East Providence, RI; $3M SBIR) received a $500,000 financing commitment from the Slater Technology Fund, according to Slater. Slater reports that the $500,000 commitment follows its initial $100,000 grant to ProThera in 2001. [Mass High Tech, Jun 25]

Proto Labs (Maple Plain,MN)

Proto Labs (Maple Plain, MN; no SBIR), which moved into the Triangle last year by acquiring a Raleigh 3D printing company, is expanding in Wake County and adding 170 jobs over the next five years. [Raleigh News & Observer, Jun 19, 15]

FineLine Prototyping (Raleigh, NC; no SBIR) that performs additive manufacturing, otherwise known as 3-D printing, has been acquired by Proto Labs (Maple Plain, MN; no SBIR, founded 1999) for $38 million. .... Proto Labs focuses on "quick-turn" manufacturing of custom parts using computer numerical control (CNC) machining and injection molding. [Jesse Burkhart, Triangle Business Journal, Apr 23, 14]

Medical devices start-ups powered Minnesota to the best quarterly VC performance in eight years just as a sagging economy curbed venture spending across the country. ... Seven medical device firms captured $130 million, led by CVRx (Brooklyn Park, MN; no SBIR) that makes a device that treats high blood pressure, raised $84 million on top of the $200 million investors have already poured into the company. Cardiac Concepts (no SBIR) first-round financing totaled a hefty $21 million. ... Other notable deals: Proto Labs (Maple Plain, MN; no SBIR) -based maker of injection molded products, attracted $67.2 million. Sage Electrochromics (Faribault, MN; $2M SBIR) raised $13.3 million, which makes glass that influences building temperatures, previously won $16 million in venture financing. [[Minneapolis Star Tribune, Oct 26, 08]

Proton Energy Systems (Wallingford, CT)

New England energy stimulus money for small biz: $2.2 million for an energy storage project at Beacon Power .... $2.1M for Proton Energy (Wallingford, CT; $1.7M SBIR) and Penn State University aim to develop an advanced energy storage device that incorporates a regenerative fuel cell .... General Compression, (Newton , MA; no SBIR) $750K for a novel compressed air energy storage process [Kyle Alspach, Mass High Tech, Jul 13, 10]

Fuel Your Senators. Proton Energy Systems (Wallingford, CT; $1.3M SBIR), a renewable hydrogen technology developer, has received a $2.62 million Army contract fto develop a regenerative fuel cell system, company officials said.... The two US Senators helped secure funding for the project... In August, Proton announced being bought from its parent company Distributed Energy Systems Corp. by F9 Investments LLC for $10.2 million. [Mass High Tech, Oct 16, 08]

Proton Energy Systems (Wallingford, CT) got a $2.3 million contract for a hydrogen technology-oriented follow-on research project for the development of fuel cell technologies [Nov 06]

High Flying Hydrogen. MDA gave Proton Energy Systems (Wallingford CT) got a $1.25M SBIR Phase 3 for continued development of regenerative fuel cell technology for high altitude airships. Proton is a a subsidiary of Distributed Energy Systems. [Mass High Tech, Oct 12] Phase 3, which isn't SBIR money, lets the government hand out a contract to the Phase 2 winner without further competition. The company is also in the middle of a three-year, $3.8 M project with the Department of Energy to develop methods to reduce the cost of high-pressure hydrogen generation from proton exchange membrane electrolysis.

Protonex Technology (Southborough, MA)

Protonex Technology said it has been selected by the defense contractor Lockheed Martin to develop power supply concepts that will enable its HULC robotic exoskeleton to support extended missions of 72 hours or more. [Boston Globe, Feb 11, 10]

Protonex Technology reports it has landed $1.5 million from the U.S. Army for supplying portable battery charger fuel cells. [Mass High Tech, Feb 4, 10]

Protonex Technology landed a [Army and stimulus] contract worth $1.85 million for the development and supply of advanced portable battery charger/auxiliary power units (APU) fuel cell systems. ... could increase to $6.4 million if three option phases are awarded. [Mass High Tech, Jan 20, 10]

A small unmanned aerial vehicle powered by a Protonex fuel cell has set an unofficial endurance record after a flight of more than 23 hours, the company. said. [Boston Globe, Oct 15, 09] The Navy sponsored the project.

Protonex Technology got a $2 million follow-on contract from the U.S. Army to make Protonex’ solid oxide fuel cell (SOFC) power systems more rugged and robust to meet the Army’s needs. [Mass High Tech, Sep 22, 09]

Protonex Technology (Southborough, MA; $1.8M SBIR) announced Thursday it received a $599,000 contract with the U.S. Naval Research Laboratory to develop fuel cell power systems for aerial drones. [Mass High Tech, Sep 17, 09]

Protonex Technology (Southborough, MA; $2M SBIR) said its fuel-cell power system has been successfully tested in a Talon military robot from Foster-Miller. [Boston Globe, Apr 21]

Protonex Technology won a $400,000 contract from the Army's ARO for further development of the use of high-performance liquid fuels in its solid-oxide fuel cell power systems. .... In April, Protonex received a $3.65 million contract from ARO to develop the next generation of the firm’s Pulse M250 military power system. [Mass High Tech, Sep 9, 08]

Protonex Technology landed its second military contract in two weeks, receiving a $3.65 million contract from the Army. [Mass High Tech, Apr 28]

Protonex Technology (Southborough, MA) got a $1.62 M contract with the NRL for advanced development of high power fuel cell systems for small UAVs. ... makes fuel cells for commercial use. It began working with Cummins on applications in the trucking industry last September. ... shares debuted on the London Stock Exchange last July [Mass High Tech, Apr 23, 08]

Protonex reports a new subcontract from Cummins to supply solid oxide fuel cell (SOFC) power systems for integration into a demonstration system for commercial mobile applications. [Mass High Tech, Sep 24, 07]

Protonex reports Raytheon has agreed to participate in the development of Protonex' portable fuel cell power system for the Army. ... Since going public last July on London's Alternative Investment Market (AIM), Protonex has doubled its head count from about 40 employees last year to 85 employees. [Mass High Tech, Sep 12]

Protonex was up 20%, back to the 90s after a drop and a day off from trading. [Jul 6, 07]

Protonex took an 18% swan dive despite announcing an $800K AF contract extension. [Jul 3, 07]

Protonex Technology (Southborough, MA; $1M SBIR) which makes high-performance proton exchange membrane (PEM) fuel cells will pay $12M for Mesoscopic Devices (Broomfield, CO; $5M+ SBIR) which makes a range of fuel cells.

They Still Speak English. Ross Kerber [Boston Globe, Jan 28] notes that four Boston area companies have gone public recently by listing on the London AIM exchange. Of the four, fuel cell developer Protonex Technology had about $1M in SBIR, and fish farmer Aqua Bounty had just one Phase 1.

Prototype Productions (Ashburn, VA)

Prototype Productions (Ashburn, VA; $1.4M SBIR) built or invented 176 gadgets over the years, spanning the defense, aerospace and medical industries. They’ve made stuff for the Patriot missile, grenade launchers and Chinook helicopters. ... hoping to [gross] $30 million to $50 million by mid-decade. ... 90 employees ... During our tour, Joe took me to a room and pointed at a box the size of two refrigerators. He called it a 3D laser printer. It’s too technical to get into, but he said the printer is the next advance in manufacturing. “Many say America is losing its industrial base, which is true to some extent,” he said. “But in the future, we won’t worry about this because we will no longer manufacture things. We will print things. Laser centering is the next trillion-dollar industry.” [Thomas Heath, Washington Post, Apr 25, 11]

Provagen

Two spinoff companies from N.C. State University and N.C. A&T State University are the first to receive loans and legal help from a new set of programs designed by the N.C. Biotechnology Center in Research Triangle Park. The programs offer companies $50,000 in startup loans as well as free legal help from area law firms. ... NCSU's company, Sirga Advanced Biopharma, uses the technology of biochemistry professor Paul F. Agris to identify therapies for drug-resistant diseases ... A&T's spinoff company, Provagen, was formed to commercialize protein technology developed by John Allen, a molecular biologist. [Raleigh News & Observer, Jun 22]

Provenance Biopharmaceuticals (Waltham, MA)

Provenance Biopharmaceuticals (Waltham, MA; no SBIR) has raised $8 million from brand new stealthy health care products acquisition company Allopexx Enterprises LLC to fund development of an anti-cancer therapy. [Rodney Brown, Mass High Tech, Dec 23, 11]

Provention Bio (Lebanon, NJ)

Provention Bio (Lebanon, NJ; no SBIR, founded 2017 with $28.4 million in seed funding) filed to raise up to $50 million in its Nasdaq IPO, which will bankroll several clinical programs, including a pair of inflammatory bowel disease assets it picked up from Janssen last fall. [Amirah Al Idrus, Fierce Biotech, May 9, 18]

Proventys

A Durham medical research company co-founded by Ralph Snyderman, former CEO of the Duke University Health System, has attracted interest from several health-care heavy hitters and enough cash to introduce its first product this year. Proventys (no SBIR) is working on software that promises to help prevent complications from chemotherapy by identifying at-risk cancer patients. The company plans to use part of its $5.65 million in private financing to test the technology, and it might target other therapeutic areas. [Raleigh News & Observer, May 15, 08]

Provista Diagnostics (Scottsdale, AZ)

Provista Diagnostics (Scottsdale, AZ; no SBIR, founded 2007) has licensed some biomarker technologies developed by Joshua LaBaer and Karen Anderson at the Biodesign Institute at Arizona State University. ... will evaluate whether the technologies are effective in the early detection of breast and ovarian cancer as well as the human papillomavirus. [Angela Gonzalez, Phoenix Business Journal, Nov 4, 13]

Pryor Medical Devices (Arvada, CO and San Antonio, TX;)

Pryor Medical Devices (San Antonio, TX; no SBIR), announced it has received FDA 510(k) clearance for the sale and distribution of its ER-REBOATM catheter. REBOA (Resuscitative Endovascular Balloon Occlusion of the Aorta) is a minimally invasive technique used by the Trauma, Critical Care and Emergency Medicine community to temporarily occlude large vessels using a balloon. [W. Scott Bailey, San Antonio Business Journal, Nov 13, 15] won a $14.3 million contract with the U.S. military that will support the advancement of the REBOA science. [Bailey, Nov 10, 15] The technology was invented and patented by a team from the U.S. military and the University of Michigan [fiercemedicaldevices.com, Apr 19, 15]

Pryor Medical Devices (Arvada, CO and San Antonio, TX; no SBIR, founded 2012, three employees) formed to provide minimally invasive solutions for noncompressible torso hemorrhage [company website] closed on $5 million in Series B funding to support the development of its flagship product — the ER-REBOA Catheter [designed to temporarily occlude large blood vessels through a less invasive procedure]. ... A pair of individuals from the U.S. military and University of Michigan invented and secured a patent for the device. They have licensed the technology exclusively to Pryor Medical, which has improved the technology and is now seeking to commercialize the device. [W. Scott Bailey, San Antonio Business Journal, Sep 22, 15]

PsiKick (Santa Clara, CA)

PsiKick (Santa Clara, CA; no SBIR) raised $16.5 million in Series B funding to develop its battery-free systems. [Gina Hall, Silicon Valley Business Journal, Dec 23, 15] Company website claims Our systems-on-chip operate at up to 1,000x lower power than existing state-of-the-art “low power” solutions. ... Harvest energy from multiple ambient sources, including indoor and outdoor solar, thermal gradients, RF, vibration, and more. Store and manage energy for reliable operation across varying environmental conditions.

pSivida (Watertown, MA)

pSivida (Watertown, MA; no SBIR) has taken a $15 million payment from Alimera Sciences (Alpharetta, GA; no SBIR) to cover licensing of its lead product Iluvien to treat diabetic macular edema (DME). ... pSivida was launched in Australia, and reincorporated as a U.S. company based in Watertown in April of 2008. [Mass High Tech, Apr 29, 10]

PTC Therapeutics (S Plainfield, NJ)

PTC Therapeutics (SOUTH PLAINFIELD, NJ; $6M SBIR) down 20% [May 24, 2023] announced the discontinuation of preclinical and early research programs in gene therapy as part of a strategic portfolio prioritization. PTC will continue its development and global commercialization of Upstaza, the first-ever approved gene therapy directly administered to the brain. [company press release, May 23, 2023]

PTC Thera down 11% [Oct 4, 18]

PTC Therapeutics (South Plainfield, NJ; no SBIR) is looking to gene therapy in a bid to broaden its pipeline, scooping up privately held Agilis Biotherapeutics (Cambridge, MA; no SBIR) in a cash and stock deal..... will pay $50 million up front, plus $150 million in PTC shares, for Agilis. Agilis, based in , could get up to $595 million more depending on the progress of its three most advanced gene therapy programs, which target rare central nervous system disorders. [Frank Vinuan, xconomy.com ,Jul 19, 18]

PTC Thera down 31% [Jun 19, 18]

PTC Thera up 28% [Jun 18, 18] announced the presentation of updated interim clinical data from Part 1 of the FIREFISH study investigating risdiplam (RG7916) in babies with Type 1 Spinal Muscular Atrophy (SMA) [company press release, Jun 16, 18]

PTC Thera up 10% [Jan 29,18]

PTC Thera up 13% [Jan 8, 18]

PTC Thera down 11% [Oct 3, 17]

RegenxBio has opted to back away from a deal to buy Dimension Therapeutics after the biotech received a better buyout offer. RegenxBio said it doesn't plan to match, or best, the unsolicited $6-per-share price that Ultragenyx Pharmaceutical is now offering to Dimension Therapeutics that's struggled with its pipeline in the last year. (Washington Business Journal, Oct 2, 17)

PTC Thera up 15% [Sep 29, 17]

Zynerba Pharma down 11% [Sep 29, 17]

A panel of [FDA] experts voted against a Duchenne muscular dystrophy drug from PTC Therapeutics. The vote is a critical blow to the company’s unusual attempt to force the review of a drug the FDA has rejected twice already. [Ben Fidler, xconomy.com, Sep 28, 17]

PTC Thera down 14% [Sep 26, 17]

PTC Therapeutics down 12% [May 8, 17] said that it would receive a net price of $35,000 annually per patient for Emflaza, the muscular dystrophy drug it acquired from Marathon Pharmaceuticals LLC last month. ... Marathon had ignited a backlash from patient advocates and politicians in February when it announced a wholesale list price of $89,000 annually for Emflaza after it was approved for sale by [FDA]. The price was some 70 times more than some U.S. patients had been paying to import Emflaza from the U.K. [Joseph Walker, Wall Strreet Journal, May 8, 17]

Akashi Therapeutics (Cambridge, MA; no SBIR, founded 2011 as Dart Therapeutics) has been cleared by the FDA to resume testing an experimental Duchenne muscular dystrophy drug roughly a year after a patient taking the treatment died in a clinical trial. ... Eteplirsen, from Sarepta Therapeutics, is meant to slow the progression of the disease, but for just a 13 percent genetic subset of Duchenne patients. The steroid deflazacort—which has been available for years in other countries—was approved in the U.S. in February for all Duchenne patients, but also only helps temporarily delay the disease’s grim march. (Deflazacort hasn’t launched yet; Marathon Pharmaceuticals sold the drug’s rights to PTC Therapeutics last week). [Ben Fidler, xconomy.com, Mar 22, 17]

PTC Therapeutics down 19% [Mar 16, 17] Marathon Pharmaceuticals LLC has struck a deal to sell its muscular-dystrophy treatment to PTC Therapeutics Inc., one month after Marathon’s $89,000 price tag for the drug spurred an outcry from patient advocates and federal lawmakers. Marathon will receive $140 million up front from the sale—$75 million in cash and about $65 million in PTC stock. ... Some analysts questioned the wisdom of the deal for PTC, considering the scrutiny around the drug’s price and the existence of alternative treatments. [Joseph Walker, Wall Street Journal, Mar 16, 17]

PTC Therapeutics is seeking FDA approval of its drug ataluren (Translarna) for Duchenne muscular dystrophy “over protest” of the agency. Ataluren has already failed three clinical trials and twice been denied an FDA review. RBC Capital Markets analyst Simos Simeonidis wrote that PTC has “very little chance” of success. The FDA will decide on ataluren by Oct. 24. [Ben Fidler, xconomy.com, Mar 10, 17]

PTC Thera down 20% [Mar 2, 17] said its cystic-fibrosis treatment failed to meet its primary or secondary endpoints in a late-stage study. [Dow Jones Newswire, Mar 2, 17]

PTC Thera up 10% [Jan 9, 17]

PTC Thera up 88% [Nov 11, 16] announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the renewal of the conditional marketing authorization of Translarna(TM) (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD) in ambulatory patients five years and older. [company press release]

PTC Thera up 13% [Nov 7, 16]

PTC Thera up 19% [Nov 4, 16]

PTC Thera down 33% [Nov 3, 16]

PTC Thera down 40% [Oct 17, 16] said [FDA] denied its first appeal of the regulator's refusal to review PTC's application for its experimental Duchenne muscular dystrophy drug. [Dow Jones Newswire]

PTC Thera up 21% [Sep 30, 16]

PTC Thera up 21% [Sep 19, 16]

PTC Thera up 28% [Aug 5, 16] Translarna revenue of $15.4M in second quarter represents 150% year-over-year growth. PTC continues to grow its global commercial footprint and expand access to Translarna. [company press release, Aug 4, 16]

PTC Therapeutics (South Plainfield, NJ; $5M SBIR) said its Duchenne muscular dystrophy drug ataluren (Translarna) faces a regulatory delay in Europe. As TheStreet.com reports, the drug is no closer to approval in the U.S. [Alex Lash, xconomy.com, Jul 29, 16]

PTC Thera down 13% [Jul 26, 16]

PTC Thera up 20% [May 20, 16]

PTC Thera up 43% [Apr 15, 16]

PTC Thera down 10% [Apr 8, 16]

PTC Thera up 15% [Mar 2,16]

PTC Thera down 30% [Mar 1,16]

PTC Thera down 29% [Feb 26, 16]

PTC Thera down 62% [Feb 23, 16] announced that it received yesterday evening a Refuse to File letter from [FDA] regarding PTC's New Drug Application (NDA) for Translarna(TM) (ataluren), an oral, first-in-class, protein restoration therapy for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD). [company press release, Feb 23, 16]

PTC Thera up 11% [Jan 20, 16]

PTC Thera down 12% [Jan 11, 16]

PTC Thera up 19% [Dec 16, 15]

PTC Thera down 13% [Nov 19, 15]

PTC Thera up 11% [Nov 2, 15]

PTC Thera down 16% [Oct 19,15]

PTC Therapeutics's (South Plainfield, NJ; $5M SBIR) experimental muscle disorder drug failed to meet the main goal in a keenly watched late-stage study, but the company said data from all trials on the drug supported a U.S. marketing application [Reuters, Oct 15, 15]

PTC Thera up 10% [Aug 26, 15]

PTC Thera up 10% [Aug 17, 15]

PTC Thera up 14% [Jul 15,15]

PTC Thera down 13% [May 5,15]

PTC Thera up 10% [Feb 24, 15]

PTC Thera (S Plainfield, NJ; $4.8M SBIR) up 18% [Feb 20, 15]

PTC Thera down 10% [Dec 15, 14]

PTC Thera up 13% [Dec 2, 14]

PTC Thera up 12% [Nov 24, 14]

PTC Thera down 10% [Oct 6, 14]

PTC Thera up 11% [Sep 15, 14]

PTC Thera up 10% [Sep 8, 14]

PTC Threa down 10% [Aug 7, 14]

PTC Thera up 10% [Jul 22, 14]

PTC Thera up 10% [Jun 5, 14]

PTC Thera up 15% [May 28, 14]

PTC Thera up 31% [May 23, 14]

PTC Thera down 12% [May 2, 14]

PTC Thera up 11% [Apr 29, 14]

PTC Thera up 12% [Apr 22, 14]

PTC Thera down 13% [Apr 10, 14]

PTC Thera down 15% [Mar 24,14]

PTC Therapeutics up 10% [Feb 10, 14]

PTC Thera down 14% [Feb 3, 14]

PTC Therapeutics up 10% [Jan 17, 14]

PTC Therapeutics (S Plainfield, NJ; $5M SBIR) up 13% [Jan 15, 14]

PTC Therapeutics ($5M SBIR) up 14% [Dec 16, 13]

PTC Thera (S Plainfield, NJ; $5M SBIR) up 26% [Sep 23, 13]

PTC Therapeutics (South Plainfield, NJ; $5M SBIR) up 10% [Jun 28, 13]

PTC Therapeutics (South Plainfield, NJ; $5M SBIR) down 10% [Jun 27, 13]

PTC Therapeutics (S Plainfield, NJ; $5.4M SBIR) up 10% [Jun 20, 13]

Genzyme will pay PTC Therapeutics (Plainfield, NJ; $5M SBIR) $100 million, as well as milestone and royalty payments, to commercialize its drug, PTC124, outside the U.S. and Canada, where PTC will commercialize the drug. [Mass High Tech, Jul 17, 08]

Pulmatrix (Lexington, MA)

Pulmatrix (Lexington, MA; no SBIR), a clinical stage biotechnology company , said that it has secured $14 million in new funding in a Series B1 round ... to accelerate the development of its drug candidate pipeline. The company is focused on discovering and developing a new class of therapies for the prevention, treatment, and control of respiratory diseases. [Chris Reidy, Boston Globe, Aug 15, 11]

Pulmatrix (Lexington, MA; no SBIR) said it has been awarded a $5.7 million grant from DARPA. ... focused on new treatments for respiratory diseases, and the DARPA grant is for developing potential treatments for respiratory infections caused by weaponized, engineered, or naturally occurring pathogens [Boston Globe, Dec 14, 10]

Pulmatrix (Lexington, MA; no SBIR)is starting a Phase 1b/2a clinical trial of its new inhaled influenza treatment PUR003, which possibly could be used against the current swine flu. .... said that its lead drug candidate PUR003 is a so-called Cationic Airway Lining Modulator drug. ... founded in 2003 by scientists from Harvard University and MIT with an eye to creating inhaled drugs and supporting technologies to treat and control disease. ... Earlier this year, Pulmatrix secured $3.5 million [VC] [Mass High Tech, May 4, 09]

Pulmatrix (Lexington, MA; no SBIR) has closed on more than $3 million in a recent funding round. Pulmatrix’s mission is to prevent the spread of airborne and respiratory infectious diseases in animals and humans with a mixed hardware-chemical combination. It was founded in 2003 by scientists from Harvard University and MIT with an eye to creating inhaled drugs and supporting technologies to treat and control disease. [Mass High Tech, Mar 13, 09]

Pulmonx (Redwood City, CA)

Pulmonx® (Redwood City, CA; no SBIR, founded 1998) announced that [FDA] approved the Zephyr® Endobronchial Valve System for treating severe emphysema patients. ... the first minimally-invasive device approved in the US for treating patients with severe emphysema, a progressive and life-threatening form of chronic obstructive pulmonary disease (COPD). [company press release, Jun 29, 18] total funding $99M [crunchbase.com]

Pulmotect (Houston, TX)

Pulmotect (Houston, TX; at least $3M SBIR) raises first part of potential $12M Series B [Jack Witthaus, Houston Business Journal, Mar 23, 18] develops products (host-directed/pathogen-agnostic) to reduce morbidity and mortality in patients at risk of severe respiratory diseases.[company website]

Pulmotect, (Houston, TX; no SBIR) which is developing an inhalant that stimulates the lungs’ immune system against inhaled pathogens, has closed on $1.75 million in Series A funding and a $1 million grant from [NIH]. [Angela Shah, xconomy.com, April 18, 16]

Pulmotect (Houston, TX; yes SBIR, founded 2007) received a $3 million [NIH] grant, which will be used to propel its immunotherapy drug into the next levels of clinical trials. ... developing products to boost the immune system and protect against lung infections. ...has raised about $18 million in total funding since inception. It received $7.1 million from the Cancer Prevention Research Institute of Texas in 2012. [Joe Martin, Houston Business Journal, May 27, 15] three-year NIH SBIR grant is the sixth award for Pulmotec ... Backed by $15 million in grant and equity funding to date [company website]

Pulse Electronics (Rockville, MD)

Pulse Electronics (Rockville, MD; one SBIR) down 34% [Sep 26, 14]

Pulse Therapeutics (St Louis, MO)

Pulse Biosciences (Hayward, CA; no SBIR, IPO May 2016) up 23% [Apr 5, 18] total funding $35M [crunchbase.com]

Pulse Therapeutics (St. Louis, MO; no SBIR, founded 2008) medical device startup, has raised about $10 million from a group of investors [Brian Feldt, St. Louis Business Journal, Jan 29, 16] The Magnetically-Enhanced Diffusion (MED) system ™ is designed to improve the fluid dynamics in stagnant flow vessels by using patented magnet-based technology to convey intravenously administered, iron-oxide MED MicroBeads and physician-selected agents at a much faster rate than otherwise possible. This promises to improve care for stroke and other diseases. [company website]

Pulse Therapeutics (St Louis, MO; no SBIR, founded 2008) uses magnets to help clear the blood clots that can cause strokes. ... Magnetically-Enhanced Diffusion (MED) system ™ is designed to improve the fluid dynamics in stagnant flow vessels by using patented magnet-based technology to convey intravenously administered, iron-oxide MED MicroBeads and physician-selected agents at a much faster rate than otherwise possible. .... continues to attract investors and garner media coverage. [company website]

Cultivation Capital has invested just short of $11 million of the $20 million tech fund it created in 2012. ... started out as a tech fund, created its life sciences fund in 2013 with plans to invest some $30 million over five years. .... its portfolio: Immunophotonics (Columbia, MO; no SBIR) developed a cancer vaccine; Molecular Sensing (Nashville, TN; no SBIR) commercializing a label-free molecular interaction assay system based on Back-Scattering Interferometry; Adarza BioSystems (WEST HENRIETTA, NY; $1.8M SBIR) early stage medical diagnostics; Cardialen (Minneapolis, MN; no SBIR) developed a treatment to keep the heart in a normal rhythm for people suffering from atrial fibrillation (AF); Euclises Pharmaceuticals (St Louis, MO; no SBIR) developing pain and cancer medications; Mobius Therapeutics (St Louis, MO; no SBIR) commercial stage venture focused on ophthalmic surgery solutions; Pulse Therapeutics (St. Louis, MO; no SBIR) developed a new approach to accelerate the concentration and delivery of physician-selected agents within the vasculature; Galera Therapeutics (Malvern, PA; no SBIR) focused on the development of breakthrough drugs targeting the oxygen metabolic pathways. [Brian Feldt, St. Louis Business Journal, Oct 27, 14]

Pulse Therapeutics (St Louis, MO; no SBIR, founded 2009) medical device company in the Downtown T-REx co-working space. ... raised $1.3 million from three investors ... founded in 2009 by Francis Creighton and Rogers Ritter, and is developing a magnet-based technology to dissolve blood clots. [Brian Feldt, St. Louis Business Journal, Mar 6, 2014]

Puma Biotechnology (Los Angeles, CA)

Puma Biotechnology shares lost about a quarter of their value after European regulators gave Puma’s drug neratinib a negative review for breast cancer. Neratinib was approved in the U.S. last year despite a marginal benefit over placebo and side effects of severe diarrhea. [Alex Lash, xconomy.com, Jan 25, 18]

Puma Biotechnology (Los Angeles, CA; no SBIR) announced that [FDA] approved NERLYNX™ (neratinib), formerly known as PB272, a once-daily oral tyrosine kinase inhibitor for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy. Puma expects neratinib to become commercially available in September 2017. [company press release, Jul 17, 17]

PUR Biologics

Histogen (San Diego, CA; no SBIR, founded 2007, a regenerative medicine company, says it has partnered with a group of medical device investors to establish a joint venture, PUR Biologics, to adapt its expertise in fibroblasts, the cells that form connective tissue, for use in orthopedics. [Bruce Bigelow, xconomy.com, Mar 11, 13]

Pure Bioscience (El Cajon, CA)

Pure Bioscience (El Cajon, CA; no SBIR) says it can provide extra safety against food-borne illnesses with a new antimicrobial product that could be approved this year. .... The company estimates the potential U.S. market for such a direct food disinfectant is $1 billion annually. Pure’s rinse uses the same nontoxic active ingredient as a product the company already has on the market, Pure Hard Surface, Lambert said. The ingredient, silver dihydrogen citrate, emits silver ions when ingested by microbes, killing them by disrupting their DNA. [Bradley Fikes, utsandiego.com, Jan 28, 14]

Purfresh (Fremont, CA)

Purfresh (Fremont, CA; no SBIR) has raised $2 million of a $2.5 million traunche of funding. The Fremont-based company makes technology used to clean and purify food and water. It's raised $26 million since March of 2010, according to financial disclosures, on top of a $25 million round the company announced in 2008.[San Francisco Business Times, Jul 8, 11]

Purillume (Cary, NC)

An LED startup with Cree roots is raising cash, prepping to debut a table lamp its CEO hopes will be a game-changer in the competitive lighting industry. .... started (Cary, NC; no SBIR in stealth mode, founded 2014] [Lauren K. Ohnesorge, Triangle Business Journal, Aug 11, 16]

Purilogics (Greenville, SC)

Donaldson Co. announced it acquired Purilogics (Greenville, SC; $5.4M SBIR) biotechnology company for $20 million. [Carter Jones, MinneInno, Jun 14, 2022]

Pursuit Vascular (Maple Grove, MN)

Pursuit Vascular (Maple Grove, MN; no SBIR, founded 2009, eight employees) nabs $2 million for infection-fighting tech [Minneapolis St Paul Business Journal, Aug 19, 16] has enjoyed at least one advantage in its quest to market its technology, which reduces catheter infections in kidney dialysis and other patients. The product is a polymer rod coated witha dry, antimicrobial agent that kills bacteria inside a catheter, reducing infections by about 75 percent. e ability to prove ClearGuard’s e ffectiveness in lab testing, rather than a clinical setting, helped Pursuit gain relatively rapid approval by the FDA. .... has used the Minnesota Angel Tax Credit as a tool in raising $4 million on its financing, which returned 25 percent to those investors ... According to the Centers for Disease Control, one of today’s top seven health care challenges is catheter related bloodstream infections. [Dan Emerson, Minnesota Business, May 2015]

Pursuit Vascular (Maple Grove, MN; no SBIR) which makes an infection-fighting antimicrobial rod, has closed on about $1.6 million in funding [Series B round] . ... to complete product evaluations and boost manufacturing capacity ahead of a commercial launch, said CEO Doug Killion. [Katharine Grayson, Minneapolis / St. Paul Business Journal, Feb 9, 15]

Pursuit Vascular (Maple Grove, MN; no SBIR) which makes an infection-fighting antimicrobial rod, has closed on about $1.6 million in funding [part of a Series B round]. ... to complete product evaluations and boost manufacturing capacity ahead of a commercial launch, said CEO Doug Killion. ... received [FDA] approval in late 2013. The company's product is inserted into hemodialysis catheters to kill infection-causing microorganisms. [Katharine Grayson, Minneapolis / St. Paul Business Journal, Feb 9, 15]

Medical-device startup Pursuit Vascular (Maple Grove, MN; no SBIR) has closed on nearly $1.6 million in capital after receiving regulatory approval to sell its infection-fighting catheter technology. .... company's product, called ClearGuard HD, is an antimicrobial rod that’s inserted into hemodialysis catheters to kill infection-causing microorganisms. Kidney-disease patients undergoing regular hemodialysis treatments often have a catheter left in their chests continuously, increasing the risk of developing a severe infection. [Katharine Grayson, Minneapoils / St Paul Business Journal, Feb 24, 14]

Pursuit Vascular (Maple Grove, MN; no SBIR) closed on about $1.3 million in capital, according to a regulatory filing. .... trying to raise a total of $2 million. ... developing a product that aims to reduce infection in hemodialysis patients, announced plans to kick off the round in April after closing on $750,000 in bridge financing. [Katherine Grayson, Minneapolis St Paul Business Journal, Aug 17, 12]

Pursuit Vascular (Maple Grove, MN; no SBIR) raised $750,000 in bridge financing during the first quarter and will soon kick off another round of fundraising, the company announced. ... has developed a catheter technology that it says could reduce the risk of infection in hemodialysis patients. In addition to the bridge financing, the company now wants to raise $2 million, which it will put toward prepping for clinical trials and intellectual-property costs. [Katherine Grayson, Minneapolis / St Paul Business Journal, Apr 30, 12]

PurThread (Durham, NC)

textile firm PurThread (Durham, NC; no SBIR) raised $7 million in an angel round led by its own board chair .... to develop its antimicrobial fabric technology. ...... also has a line of anti-odor sportswear based on the same technology [Lauren Ohnesorge, Triangle Business Journal, Nov 4, 13]

PvP Biologics (San Diego, CA)

Takeda Pharmaceutical and PvP Biologics (San Diego, CA; no SBIR) announced a global agreement for the development of KumaMax, a novel enzyme designed to break down the immune-reactive parts of gluten in the stomach, thereby avoiding the painful symptoms and damage done in the small intestine from accidental gluten ingestion. ... PvP will conduct all [R&D] through phase 1 proof-of-principle studies per a pre-defined development plan. Takeda will fund $35 million for PvP’s expenses related to the plan in exchange for an exclusive option to acquire PvP following receipt of a pre-defined data package. Upon PvP’s successful completion of the development plan, Takeda may exercise its option to acquire PvP by paying an undisclosed fee as well as development and regulatory milestones. [joint companies press release, Jan 5, 17]

Takeda Pharmaceutical (Japan) and a subsidiary have decided to invest in two San Diego biotech companies ... PvP Biologics (no SBIR) will get $35 million to develop celiac therapy, which breaks down gluten in the stomach before it reaches the intestine. Avidity Biosciences (no SBIR) has raised $16 million in a venture-financing round led by the subsidiary, Takeda Ventures. Avidity has invented a technology that delivers a class of RNA medications more widely throughout the body. [Bradley Fikes, San Diego Union Tribune, Jan 9, 17]

PvP Biologics (San Diego, CA and Seattle, WA; no SBIR yet) a University of Washington spin-out, is advancing a scientifically designed enzyme that could help people with celiac disease. The UW Institute for Protein Design created the enzyme, called KumaMax. It targets parts of gluten that cause the autoimmune reaction leading to celiac disease. The disease affects an estimated 2.4 million Americans. ... was launched through CoMotion at the UW, the collaborative innovation hub dedicated to expanding the societal impact of the UW community. [company press release, Dec 20, 16]

last updated Feb 13, 2024